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Dendritic cell (DC) vaccine is a potent form of therapy useful for the treatment 
of cancer. DCs are professional antigen-presenting cells (APCs) that are 
essential in regulating and orchestrating T-cell mediated immunity and this 
property has prompted intense research in the use of DC-based 
immunotherapy. However, DC vaccination is still in its infancy and 
improvements in terms of DC preparation, antigen-loading and increasing 
their immunostimulatory capacity are required. Here, we describe a potent 
and novel type of DCs generated by CD137 ligand (CD137L) reverse 
signalling into peripheral monocytes which have the capacity to induce 
superior antigen-specific T-cell response. 
 CD137L is expressed on peripheral human monocytes and delivers a potent 
activating signal via reverse signalling. Treatment of monocytes with a 
recombinant CD137 protein that induces reverse signalling through CD137L 
was reported to induce their differentiation to DCs that are capable of 
stimulating allogeneic naïve T cells to high perforin expression. In this study, 
we show that CD137L-generated DCs (CD137L-DCs) can be further matured 
leading to increased expression of DC markers such as CD83, CD86 and 
HLA-DR. This in turn enables a stronger activation of allogeneic T cells. We 
also tested the ability of CD137L-DCs to trigger antigen-specific T-cell 
activation in an autologous setting. Using cytomegalovirus (CMV) pp65 
peptides, we show that CD137L-DCs are able to potently activate both CD8+ 
and CD4+ pp65-specific T cells to a level superior than T cells activated by 
conventional GM-CSF/IL-4 generated DCs (classical DCs). pp65-specific T 
cells restimulated by CD137L-DCs also secrete higher levels of IFN- and IL-
13 than mature classical DCs which suggest their capacity to activate both 
 xi 
 
Th1 and Th2 subpopulations of CD4+ T cells. Maturation of CD137L-DCs 
further potentiates this response. More importantly, these CD137L-DC-
activated T cells are able to induce a stronger antigen-specific killing of HLA-
matched target cells than T cells activated by classical DCs. To further 
characterise CD137L-DCs, their transcriptional profile was assessed. 
Through clustering and cMAP analyses, we determined that CD137L-DCs are 
more similar to mature classical DCs than to immature classical DCs or 
macrophages. Nonetheless, macrophage-specific genes such as podoplanin 
and CLEC5A were upregulated in CD137L-DCs suggesting a phenotypically 
different form of DC. 
As a whole, in silico and in vitro data show that CD137L-DCs are 
phenotypically unique DCs with potent T-cell activating capacity and should 
be evaluated for human immunotherapy.     
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CHAPTER 1: INTRODUCTION 
1.1. Cancer and the immune system 
1.1.1. Overview on cancer immune surveillance 
It is well established that the immune system combats pathogens such as 
microbes and viruses. Its function towards eliminating nascent transformed 
cells have, however, been heavily debated (Dunn et al., 2002). More recently, 
intense research by independent groups has provided overwhelming 
evidences on the existence of immune surveillance (Gao et al., 2003; Girardi 
et al., 2001; Street et al., 2002).    
The concept of immune surveillance is based on the paradigm that the 
immune system tracks and detects anomalies developed by cells and tissues, 
and that before potential nascent tumours can form, these transformed cells 
are eliminated by the immune system. It is thought that a breach in the 
immune surveillance and subsequent immunological killing initiates the 
progression towards the formation of solid tumours and malignancies. Indeed, 
the identification of tumour antigens supported the notion of the immune 
system being able to differentiate between healthy and transformed 
neighbouring cells (Klein, 1966; Yang and Yang, 2005).  
 
1.1.1.1. Evidences of immune surveillance 
Immune surveillance is mediated by both the innate and adaptive arms of the 
immune system. Immunodeficient mice have been observed to have an 
increased carcinogen-induced tumour burden compared to their 
immunocompetent counterparts. Mice models depleted of innate NK and NKT 
cells had 2-3 times more methylcholanthrene (MCA)-induced tumour 
formation than the corresponding control mice (Smyth et al., 2001). Similar 
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results were observed in C57BL/6 mice depleted of only NK cells (Kim et al., 
2007). Several elegant studies also provided compelling evidences on the 
immune surveillance contributed by the adaptive arm of immunity. Shankaran 
et al. genetically engineered Rag2-/- and Stat1-/- mice which were deficient for 
mature B and T cells, and downstream IFN- signalling, respectively. The 
group also cross-bred the mice to generate Rag2-/-, Stat1-/- progeny. Mice that 
were Rag2-/-, Stat1-/- were highly susceptible to MCA-induced tumourigenesis  
as 13 out of 18 mice developed tumours while this was seen in only 11 out of 
57 wild-type mice. Mice that were either Rag2-/- or Stat1-/- had similar tumour 
incidence as Rag2-/-, Stat1-/- mice, suggesting that B cells, T cells, and/or IFN-
 signalling are equally important in suppressing tumour development 
(Shankaran et al., 2001). Further, Girardi et al. confirmed the significance of 
functional T cells as TCR- knockout mice, which lack functional T cells, 
were highly susceptible to DMBA-induced and TPA-induced carcinogenesis 
(Girardi et al., 2001).  
Epidemiological studies also support the prevalence of immune surveillance 
in humans. Follow-up studies of transplant patients who were 
immunosuppressed or those with primary immunodeficiency demonstrated 
heightened preposition to development of cancer (Gatti and Good, 1971). 
Additionally, histopathological observation of human tumours provided clear 
indication of the presence of tumour infiltrating lymphocytes (TILs) and other 
immune cells in the tumour microenvironment (Busam et al., 2001; Holmes, 
1985). Although certain immune cells in the microenvironment may be pro-
tumour in nature, such as IL-10 and TGF- producing tumour-associated 
macrophages (TAMs) and regulatory T cells (Tregs), there is a positive 
correlation between the presence of high-density tumour-specific CD8+ T cells 
with good prognosis in various types of cancer such as colon cancer, lung 
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carcinoma, breast cancer and malignant melanoma (Haanen et al., 2006; 
Kawai et al., 2008; Naito et al., 1998; Yoshimoto et al., 1993). Again, the 
importance of CD8+ T cells was highlighted by Pages and colleagues in a 
study on colorectal cancer. Patients with large mass of effector CD8+ 
cytotoxic T lymphocytes (CTLs) together with effector CD4+ T helper 1 (Th1) 
cells in the tumour corresponded to lack of metastasis and protection against 
tumour recurrence (Pages et al., 2005). However, in certain patients with high 
numbers of infiltrating lymphocytes, metastasis was still prevalent. 
Comprehensive phenotyping of TILs in a large cohort of patients revealed that 
protective T cells have a memory phenotype (CD3+CD45RO+) while 
metastatic patients generally lack these memory T cells (Camus et al., 2009). 
Therefore, both quantity (density) and quality (phenotype) of the tumour 
infiltrating T cells govern the overall tumourigenesis and possibly the outcome 
of the disease. Collectively, increasing data obtained from murine and human 
studies provide strong evidence for the existence of cancer 
immunosurveillance. 
 
1.1.1.2. TILs and the tumour microenvironment 
The abovementioned clearly illustrates the involvement of the immune system 
in the control of tumourigenesis. While different types of immune cells do 
infiltrate the tumour microenvironment, the key effector contributors have 
been described to be the NK cells and cytotoxic CD8+ T cells. These two 
cellular subsets were initially designated as front line soldiers during infection 
and instigate the demise of infected cells; e.g. intracellular bacteria or virus 
infected cells (Sun and Lanier, 2011). Further investigation showed that these 
NK cells and CD8+ T cells also display anti-tumour capabilities by directly 
exerting cytotoxic killing effects onto tumour cells, in both in vitro and in vivo 
situations in murine systems and this also occurs in humans (Budhu et al., 
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2010; Kang et al., 2013; Koshy et al., 2013; Liddy et al., 2012). Even though 
many of these experiments performed required an additional adjuvant such 
as coating antigenic peptides onto tumours or redirecting tumour-specific 
CD8+ T cells into the local tumour environment to instil clinical effects, there is 
no denying the tumour-suppressing potential of these immune effector cells.  
Then why do malignancies still occur despite the existence of these defensive 
mechanisms? First and foremost, in hosts with spontaneously arising 
tumours, anti-tumour effector T cells by themselves are few and far between, 
and those that do arise are functionally incompetent thus reducing their ability 
to destroy tumour targets. Secondly, the tumour microenvironment is, 
unfortunately, a complex system encompassing inflammatory cells, that are 
both tumour-antagonising and tumour-promoting (Hanahan and Weinberg, 
2011). Cells such as mast cells, neutrophils, B cells and M2-like 
macrophages (i.e. TAMs) are several tumour-promoting inflammatory cells 
that are often associated with neoplastic tissues lesions (Coffelt et al., 2010; 
DeNardo et al., 2010; Egeblad et al., 2010). Such infiltration of tumour-
promoting cells leads to chronic inflammation and also to the release of 
epidermal growth factors (EGF), vascular endothelial growth factor (VEGF), 
matrix metalloproteinase-9 (MMP-9), among others, all of which facilitate 
tumourigenesis  (Qian and Pollard, 2010).  
More critically, a certain class of myeloid-derived cells in the tumour proximity 
has been regarded as direct inhibitors of tumour-antagonising NK cell and 
cytotoxic CD8+ T cells. These myeloid-derived suppressor cells (MDSCs) are 
able to induce immune tolerance via direct and indirect means. An avenue of 
direct inhibition is to produce ROS and peroxynitrite which inhibits CD8+ T 
cells by preventing T-cell-tumour interaction (Nagaraj et al., 2007). Secretion 
of immunosuppressive cytokines such as IL-10 and TGF- act directly to 
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reduce the functions of anti-tumour CD4+ Th cells and can also induce M2 
macrophage polarization thus reducing IL-12 secretion required for Th1 
responses (Sinha et al., 2007). IFN- production by NK cells are also 
negatively regulated by MDSCs via the blockade of NK cell activation 
receptor, NKG2D. This leads to NK cell anergy (Li et al., 2009). Indirectly, 
MDSCs can also down-regulate cell-mediated immunity by anti-tumour TILs 
via the expansion of Tregs (Serafini et al., 2008).  
As a whole, coupled with the already low number of anti-tumour effector T 
cells in patients, MDSCs and other immunosuppresive cells in the tumour 
microenvironment virtually render anti-tumour T-cell response futile. 
 
1.1.1.3. Inadequate anti-tumour T-cell numbers and function are 
contributed by aberrant dendritic cells 
In order to generate a tumour-specific CD8+ and CD4+ T-cell response, 
tumour antigens need to be processed and subsequently presented to T cells 
by antigen-presenting cells (APCs). In normal physiological conditions, 
dendritic cells (DCs) are the most potent APC and are able to activate not 
only memory but also resting naive T cells, and are thereby critical 
components required for efficient mounting of an immune response. On the 
contrary, DCs in cancer patients are usually numerically infrequent, 
functionally aberrant and are not able to instigate efficient activation of 
tumour-specific effector T cells (Gabrilovich, 2004).  
Many early studies have observed a low total number of functionally 
competent DCs in cancer patients such as those with head and neck 
squamous-cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC) 
and breast cancer (Almand et al., 2000; Della Bella et al., 2003; Wojas et al., 
2004). Indeed, patients with early stage HNSCC had 2-folds lower amount of 
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DCs in their peripheral blood as compared to control healthy donors while 
further reduction of up to 4-folds was present in advanced tumour patients 
(Almand et al., 2000). Seemingly, the presence of larger tumours correlated 
with curtailed overall DCs as the surgical removal of tumours reconstituted 
the number of peripheral blood DCs (Hoffmann et al., 2002; Wojas et al., 
2004). This is suggestive of a direct influence of tumours onto DC 
homeostasis. Overall, the repercussion of a reduced number of functional 
DCs is that anti-tumour T cells are not adequately stimulated and mobilised, 
leading to a progressing in tumourigenesis.  
To initiate a DC response, apoptotic bodies or soluble antigens are engulfed, 
and this is followed by their activation (and therefore maturation) and 
migration to the secondary lymphoid organs where interaction with peripheral 
T cells occurs. Proper activation of DCs is an integral requirement as it arms 
DCs with co-stimulatory molecules such as CD80, CD86 and MHC class II, 
all of which provide necessary signals for adequate T-cell activation (Skalova 
et al., 2010). Nevertheless, on top of the sparse amount of DCs in tumours of 
cancer patients, DCs are usually phenotypically immature. No or low levels of 
CD80 and CD86 were previously detected in tumour-bearing DCs of patients 
with renal-cell carcinoma or prostate cancer (Troy et al., 1998a; Troy et al., 
1998b). In basal-cell carcinoma (BCC), about 10 % of peritumoral DCs were 
either CD80 or CD86 positive and this value dropped to 1 % of intratumoral 
DCs (Nestle et al., 1997). Efforts to mature tumour-infiltrating DCs in rat 
models proved to be futile since the addition of exogenous GM-CSF and TNF 
or CD40L during in vitro cultures were not able to potentiate expression of 
either CD80 or CD86 (Chaux et al., 1997). This suggests that defective 
development of DCs starts from their precursors, rather than simply the 
antagonistic effect of immunosuppressive tumour microenvironment 
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contributing towards biologically abnormal DCs. Nevertheless, one cannot 
discount the immunosuppressive contribution by tumours as they are able to 
secrete anti-inflammatory cytokines such as IL-10 and TGF- that recondition 
DCs and render them tolerogenic (Koido et al., 2010). Together, the lack of 
co-stimulatory molecule expression by DCs and their inability to be activated 
has detrimental consequences towards the initiation of an anti-tumour 
humoral and cell-mediated immunity. For instance, DCs isolated from colon 
cancer tissues and melanoma were not able to evoke potent T-cell 
proliferation and furthermore, primed T cells were anergic or induction of 
tolerance had occurred (Bonifaz et al., 2002; Chaux et al., 1997; Enk et al., 
1997).  
Another avenue utilised by tumours to induce DC dysregulation is through 
the means of inhibiting differentiation of immature myeloid cells (iMCs) into 
DCs by secreting tumour-promoting factors such as VEGF (Saito et al., 
1998). In certain tumour-bearing individuals with lung or breast cancer, 
CD33+ iMCs accumulate in peripheral blood in tandem with the decrease in 
DCs (Almand et al., 2000). These iMCs not only fail to differentiate into DCs 
but are by themselves immunosuppressive. Using an influenza-derived 
peptide model, iMCs were shown to inhibit IFN- production by peptide-
specific CD8+ T cells (Almand et al., 2001). Another study described a 
reduction in CD3 chain expression in T cells (CD3 is essential for the 
induction of intracellular signal-transduction pathways) in the presence of 
iMCs (Schmielau and Finn, 2001). 
Collectively, aberrant DC development in cancer patients is predominant and 




1.1.2. Harnessing anti-tumour T-cell mediated defence mechanism for 
immunotherapy 
The failure to reject tumours by CTLs is attributed to immunosuppression and 
tolerance mechanisms such as the malfunction of DCs as previously 
described. A method to circumvent this effect would be to introduce a more 
vigorous CTL response (Melief and van der Burg, 2008). Various approaches 
are currently being used as immunotherapy tools to augment this reaction 
and these include T-cell adoptive transfer and DC-based vaccines. The 
former approach involves the isolation, ex vivo expansion and reinfusion of 
tumour-reactive T cells into patients. As previously noted, T cells have the 
ability to target and destroy tumours, however, such anti-tumour effects are 
more often than not dampen by the immunosuppressive tumour environment 
and also inefficient DC activation. Thus, the isolation of T cells from the 
tumour environment allows for their enrichment a more conducive ex vivo 
setting. Once a favourable number of tumour-specific T cells has been 
achieved, they can be infused back into the patient in combination with a 
lymphodepleting preparative regimen to deplete T cells and B cells (Restifo et 
al., 2012). This form of immunotherapy has been done with relative success 
in melanoma patients (Dudley, 2011; Rosenberg et al., 2011). 
While adoptive T-cell therapy employs direct reconstitution of large numbers 
of antigen-specific T cells back into the patient, DC-based vaccines utilise the 
body’s ability to mount their own T-cell-mediated response. DCs in cancer 
patients, especially those in late-stage disease, are systemically deregulated 
and may not be able to mount adequate T-cell responses. Thus, avenues 
such as to manipulate DC function, activation and antigen presentation are 
being studied to enhance the capacity of DC-induced T-cell activation which 
will enable a more sustainable and potent anti-tumour response. Currently, 
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three main approaches are being used as DC-based vaccines; (1) Non-
targeted vaccines, (2) in vivo DC targeting and (3) vaccination using ex-vivo 
generated DC. Ongoing research and clinical trials on DC-based vaccines will 
be later discussed in section 1.3.4.  
 
1.2. Dendritic cells 
1.2.1. An overview 
Dendritic cells (DCs) are key regulators of the immune system and their 
physiological properties allow them to serve as a crucial link between the two 
arms of immunity; that is, the innate and adaptive immunity. DCs continuously 
survey their environment for soluble antigens and foreign antigens, and if 
necessary, initiate and control an array of adaptive responses (Steinman, 
1991). To do this, DCs acquire antigen material, process them and present 
the resulting peptide antigens to T cells and are therefore regarded as APCs. 
Their sheer efficiency to induce a primary immune response in resting naive T 
cells gives them the nickname of ‘professional APC’ (Steinman, 1991).  
DCs were first discovered by the late Nobel Laureate Ralph Steinman in 
1973. However, their unique role in the immune system was met with high 
scepticism. Forty years and countless discoveries later, we have gathered 
unequivocal evidence of DCs being an eminent constituent of the immune 
system; orchestrating the fine balance of immune function and regulation 
(Steinman, 2012). 
 
1.2.2. Fundamentals of dendritic cell biology 
DCs are of haematopoietic origin and are distributed widely in peripheral 
tissues. They express numerous pattern-recognition receptors (PRRs) which 
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sense danger signals via detection of pathogen-associated molecular 
patterns (PAMPs) in microbial pathogens or damage-associated molecular 
patterns (DAMPs), which are released by apoptotic or necrotic cells. 
Activation of  pattern recognition receptors (PRRs), such as toll-like receptors 
(TLRs), enables recognition of a class of pathogens and subsequently 
initiates an appropriate DC activation program (Iwasaki and Medzhitov, 2004). 
Besides, DCs are specialised to capture and process antigens in vivo, 
converting proteins into immunogenic peptides that are subsequently loaded 
onto major histocompatability complex (MHC) molecules to be presented to T 
cells (Guermonprez et al., 2002; Trombetta and Mellman, 2005). Upon 
acquisition of antigens in the periphery, tissue-resident DCs undergo 
activation and migrate to the secondary lymphoid organs such as the lymph 
nodes via afferent lymphatics where they interact with the circulating T cells to 
initiate clonal selection (Cyster, 1999; Itano and Jenkins, 2003; Randolph et 
al., 2005). Alternatively, lymph node-resident DCs can capture antigens which 
directly reach the lymph node (Itano and Jenkins, 2003). Essentially, DCs are 
able to recognise and select specific clones of naive T cells from a large 
repertoire of lymphocytes with distinct and unique antigen receptors.  
The kind of response elicited is highly dependent on the type of antigen the 
DCs acquire. Self-antigens are presented by immature DCs, which are not 
subsequently activated, and therefore lead to immune tolerance through the 
activation of Tregs or suppressor T cells (Albert et al., 1998; Heath and 
Carbone, 2001). On the other hand, uptake of foreign (non-self) antigens 
often evokes clonal expansion of both antigen-specific CD4+ Th cells and 
CD8+ CTLs, though the exact response elicited is partly dependent on the 
subset of DC presenting the antigen and the maturation signals it receives 
(Banchereau and Steinman, 1998; Pulendran, 2005; Reis e Sousa, 2006). 
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Currently, three major signals dictated by the DCs are thought to contribute to 
the regulation of T-cell responses. The first is the presentation of antigenic 
peptide moiety on MHC molecules; known as signal 1. Expression of co-
stimulatory molecules such as CD80, CD86, CD70, and OX40L are 
responsible for signal 2. Soluble factors such as cytokines secreted by DCs 
contribute to signal 3 and these factors influence the differential development 
of both CD4+ and CD8+ T cells (de Jong et al., 2005; Kalinski et al., 1999; 
Nestle et al., 1998b). Working in concert, these signals drive cell division and 
differentiation of CD4+ T cells, giving rise to polarised subsets of effector cells. 
Th1 and Th2 are the best defined subsets, characterised by their production 
of interferon- (IFN-) and interleukin-4 (IL-4), respectively (Mosmann et al., 
1986). More recently, pro-inflammatory IL-17-secreting Th17 cells, Tregs that 
can dampen effector function of other lymphocytes as well as T follicular 
helper (Tfh) cells that are specialised B cell helpers have been described as 
additional effector CD4+ T cells (Harrington et al., 2005; Lund et al., 2008). In 
addition to their influence on cell-mediated immunity, DCs are also involved in 
humoral immunity by direct contact with B cells to present unprocessed 
antigens or via Th2 and Tfh cells (Bergtold et al., 2005; Qi et al., 2006). 
Furthermore, DCs also interact with NK cells of the innate immune system 
(Fernandez et al., 1999; Lucas et al., 2007). 
 
1.2.3. Subsets of dendritic cells 
1.2.3.1. Murine dendritic cells 
DCs are heterogeneous and many subtypes have been described in mice. 
Historically, research had been done mainly on the splenic and lymphoid 
tissue DCs however, much attention is now focused on the non-lymphoid 
tissue counterparts such as skin and lung DCs (Helft et al., 2010).  
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DCs in the spleen are classified into CD8+CD11b-CD4- (CD8+ DCs), CD8-
CD11b+CD4+ (CD4+ DCs) and CD8-CD11b+CD4- (double negative DCs) 
(Vremec et al., 2000). The double negative DCs also predominate in the 
lymph node while Langerhans cells (LCs) predominate in the skin (Henri et 
al., 2001). In the non-lymphoid tissue, DCs are broadly divided into CD103+ 
and CD11b+ DCs while in the lamina propria, an additional subset, 
CD103+CD11b+ double positive DCs, is found (Bogunovic et al., 2009; 
Ginhoux et al., 2009). CD103+ DCs have been described as the non-lymphoid 
tissue counterpart of lymphoid tissue CD8+ DCs, in which both subsets are 
specialised in cross-presentation; a feature whereby exogeneous antigens 
are processed and presented onto MHC class I (Ginhoux et al., 2009). Other 
subsets found in mice include plasmacytoid DCs (pDCs) and inflammatory 
DCs which are characterised by MHC-II+CD11cloCD4+ and MHC-II+CD11cint 
CD11b+ phenotypes respectively. 
 
1.2.3.2. Human dendritic cells 
Human DCs can be broadly divided into lymphoid- or myeloid-derived DCs. 
The former consist of pDCs which are defined by the surface expression of 
CD303 (aka BDCA2), CD304, ILT7 and CD123 (Colonna et al., 2004; 
Dzionek et al., 2000). While resting pDCs are involved in tolerance, their 
activation in response to viral infection, induces the production of type I 
interferon and their large stores of MHC class I molecules suggest a 
subsequent rapid CD8+ T-cell response (Di Pucchio et al., 2008; Liu, 2005; 
Siegal et al., 1999). Thus, pDCs have been suggested to be involved in front-
line anti-viral defence. 
Myeloid-derived DCs are predominant and are widely distributed throughout 
the body. These DCs are generally categorised as CD141+ DCs, CD1c+ DCs 
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or CD14+ DCs. Myeloid CD141+ DCs and CD1c+ DCs are found in lymphoid 
tissues, non-lymphoid tissues and blood. In non-lymphoid tissues, CD141+ 
DCs express high levels of CD141 and are designated as CD141hiCD14-
CD11bloCD11clo (Haniffa et al., 2012). These DCs are regarded as the 
homologues of CD8+ DCs in mice as both subsets have a high capacity to 
cross-present antigens and activate naive CD8+ T cells in vitro (Bachem et 
al., 2010). CD1c+ subset DCs are also defined by the expression of CD11c, 
CD13, CD33 and CD172 (MacDonald et al., 2002; Mittag et al., 2011). These 
DCs constitute about 1 % of mononuclear cells in the blood, and in non-
lymphoid tissues they are the main DC subset during steady-state. CD14+ 
DCs are the third subset and are found only in tissues (lymphoid and non-
lymphoid) but not in the blood. These dermal DCs are involved in humoral 
responses and can induce antibody-secreting B-cell differentiation as well as 
naive T cells to Tfh cells (Klechevsky et al., 2008; Matthews et al., 2012). 
Intriguingly, CD14+ DCs are functionally and phenotypically intermediate of 
DCs and monocytes/macrophages and this population has been described to 
be recapitulated by peripheral blood CD14+ monocytes (Chu et al., 2012; 
Penel-Sotirakis et al., 2012). Together, CD1c+ DCs and CD14+ DCs are the 
two main DC subsets located in the dermal region of the skin and this is in 
addition to epidermal LCs (Nestle et al., 1993).  
The abovementioned DCs are present in steady-state during normal 
physiological conditions. Inflammatory DCs, on the other hand, only appear 
during inflammation or upon microbial insult and are considered as non-
conventional DCs, (Liu and Nussenzweig, 2010). An example of such DCs 
are the TNF and iNOS-producing Tip-DCs which are phenotypically CD14-
CD1c- (Zaba et al., 2009). During inflammation or infection, the population of 
inflammatory DCs is substantially heightened within a short time-frame and 
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this is thought to be contributed by peripheral blood monocytes which have 
been shown in mice to be able to differentiate into inflammatory-like DCs in 
vivo (Cheong et al., 2010). Nevertheless, their origin and potential role in 
inflammation are still unclear and are currently being investigated. 
 
1.2.4. Monocyte-derived dendritic cells for DC-based immunotherapy 
Monocyte-derived DCs (moDCs) are also designated as non-conventional 
DCs given the fact that they do not give rise to resident DCs in various 
lymphoid and non-lymphoid tissues in physiological steady-states (Liu and 
Nussenzweig, 2010). Owing to favourable factors, this subset of cells is 
considered ideal for DC-based immunotherapy. Human peripheral blood 
monocytes can be easily acquired by leukapheresis in large amounts and 
hence can be a useful source for generating DCs for use in vaccines (Wolf et 
al., 2005). Biologically, monocytes can be easily differentiated into immature 
DCs simply by the addition of exogeneous GM-CSF plus IL-4 (Banchereau et 
al., 2000). The resulting moDCs are highly phagocytic and therefore are able 
to take up soluble antigens and migrate to the draining lymph nodes. More 
importantly, this DC subset can be easily activated and matured by using 
various combinations of TLR-agonist and/or cytokine cocktails thereby 
improving subsequent T-cell activation (Rissoan et al., 1999). These 
characteristics are key factors that make moDCs an attractive tool for DC-
based vaccine therapy. In the next section, we will discuss the use of such 






1.3. Cancer immunotherapy 
1.3.1. An overview 
Immunotherapy utilises the immune system to mount a response as a 
treatment against cancer. Immunotherapeutic protocols can be applied 
individually but are often used in combination with traditional treatments such 
as chemotherapy and radiotherapy. An array of strategies is currently being 
implemented to harness and evoke specific immune responses and these 
include the use on immunomodulatory antibodies, adoptive cell transfer and 
cellular vaccines (Alatrash et al., 2013). Although much will be reviewed on 
the current understanding and development of DC-based cellular vaccines, 
immunomodulatory antibodies and adoptive cell transfer approaches may be 
applied in parallel with cellular vaccines and will therefore be briefly 
discussed. 
 
1.3.2. Immunomodulatory antibodies 
Antibody-based anti-cancer therapy has been used to relative success in a 
number of clinical trials and there are currently 13 FDA-approved antibodies 
for various oncological applications (Sliwkowski and Mellman, 2013). Recent 
developments have allowed the generation of humanised monoclonal-
antibodies (mAbs) that are non-immunogenic in humans and this has 
propelled wide spread clinical-based research to be endowed upon (Clynes, 
2006).  
Antibodies can function to kill tumour cells in a variety of mechanisms and are 
broadly divided into two groups; (1) direct tumour cell killing and (2) immune 
mediated tumour cell killing (Scott et al., 2012). In the former, agonistic 
antibodies can directly bind to certain tumour-associated receptors therefore 
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leading to activation and downstream proapoptotic mechanism. Examples of 
mAbs associated with this mechanism are Rituximab and Alemtuzumab 
which interact with CD20 and CD52, respectively in B cell leukaemia (Weiner, 
2010). Other mAb such as 90Y-labelled ibritumomab tiuxetan can deliver 
targeted radioisotopes to CD20+ non-Hodgkin lymphoma and induce direct 
the demise of tumour cells (Cheson and Leonard, 2008).  
Immune mediated tumour cell killing, as the name suggests, requires the 
association with various types of immune effector cells. Depending on the 
approach taken, T cells, macrophages, NK cells and complement pathway, 
amongst many others, are involved in this process. For instance, agonistic 
anti-CD137 mAb are able to co-stimulate T cells and demonstrate an anti-
tumour efficacy in phase I clinical trials in melanoma patients (Molckovsky 
and Siu, 2008). Other mAbs bind to tumour antigens which lead to 
opsonisation and subsequent phagocytosis by macrophages or induction of 
complement pathways (Scott et al., 2012). MAbs that function as checkpoint 
blockade are also being actively studied in clinical trials. CTLA-4 is a negative 
regulator on T cells and acts as a checkpoint to prevent overstimulation. 
Thus, using antagonistic anti-CTLA-4 mAb such as tremelimumab or 
ipilimumab serves to ignore this checkpoint, allowing for prolonged T-cell 
activation (Hodi et al., 2010). The success of using this strategy has brought 
about further interest in developing mAb for checkpoint blockade. For 
example, PD-1 is expressed on activated T cells and upon engagement by its 
ligand, PDL-1 on APCs, induces apoptosis. Early clinical trials on PD-1 
blockade have shown promising responses in patients with melanoma, 





1.3.3. Adoptive cell transfer 
The first report describing the use of adoptive cell transfer (ACT) was in 1988 
in which Rosenberg and colleagues demonstrated the regression of tumours 
using TILs for immunotherapy on patients with metastatic melanoma 
(Rosenberg et al., 1988). Since then, much research has been undertaken to 
optimise various protocols and strategies in order to boost clinical efficacy.  
ACT requires the identification of tumour-reactive TILs in excised tumour 
mass, ex vivo expansion, followed by reinfusion of large number of cloned 
TILs back into the cancer patient. Being an ex vivo procedure, it has the 
advantage of being able to be pre-selected for tumour-specific T cells (both 
CD8+ and CD4+) with high avidity and expanded in an environment free from 
immunosuppressive factors (Morgan et al., 2006). A recent completed phase 
II clinical trial (NCT00314106) on metastatic melanoma showed clinical 
benefits when lymphodepletion prior to autologous TIL transfer plus IL-2 
treatment was administered to patients refractory to standard therapies 
(Dudley et al., 2008).  
Activation of T cells is MHC-restricted and is therefore logistically laborious for 
large-scale therapy. To alleviate this drawback, T cells are being engineered 
to express chimeric antigen receptors (CARs) whose activation is not MHC-
restricted but dependent on direct interaction with tumour antigens. CARs 
consist of an extracellular domain that recognise antigens and an intracellular 
co-stimulation activator domain such as those of CD28 and CD137 origin 
(Zhang et al., 2013). Such engineered T cells are currently in clinical trials as 
an alternative to autologous natural T-cell ACT. Other lymphocytes that are 




1.3.4. Dendritic cell-based immunotherapy 
1.3.4.1. An overview 
As earlier mentioned, DCs are crucial mediators that initiate the adaptive arm 
of immunity including the activation of antigen-specific naive T cells. Their 
properties have prompted DCs to be designated a natural adjuvant for 
antigen delivery and aptly enough, are currently being exploited as an 
immunotherapeutic tool. A quick search on clinicaltrials.gov generated 289 
clinical trial studies (as of 15th December 2013) that have been or are 
currently being undertaken, and this clearly indicates the keen interest in the 
pursue of DC-based vaccines. Presently, there are three main regimens for 
DC-based vaccines. The first two groups exploits endogeneous DCs; (1) non-
targeted vaccines and (2) in vivo DC targeting vaccines, while (3) ex vivo 
generated DC vaccines, as the name suggest, requires DCs to be generated 
in a laboratory setting. Emphasis will be subjected to the latter mode of 





Figure 1. Overview of ex vivo dendritic cell vaccine protocol. 
 
 
1.3.4.2. Conventional vaccination 
Conceptually, conventional vaccinations are non-targeted and focus on 
loading endogenous DCs with antigens, or by manipulating certain aspects of 
tumours or the immune system to improve DC efficacy. 
Early development using tumour-derived peptide antigens were focused on 
eliciting CD8+ T cells using short 8-9 amino acid (aa) sequences (Boon et al., 
2006). Although it was successful in propagating the effector T cells, the lack 
of CD4+ Th1 response meant that using such peptides was not optimal to 
bring about potent CTL and associated memory cell responses (Filipazzi et 
al., 2012). Longer peptides that contains multiple epitopes that can activate 
both CD4+ and CD8+ T cells are the current mainstay and have been shown 
to be clinically effective in patients with high-grade vulvar intraepithelial 
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neoplasia (Kenter et al., 2009). More personalised protocols are also 
presently being explored whereby instead of using a pre-existing marker for a 
certain tumour, peptides representing antigens from an individuals’ tumour 
are used as vaccines. 
Other avenues of non-targeted vaccines encompass the usage of viral 
entities. Oncolytic viruses that preferentially infect tumour cells and destroy 
them can be modified to express GM-CSF in the hosts. This growth factor will 
in turn congregate DCs to the tumour microenvironment thereby increasing 
the likelihood of antigen uptake ensuing T-cell activation in the lymph nodes 
(Russell et al., 2012). Caution has to be taken as the tumour 
microenvironment is bathed in anti-inflammatory factors and therefore a 
parallel regime to reduce the immunosuppressive effects is often required. 
Additionally, addition of adjuvants to mature and polarise in vivo DCs are also 
necessary.  
 
1.3.4.3. In vivo dendritic cell targeting 
An array of surface proteins are expressed specifically on DCs and by 
targeting these markers, antibodies conjugated with tumour antigens can be 
delivered directly to the DCs. One of the pioneering investigation was to 
target DEC205+ DCs in vivo (Hawiger et al., 2001). However, antigen-specific 
tolerance prevailed thus suggesting the need to administer DC maturation 
agonists such as those activating TLR3 or CD40. Indeed, the presence of 
such adjuvants skewed the response towards a more potent anti-tumour 
CD4+ T-cell and CD8+ CTL activation when CLEC9A was targeted using 
antibody-tumour antigen conjugate (Joffre et al., 2010). Alternative DC 
markers that can be targeted are DC-SIGN and CD40, as recent evidence 
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has suggested that targeting the latter leads to efficient cross-presentation 
correlating to strong CD8+ T-cell responses (Chatterjee et al., 2012). 
It is therefore apparent that the desired anti-tumour T-cell response can be 
predominantly acquired if the right DC-specific marker is targeted together 
with the addition of an ideal adjuvant. However, further appreciation of 
endogenous DC subsets in humans to determine the best candidate DCs to 
be targeted is required to further refine the clinical efficacy when opting for in 
vivo DC targeting therapy.  
 
1.3.4.4. Ex vivo generated dendritic cells 
Generating DCs in a laboratory setting has its benefits as they can be 
propagated in an immunosuppressive-free environment and grants greater 
possibility for DC manipulation (Schuler, 2010). The aim here is to cultivate 
large amount of potent DCs that can subsequently prime robust anti-tumour-
specific T cells in vivo upon their reinfusion into patients (figure 1). 
Several subsets of DCs and their precursor cells are being exploited for this 
purpose and an example are the peripheral blood pDCs. Early studies in 
metastatic-melanoma patients were promising as tumour-peptide pulsed 
pDCs were able to activate both CD4+ and CD8+ antigen-specific T cells (Tel 
et al., 2013). Alternatively, CD34+ hematopoietic progenitor cells may be 
applied as a DC precursor although their usage in clinical trials are few and 
far between owing to a more challenging production process (Ueno et al., 
2010). In 2010, Sipuleucel-T (tradename: ProvengeTM) received FDA-
approval for treatment of prostate cancer, a first of its kind for DC-based 
vaccines. Enriched blood APCs, including DCs, were exposed to a fusion 
protein of GM-CSF and prostatic acid phosphatase antigen before being 
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reinfused back into patients. Overall survival was improved by ~4 months 
(median) and the risk of death was reduced by ~25% as referenced to control 
group (Higano et al., 2009).  
Nevertheless, due to the ease for isolation and their availability in large 
quantities, CD14+ peripheral monocytes are often used as precursors to 
develop autologous ex vivo DCs. Most clinical trials employ the standard 
culture protocol using GM-CSF plus IL-4 for a period of 2-6 days to generate 
immature moDCs followed by their exposure to maturation factors such as the 
Jonuleit cocktail (TNF, IL-1, IL-6 and PGE2) to induce full DC activation 
(Erdmann and Schuler-Thurner, 2010; Jonuleit et al., 1997). This step is 
critical as different combinations of DC activating factors can determine the 
later polarisation of antigen-specific T-cell response and therefore the 
eventual clinical outcome. Next, antigens in various forms such as peptides, 
soluble proteins and whole tumour lysates, and more recently, transfection of 
mRNA encoding for defined tumour antigens are loaded into DCs to educate 
them for the desired antigen-specific T-cell response (Erdmann and Schuler-
Thurner, 2010; Van Nuffel et al., 2012).  
The convenience of utilising moDCs translated to widespread research and 
clinical trials involving this DC subset. Table 1 summarises some of the recent 
or ongoing clinical trials that involve ex vivo generated DCs. Many of these 
trials were able to show immunogenicity however, the discrepancy between 
the blood immune response and the rate of objective clinical response is all 
too obvious (Palucka and Banchereau, 2012). For instance, a study by 
Soleimani et al. on metastatic renal-cell carcinoma showed that upon 
vaccination of mature moDCs pulsed with autologous tumour lysate, specific 
T-cell sensitization was acquired as determined by the increased IFN- 
secretion and proliferation. However, none of the 14 vaccine-recipients 
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obtained complete remission (Soleimani et al., 2009). This clearly highlights 
the need for further refinement of DC-based protocols, whether in terms of 
DC generation, maturation, antigen loading or route of DC re-infusion. Also, 
combinational treatment aimed to reduce immunosuppressive effects or 
utilising DC vaccines in tandem with traditional radiotherapy and/or 
chemotherapy can be tested for their overall treatment efficacy. 
 
Table 1: Examples of clinical trials using ex vivo generated monocyte-derived DCs  
(Adapted from Palucka et al., 2012) 
Vaccine & antigen Indication Key observations Reference 
GM-CSF + IL-4 




peptides alone  
Metastatic 
prostate cancer  
 
One of the first studies that 
tested the immunogenicity 
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• Objective clinical 
responses  




Yu et al., 
2001) 
Mature GM-CSF + 
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better responses than intra-
nodal administration  
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1.3.4.5. Maturation and development of type 1, 2 and 17 dendritic cells 
DCs are immunomodulators and can not only mediate pro-inflammatory 
conditions but may also skew immune responses towards tolerance. 
Evidence has suggested that this is dependent on the activation status and 
that immature or partially-mature DCs are prone to inducing tolerance via 
expansion of both allogeneic and autologous antigen-specific Tregs (Albert et 
al., 2001; Dhodapkar et al., 2001; Jonuleit et al., 2000). On the other hand, 
DCs pre-activated with a variety of cytokines could polarise naive CD4+ T 
cells towards a predominantly Th1 phenotype while CD8+ T cells were highly 
activated as evidenced by high IFN- release (Jonuleit et al., 1997). 
Essentially, competent anti-tumour effects are synonymous with strong Th1 
and CD8+ CTL response and that has prompted a plethora of explorations to 
determine the conditions required to optimally activate DCs. IL-12 is an 
important factor secreted by DCs which has positive implications on Th1 
development (Hsieh et al., 1993). Therefore, much is being focused on 
designing maturation cocktails that can propel IL-12 production.  
The Jonuleit cocktail was one of the pioneering cocktails developed for 
maturation of human moDCs (Jonuleit et al., 1997). Despite the absence of 
IL-12 upon DC activation, it still led to a predominantly Th1 and CD8+ CTL 
response. This fully cytokine-based cocktail consists of IL-1, IL-6, TNF and 
PGE2. The first three are known pro-inflammatory cytokines while PGE2 
supports overall growth of DCs and also increases CCR7 that allows for their 
migration to the lymph node: a character that is desired in a DC-based 
vaccine (Bruckner et al., 2012). This cocktail is widely used in many clinical 
trials and although it is considered the current gold-standard, other cocktails 
are being developed to refine DC activation especially in terms to increase IL-
12 expression (Skalova et al., 2010). Kalinski and colleagues derived a 
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cocktail combining cytokines with TLR-ligands as IL-12 has been shown to 
require at least 2 ‘danger’ signals for its production. Using poly (I:C), a TLR3 
agonist, together with inflammatory cytokines IFN-, IFN-, IL-1 and TNF, 
they were able to conjure potent IL-12 production (Mailliard et al., 2004). DCs 
were fully activated based on surface marker expression and were able to 
instil potent antigen-specific CTLs. However, a drawback was a decrease in 
their migration capacity as compared to DCs matured by Jonuleit’s cocktail. 
Interestingly, a study by Zobywalski determined that although Kalinski’s 
cocktail was able to fully mature DCs, their viability was compromised leading 
to lower yields during harvesting (Zobywalski et al., 2007). His team also 
proposed that instead of using poly (I:C), the TLR7/8 agonist, R848, should 
be used as it does not hinder expression of antigens inserted through 
exogenous RNA electroporation.  
The preceding research was motivated by the desire to produced type-1 DCs 
that are expected to initiate Th1-mediated immunity, suggested to be integral 
for anti-tumour effects. Using different combinations of maturation factors, 
DCs can also be activated towards type-2 or type-17 phenotype (pro-Th2 and 
Th17, respectively), (Cintolo et al., 2012). Although classically associated with 
anti-parasitic defence and allergic reactions, Th2-mediated immunity 
stimulated by type-2 DCs may also have an anti-tumour role. It was found that 
Th2-mediated immunity initiated eosinophil influx into tumours and was able 
to clear lung metastasis of B16 melonoma in C57Bl/6 mice (Mattes et al., 
2003). This anti-tumour effect was later shown to be dependent on Th2-cell 
release of the eosinophil chemokine, eotaxin. More recently, Th17 cells were 
identified as a separate helper T-cell subset (Harrington et al., 2005). 
Differentiation of IL-17 secreting T cells is dependent on IL-23 production by 
DCs that in turn require TLR signalling via TLR2, TLR4 or TLR7/8. There is 
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currently no consensus on whether Th17 are tumour-promoting or 
antagonising as evidence supporting either argument does exists. Still, Th17 
cells demonstrated effective tumour regression in B16 melanoma mouse 
models (Muranski et al., 2008). Therefore, alternative modes of maturation 
should be carefully explored in order to exploit desired anti-tumour 
characteristics from differentially activated DCs. Instead of focusing solely on 
generating potent Th1 responses, alternative activation protocols that 
ultimately propel DCs to optimally induce widespread anti-tumour effects 
should be the key issue of future studies.  
 
1.3.4.6. Delivering immunodominant tumour antigens 
A critical but often challenging factor in designing DC-based vaccines is to 
identify effective immunogenic antigens and the approach for antigen 
delivery. Most tumour antigens are derivatives of self-antigens and may either 
be mutated or overexpressesed in tumours thus making them less 
immunogenic than non-self antigens. Therefore, an important criterion is to 
select tumour epitopes that will elicit a sufficient tumour-specific T-cell 
response.  
Currently, peptides are the main form of antigens for DC-based vaccines. 
Short peptides such as those derived from melanoma MART-1/MelanA are 
often pulsed onto DCs to successfully elicit antigen-specific CD8+ T-cell 
responses (Fay et al., 2006; Oshita et al., 2012). These 8-10 aa long peptides 
are however HLA haplotype-restricted and will only be immunogenic in the 
specific population harbouring the haplotype. Additionally, CD4+ Th 
responses cannot be elicited thus reducing synergistic effects that are 
beneficial for overall clinical efficacy. Thus, current peptide design concepts 
are being redirected towards acquiring peptides that can evoke stronger CD8+ 
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T-cell responses, and at the same time bring about sensitisation of the CD4+ 
T cells (Palucka and Banchereau, 2013). In order to heighten efficiencies in 
activating CD8+ CTLs, Chauvin and colleagues utilised long peptides (26 aa) 
of MART-1/MelanA. The peptides were also modified at position 27 (A27L) 
which is known to be an essential residue for the anchorage of peptide to 
MHC class I (Chauvin et al., 2012). The elongated peptide coupled with a 
more robust peptide-MHC interaction translated towards a favourable 
increase in CD8+ T-cell activation. Peptides that can elicit CD4+ T cells are 
also available albeit less common. However, the use of combination of 
peptides or peptides pools (usually 15-mer peptides with 11 aa overlap 
covering the entire immunodominant antigen) is an attractive option as both 
CD4+ and CD8+ T cells can be stimulated (Lachmann et al., 2012). 
Furthermore, employing peptide pools can circumvent the issue of HLA-
restriction.  
Other researchers are also exploring novel methods to present tumour 
peptides onto DCs. This includes the use of whole tumour lysates as a source 
of antigen, RNA transfection into DCs to artificially induce expression of 
immunogeneic tumour proteins and fusion of DCs with autologous tumour 
cells (Koido et al., 2013; Nair et al., 2002; Nestle et al., 1998a; Salcedo et al., 
2006).  
 
1.3.4.7. Future direction for DC-based vaccines 
Ultimately, the goal of DC-based vaccines is to instruct the immune system to 
generate an anti-tumour response. Although DCs can contribute to the innate 
arm of immunity by activating cytotoxic NK cells against tumours, the T-cell 
mediated defence is the predominant mechanism. Thus, future DC-based 
vaccines should be able to elicit (1) potent CD8+ CTLs, (2) CD4+ Th cells 
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which complement CD8+ T-cell function and (3) effector T cells that are able 
to escape from the hostile tumour microenvironment and induce the demise 
of the tumours (Palucka and Banchereau, 2013).  
At present, the conditions required to create a robust DC phenotype, capable 
of satisfying all three criteria has eluded scientists. Alternative avenues for DC 
preparation, maturation, antigen-loading and route of immunisation need to 
be thoroughly investigated. For example, two independent laboratories 
previously discovered a novel method to generate potent DCs by stimulating 
CD137 ligand signalling into peripheral monocytes (Ju et al., 2009; Kwajah 
and Schwarz, 2010). These DCs were found to be excellent activators of both 
CD4+ and CD8+ T cells in allogeneic settings. Riding upon this finding, this 
thesis will further characterise these novel DCs.   
 
1.4. CD137 receptor-ligand system 
1.4.1. Biology of CD137 
There are currently nearly 30 members of the tumour necrosis factor receptor 
super family (TNFRSF) and a member that has recently earned much 
attention is the co-stimulatory molecule CD137. This receptor is also known 
as induced by lymphocyte activation (ILA), 4-1BB and is officially designated 
as TNFRSF9. Members in this family are characterized by the cysteine-rich 
pseudo-repeats in the extracellular domain (Mallett and Barclay, 1991). 
CD137 exists in two forms; either as a type I transmembrane glycoprotein on 
cells, or as a soluble protein produced via mRNA splicing (Michel et al., 1998; 
Schwarz et al., 1993; Setareh et al., 1995). 
The initial discovery of this molecule was made more than two decades ago 
when Kwon et al. identified an activation inducible protein in murine T cells 
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and termed it 4-1BB. Its human counterpart was later independently identified 
by Schwarz et al. in activated T cells and was designated as ILA due to its 
nature of expression (Schwarz et al., 1993). CD137 is located on 
chromosome 4 and chromosome 1p36 in mice and humans, respectively 
(Kwon and Weissman, 1989; Schwarz et al., 1997). The human CD137 gene 
consists of eight exons and seven introns and encodes for a 255 aa protein 
which can exist as either a 30 kD monomer or 55 kD dimer (Kwon et al., 
1994).  
Expression of the functional glycoprotein is observed on the surface several 
immune cells including activated CD4+ and CD8+ T cells, monocytes, DCs, 
follicular DCs (FDCs), NK cells and neutrophils (Futagawa et al., 2002; Garni-
Wagner et al., 1996; Lindstedt et al., 2003; Melero et al., 1998; Pauly et al., 
2002; Pollok et al., 1993). Non-immune cells such as inflamed vascular 
endothelial cells, neurons, astrocytes, chondrocytes and microglia have also 
been reported to express membrane-bound CD137 (Curto et al., 2004; 
Drenkard et al., 2007; Olofsson et al., 2008; Reali et al., 2003; von Kempis et 
al., 1997). Furthermore, heightened CD137 expression has also been co-
related with several neoplastic pathologies such as in osteosarcoma and 
Hodgkin’s lymphoma (Ho et al., 2013; Lisignoli et al., 1998). 
 
1.4.1.1. Biological activities of CD137 
The bulk knowledge pertaining to the functions of CD137 has been 
deciphered from studies performed in T cells. Expression of CD137 on T cells 
is strictly activation dependent and is not found on resting T cells 
(DeBenedette et al., 1995; Wilcox et al., 2002). Upon cross-linkage of CD137 
by either its natural ligand or by agonist anti-CD137 antibody, the activity of T 
cells, especially the CD8+ population, is highly potentiated. Signalling through 
 30 
 
CD137 induces T-cell proliferation and production of pro-inflammatory 
cytokines (Alderson et al., 1994; DeBenedette et al., 1995; Pollok et al., 
1993). CD137 acts independently of the CD28-B7 co-stimulatory system as 
the latter functions to initiate T-cell activation while the former drives T-cell 
maintenance and viability via inhibition of activation-induced cell death (AICD) 
and upregulation of anti-apoptotic protein Bcl-XL (Laderach et al., 2002; 
Starck et al., 2005).  
Due to its potent T-cell co-stimulatory potential, in vivo activation of T cells 
using agonist anti-CD137 antibody was proposed to be able to elicit a strong 
anti-tumour T-cell reaction. Indeed, the antibody treatment was able to 
supplement the anti-tumour T-cell response to an extent whereby established 
carcinoma and melanoma were rejected in animal models (Melero et al., 
1998). Such was the potency that humanised agonist antibodies are currently 
being developed for cancer immunotherapy. 
Besides T cells, DCs also express surface CD137. Studies by Futugawa et al. 
and Wilcox et al. showed that triggering CD137 lead to the upregulation of 
inflammatory cytokines IL-6 and IL-12 and also increased CD80 and CD86 
expression, thus essentially priming these cells (Futagawa et al., 2002; 
Wilcox et al., 2002). Not only does triggering CD137 on DCs lead to a more 
potent immune response, but its mere presence on splenic DCs is essential 
for their survival. DCs from CD137 knockout mice were virtually devoid of 
anti-apoptotic proteins Bcl-2 and Bcl-XL thus making them prone to apoptosis 
(Choi et al., 2009). Non-immune cells such as epithelial and endothelial cells 
also expresses CD137 and its ligation boosts cytokine and chemokine 
secretion that ultimately enhances leucocytes infiltration (Quek et al., 2010; 




1.4.2. Biology of CD137 ligand 
CD137 interacts with its ligand, CD137L, which is expressed as a type II 
membrane glycoprotein on the surface of APCs such as monocytes, 
macrophages, B cells and DCs (Ju et al., 2003; Jung et al., 2004; Kim et al., 
2002; Laderach et al., 2003; Lee et al., 2003; Pollok et al., 1994). This 
member of the TNF superfamily has its gene located on chromosome 
19p13.3 and 17 in man and mouse, respectively. The gene contains three 
exons and two introns and the translated human CD137L polypeptide 
contains 254 aa with a molecular weight of 34kD (Alderson et al., 1994; 
Armitage, 1994; Goodwin et al., 1993). As with all members of the TNF 
superfamily, CD137L protein harbours a TNF domain which is structurally 
comparable to that of lymphotoxin (LT)-alpha and TNF. In its activated form, 
CD137L is arranged as homotrimeric or oligimeric aggregates on cellular 
surface membranes (Rabu et al., 2005; Won et al., 2010).  
A peculiar aspect of CD137L is its low degree of sequence homology (15-
20%) with other members of the TNF superfamily (Compaan and Hymowitz, 
2006). In a study by Won et al., they discovered that human CD137L has 
structural features that are distinct from other TNF ligands. The trimerised 
form resembles a three-bladed propeller feature which is unique amongst the 
TNF superfamily (Won et al., 2010). Additionally, CD137L is able to physically 
associate with several TLRs including TLR4 to maintain long-term LPS-
induced TNF release in murine macrophages, and this is independent of 
CD137 receptor binding (Kang et al., 2007; Ma et al., 2013). Similarly, 





1.4.3. Bidirectional signalling in CD137-CD137L system 
An interesting aspect of CD137L biology is its ability to not only interact and 
activate its receptor, but also signal via its cytoplasmic domain (figure 2). 
Although rare, this phenomenon of bidirectional signalling has been 
previously observed in other members of the TNF receptor-ligand superfamily 
such as TNF, CD40 ligand, CD95 ligand, OX40 ligand and CD30 ligand. 
Downstream signal transduction of the ligand is known as reverse signalling 
and an advantage of such two-way signalling is that it allows for efficient 
communication and cross-talk between two sets of cells. And since the 
members of TNF-TNFR superfamily are predominantly found in immune cells, 
this possibly translates to more effective fine-tuning of the immune response 
(Eissner et al., 2004). Indeed, CD137-CD137L bidirectional signalling 
cascade occurs during T-cell activation and due to the temporal-dependent 
increase in their expression, CD137 receptor-ligand system likely provides 
late-acting signals that allow for the survival of activated T cells. This in turn 
provides an overall sustained immune response (Croft, 2003). 
 
 
Figure 2. Bidirectional signal transduction and reverse signalling in the 
CD137 receptor-ligand system. Crosslinking of CD137 and CD137 ligand 




1.4.4. Reverse signalling 
As CD137 is found on activated T cells, it comes as no surprise that CD137L 
is mainly expressed on APCs such as monocytes and DCs. Besides, CD137L 
is also expressed on hematopoietic stem and progenitor cells (HSPCs) and 
reverse signalling in these cells has been shown to greatly impact 
myelopoiesis, details of which are beyond the scope of this thesis (Tang et 
al., 2013). In this section, we will discuss the current views of CD137L reverse 
signalling in DCs and monocytes. 
 
1.4.4.1. Reverse signalling in dendritic cells 
DCs are the most potent professional APCs with the capacity to stimulate 
both memory and naive T cells (Banchereau and Steinman, 1998; Mellman 
and Steinman, 2001). Upon activation, T cells express high levels of surface 
CD137 within 24 h which interacts with its ligand on DCs initiating a 
bidirectional signalling cascade. (Alderson et al., 1994; Hurtado et al., 1995; 
Pollok et al., 1993). 
CD137L is expressed at low levels on human moDCs, CD34+ hematopoietic 
progenitor cell (HPC)-derived DCs and also on murine DCs. Its expression is 
strongly enhanced in the presence of inflammatory stimuli such as LPS, 
double-stranded viral RNA, CD40L and also soluble factors such as TNF and 
IL-1 (Diehl et al., 2002; Laderach et al., 2003; Lee et al., 2003). The fact that 
the expression of both CD137 on T cells and CD137 ligand on DCs is 
enhanced upon initiation of an adaptive immune response indicates the 
importance of this receptor-ligand interaction for the development of T-cell 
mediated immunity. Studies have shown that reverse CD137L signalling in 
DCs, elicited by recombinant CD137 protein, induces TNF secretion which in 
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turn functions in an autocrine manner to mature DCs as evidenced by the 
increase in CD83, CD86 and HLA-DR expression (Lippert et al., 2008). 
Chemokine receptors such as CXCL4 and CCR7, which coordinate DC 
migration, are also upregulated upon reverse CD137L signalling (Lippert et 
al., 2008; Van Gool et al., 1996). More importantly, these CD137L-matured 
DCs are functionally more potent and are able to induce a stronger Th1 
response in autologous T cells than classical DCs as shown by high IFN- 
and IL-12p70 secretion (Lippert et al., 2008).  
 
1.4.4.2. Reverse signalling in monocytes 
Cross-linking of CD137L on human peripheral monocytes leads to activation 
as observed by enhanced adherence, morphological changes and production 
of pro-inflammatory cytokines such as TNF, IL-6 and CXCL8 (Langstein et al., 
2000; Langstein et al., 1998; Sollner et al., 2007). Concurrently, secretion of 
anti-inflammatory IL-10 is downregulated (Langstein et al., 1998). Further, the 
growth factor M-CSF (CSF-1) is induced by CD137L signalling and autocrine 
intake of this cytokine is essential for prolonging survival and proliferation of 
monocytes (Langstein et al., 1999; Langstein and Schwarz, 1999).  
Additionally, CD137L activation on monocytes seems to have a role in 
promoting extravasation. In a pro-inflammatory environment, endothelial cells 
increase expression of CD137 and interact with circulating monocytes. Quek 
et al. demonstrated that CD137 on activated endothelial cells enhances 
intercellular adhesion molecule-1 (ICAM-1) and lymphocyte function-
associated antigen (LFA-1) mediated adhesion of monocytes and therefore 
supports a role of CD137-CD137L in the recruitment of monocytes into 
inflammatory tissues (Quek et al., 2010). 
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More recently, our laboratory demonstrated that CD137L signalling can 
influence the differentiation of human monocytes to become cells with DC 
characteristics including enhanced CD83 and CD86 expression (Kwajah and 
Schwarz, 2010). At the same time, these findings were also corroborated by 
another independent group (Ju et al., 2009). Monocytes treated with 
recombinant CD137 protein or with agonistic anti-CD137L antibody plus IL-4 
for a minimum of four days gained the capacity to stimulate allogeneic T cells, 
preferentially towards an inflammatory phenotype as apparent by the 
presence of IFN-, in both CD4+ and CD8+ T cells, and IL-17 together with the 
reduction of IL-4 (Ju et al., 2009; Kwajah et al., 2011; Kwajah and Schwarz, 
2010). Moreover, these CD137L-stimulated DCs (CD137L-DCs) inhibit Treg 
development as the expression of the Treg-specific transcription factor, 
Foxp3, is reduced (Kwajah and Schwarz, 2010). Even more intriguing was the 
heightened effectiveness of these CD137L-DCs when compared to classical 
DC (generated by GM-CSF plus IL-4). Allogeneic T cells co-cultured with 
CD137L-DCs were more effective in a MLR compared to classical DCs 
matured by LPS plus IFN- or by TNF. Altogether, CD137L-DCs are able to 
mount a potent pro-inflammatory response suggesting their potential use for 
immunotherapy.  
Although CD137L-DCs promote adaptive inflammatory responses, this 
activity is evident only after four days of treatment with CD137-Fc protein. 
During the initial stages, CD137L-signaling into monocytes actually induces 
T-cell apoptosis instead of promoting T-cell proliferation (Kwajah et al., 2011; 
Michel et al., 1999; Schwarz et al., 1996). A recent study showed that the 
interaction of CD137-Fc-treated monocytes with T cells initiates ROS 
production in the latter leading to their demise by apoptosis (Kwajah et al., 
2011). Though seemingly counterproductive for an immune response, such a 
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mechanism has been described as infection-induced T-cell attrition where 
there is a massive clearance of non-specific T cells early in an anti-pathogen 
response thereby facilitating the later expansion of antigen-specific T cells, 
and an effective anti-pathogen immune response (Bahl et al., 2006; Jiang et 
al., 2003; McNally et al., 2001). 
 
1.4.4.3. Differential species response towards CD137L reverse 
signalling 
To further characterise CD137L-DCs for immunotherapy, a study using the 
murine system as a model was undertaken (Tang et al., 2011). Similar to the 
response by human monocytes, CD137-Fc treated CD11b+Ly6G- monocytes 
displayed enhanced adhesion, morphological changes, increased proliferation 
and CD80 and CD86 expression. However, the upregulation of F4/80 and 
CD11c expression prompted the idea that these cells were both macrophage-
like and DC-like. Several differences such as increased IL-10 secretion and 
enhanced phagocytosis meant that perhaps reverse signalling induces 
different responses in different species. Critically, CD137-Fc treatment of 
murine monocytes was not able to stimulate T cells.  Also, the inability of 
CD137L reverse signalling to activate immature DCs is strong evidence that 
there is a species difference in the effects of CD137L signalling between 
human and murine monocytes (Tang et al., 2011). This discrepancy in the 
functional biology of CD137L between mouse and man prevents the 






1.5. Research scope and objectives 
The recent development of CD137L-DCs, generated by inducing CD137L 
signalling into human peripheral monocytes, is of clinical relevance as they 
can potentially be use for more efficient DC-based immunotherapy protocols. 
These novel DCs are better equipped to activate allogeneic T cells as 
evidenced by the potent induction of T-cell proliferation, high IFN- production 
in CD4+ T cells and high perforin in CD8+ CTLs (Ju et al., 2009; Kwajah and 
Schwarz, 2010). However, nothing is known about their efficiency to induce 
autologous, antigen-specific immune response. Further characterisation of 
these CD137L-DCs such as determining their ability to initiate antigen-specific 
T cells should be looked upon. These data would provide essential 
information for the use of these CD137L-DCs for future immunotherapeutics. 
Therefore, this project aims to investigate the following; 
i. Maturation factors required to further activate CD137L-DCs 
Activation by LPS plus IFN- was shown to be unable to increase 
the T-cell activating capacity of CD137L-DCs. However, certain 
aspects of maturation such as an increase in CD86 and HLA-DR 
expression were observed. Thus, this suggested that CD137L-
DCs can be further matured and activated by an optimised 
maturation cocktail.  
ii. The ability of CD137L-DCs to stimulate autologous T cells in an 
antigen-specific manner 
CD137L-DCs are potent stimulators of allogeneic T cells. This 
feature has not been tested in an autologous, antigen-specific 
setting, and it is therefore critical that it is characterised in order to 




iii. Effects of CD137L-DC-stimulated antigen-specific T cells towards 
tumour cells 
Upon re-stimulation by CD137L-DCs, the T-cell function and their 
potency has to be resolved. Hence, it is of interest to determine if 
these alternatively stimulated T cells are able to potently induce 
the demise of tumour cells.  
iv. Transcriptional profiling of CD137L-DCs 
To better understand the key elements that make CD137L-DCs 
potent APCs, transcriptional profiling can be undertaken. This may 
shed light onto the specific genes and proteins that are 
differentially regulated upon CD137L reverse signalling in 
monocytes and may be essential in the functional biology of 
CD137L-DCs.  
 
Essentially, it is anticipated that these findings will strengthen the justification 




CHAPTER 2: MATERIALS AND METHODS 
2.1. Recombinant proteins, antibodies and reagents 
Recombinant human CD137-Fc fusion protein was purchased from R&D 
Systems. It consist of an extracellular domain of the human CD137 protein 
(Leu24-Gln186) fused with a human Fc fragment from human IgG1 (Pro100-
Lys186) with a linker sequence of DIEGRMD linking the two portions. Human 
IgG1 Fc fragment was purchased from Millipore. GM-CSF, M-CSF, IL-4, TNF, 
IL-1, IL-6, IL-7, IL-15 and IFN- were purchased from Peprotech (NJ, USA) 
while IL-2 was from R&D Systems. Lipopolysaccharide (LPS) derived from 
E.coli of serotype 0111:B4 and prostaglandin E2 (PGE2) were obtained from 
Sigma-Aldrich. Resiquimod (R848), poly (I:C) and recombinant flagellin were 
purchased from Invivogen. Anti-human antibodies procured were applied to 
either flow cytometric analysis or neutralisation studies. The full list of 
antibodies employed for the project is shown in table 2.  
Table 2. List of antibodies 
Human antigen Conjugate Clone Vendor 
ALCAM (CD166) Unconjugated 105901 R&D Systems PE 3A6 eBioscience 
CCR7 APC 3D12 eBioscience 
CD137 PE 4B4-1 BD Pharmigen 
CD137L Unconjugated 41B436 AdipoGen 
CD14 PerCP-Cy5.5 61D3 eBioscience 
CD154 eFluor® 450 24-31 eBioscience PerCP-eFluor® 710 24-31 eBioscience 
CD20 APC 2H7 eBioscience 
CD3 FITC SK7 eBioscience APC SK7 eBioscience 
CD4 eFluor® 605NC OKT4 eBioscience Alexa Fluor® 700 OKT4 eBioscience 
CD70 PE 113-16 BioLegend 
CD8 APC SK-1 eBioscience 
CD80 PE 2D10.4 EBioscience 
CD83 APC HB15E EBioscience 
CD86 PE IT2.2 eBioscience 
CLEC5A APC 283834 R&D Systems 
CXCR4 PE 12G5 eBioscience 
HLA-A2 PE BB7.2 BD Pharmigen 
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HLA-ABC FITC W6/32 eBioscience 
HLA-DR eFluor® 450 L243 eBioscience 
ICAM-1 (CD54) PE HA58 eBioscience 
IFN- PE 4S.B3 eBioscience eFluor® 450 4S.B3 eBioscience 
Mouse IgG1 Unconjugated MOP-C21 Sigma-Aldrich 
OX40L (CD252) PE 11C3.1 BioLegend 
PDPN APC NZ-1.3 eBioscience 
TNF FITC MAb11 eBioscience 
 
Calcium ionophore A23187 and phorbol myristate acetate (PMA) were 
obtained from Sigma-Aldrich. CytoStim (human), an antibody-based reagent 
that functions to restimulate T cells in the presence of APCs, was obtained 
from Miltenyi Biotec. Brefeldin A was purchased from eBioscience. 
 
2.2. Protein and peptide antigens 
CMV pp65 recombinant protein and tetanus toxoid (Clostridium tetani) were 
procured from Miltenyi Biotec and Calbiochem (Merck) respectively. 
PepTivator® CMV pp65, EBV LMP2A and melanoma MelanA/MART-1 
antigen peptide pools were purchased from Miltenyi Biotec. Each peptide pool 
is composed of 15-mer sequence with 11 amino-acid overlap, covering the 
complete sequence of the human pp65 protein of CMV strain AD169 (Swiss-
Prot Acc. no. P06725), LMP2A protein of EBV strain B95-8 (Swiss-Prot Acc. 
no. P13285) and human MelanA/MART-1 protein (Swiss-Prot Acc. no. 
Q16655), respectively. Immunodominant pp65 NLVPMVATV (NLV) peptide 







2.3. Isolation of primary cells 
Human peripheral blood mononuclear cells (PBMCs) were isolated from 
either buffy coat or fresh blood of healthy donors and were prepared by Ficoll-
Paque (GE Healthcare) density gradient centrifugation. PBMCs were washed 
with PBS containing 2 mM ethylenediaminetetraacetic acid (EDTA), (PBS 2 
mM EDTA). When required, red blood cells were lysed by a lysis buffer. 
PBMCs were washed at least twice more with PBS 2 mM EDTA. PBMCs 
were either used whole or cellular subsets were subsequently isolated.  
Monocytes were isolated from prepared PBMCs by negative selection using 
the Monocyte Isolation Kit II (Miltenyi Biotec) according to manufacturer’s 
instructions. The kit consists of a cocktail of biotin-labelled antibodies against 
CD3, CD7, CD16, CD19, CD56, CD123 and glycophorin A. In brief, whole 
PBMCs were treated with the antibody cocktail and FcR blocking reagent for 
10 min followed by incubation with anti-biotin microbeads for a further 15 min. 
Treated PBMCs were then passed through a column in a strong magnetic 
field in which cells bound to the antibodies were retained while desired 
monocytes were collected as column flow-through. Isolated monocytes were 
>95 % pure based on antigenic phenotyping by CD14 staining.  
Isolation of pan T cells was performed using anti-CD3 microbeads (Miltenyi 
Biotec). After 15 min of incubation with microbeads, PBMCs were passed 
through a column in a strong magnetic field. Flow-through was discarded 
while desired cells were retained in the column and were flushed out after 
removal from the magnetic field. Isolated pan T cells were >98 % pure based 




2.4. Generation of DCs and macrophages, and maintenance of EBV-
transformed B lymphoblasts 
To generate CD137L-DCs, freshly isolated monocytes were seeded onto 6-
well polystyrene plates (Becton Dickinson) pre-coated with 10 g/ml of 
CD137-Fc protein, in RPMI-1640 supplemented with 10 % FBS, 50 g/ml 
streptomycin and 50 IU/ml penicillin (R10 PS media) for 7-8 days. Final 
density was 106/ml. When further maturation with various maturation cocktails 
was performed, this was done during the final 18 h of incubation.  
Classical DCs were generated by culturing monocytes at a density of 106/ml 
in R10 PS media in the presence of GM-CSF (80 ng/ml) and IL-4 (100 ng/ml) 
for a total of 7-8 days on 12-well polystyrene plates. Fresh media was added 
on day 3. For the last 18 h, cells were matured with either LPS (1 g/ml) plus 
IFN- (50 g/ml) or with TNF (10 ng/ml), IL-1 (10 ng/ml), IL-6 (10 ng/ml) and 
PGE2 (1 g/ml).  
Macrophages were generated by culturing monocytes in R10 PS media in the 
presence of M-CSF (100 ng/ml) for a total of 7-8 days. Fresh media was 
added on day 3. 
HLA-A2+ EBV-transformed B lymphoblasts (clone CM371) were a gift from 
Dr. Laura Rivino (National University of Singapore) and were maintained in 
R10 PS media. 
 
2.5. Antigen-recall assay 
To determine responders to several different recall antigens, isolated donor 
PBMCs were resuspended in RPMI supplemented with 2 % human Ab serum 
(Sigma-Aldrich), 50 g/ml streptomycin and 50 IU/ml penicillin (R2Ab PS 
media) at 107/ml and seeded into 96-well round-bottom plates at 100 l well. 
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Various PepTivator® peptide pools (pp65, LMP2A or MelanA/MART-1) were 
added at 1 g/ml per peptide and incubated at 37ºC for 18 h. Unpulsed and 
CytoStim conditions acted as negative and positive controls, respectively. 
When intracellular staining was desired, Brefeldin A was added 2 h after 
initiation of restimulation with peptide pools.  
To study the potency of CD137L-DCs to restimulate antigen-specific T cells, 
compatible donors were recruited. Classical and CD137L-DCs were 
generated, matured with TNF (50 ng/ml) or LPS (1 g/ml) for 16-18 h and 
then pulsed with pp65 NLV peptide (1 g/ml), pp65 peptide pool (1 g/ml per 
peptide) or LMP2A peptide pool (1 g/ml per peptide) for 1-2 h at 37ºC in 
R2Ab PS media. Unpulsed and CytoStim conditions acted as negative and 
positive controls, respectively. In cases where whole protein tetanus toxoid 
was used as antigen of interest, pulsing of antigen (1 or 5 g/ml) and 
maturation were performed simultaneously for 16-18 h. After washing with 
PBS, pulsed DCs were co-cultured with autologous pan T cells at a ratio of 
1:10. Co-cultures were incubated at 37ºC for either 18 h for flow cytometric 
and ELISA analyses or 5 days for 3H-thymidine proliferation analysis. 
 
2.6. Maturation of CD137L-DCs and classical DCs 
Monocytes were seeded onto CD137-Fc coated plates, and on day 6 various 
cytokine cocktails (refer to tables 4, 5 or 6) were added into the culture for an 
additional 18 h to induce maturation. Cells were then analysed for expression 
of CD14, CD80, CD83, CD86, CCR7, CXCR4, HLA-ABC, and HLA-DR. 
Supernatants were harvested and tested for IL-12p40, IL-12p70 and IL-23 
secretions by ELISA. Additionally, their ability to induce T-cell activation as 
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measured by proliferation of allogeneic T cells and IFN- production was also 
tested.  
For autologous, antigen-specific experiments, CD137L-DCs were matured 
using the optimized cocktail of R848 (1 g/ml) plus IFN- (50 ng/ml) while 
classical DCs were matured by TNF (10 ng/ml), IL-1 (10 ng/ml), IL-6 (10 
ng/ml) and PGE2 (1 g/ml) for 18 h. 
For transcriptional profiling assays, classical DCs were matured by LPS (1 
g/ml) plus IFN- (50 ng/ml) for 18 h. 
2.7. Dissociation assay upon DC maturation 
Monocytes were seeded onto CD137-Fc coated plates, and on day 6 various 
cytokine cocktails (refer to table 4) were added into the culture for an 
additional 18 h to induce maturation. Culture supernatants were decanted, 
cells gently washed twice with PBS and subsequently treated with 1 × trypsin-
EDTA. Culture plates were placed on a bidirectional rotator with gentle 
agitation to enhance cell dissociation. The time required (at a resolution of 30 
seconds) for complete dissociation of DCs from the culture plate was 
recorded. Each condition was assayed with a minimum of triplicates. 
 
2.8. Allogeneic mixed-lymphocyte reaction 
Allogeneic mixed-lymphocyte reaction (MLR) was performed to determine the 
ability of DCs to induce T-cell proliferation and activation.  
Day 7-8 DCs were co-cultured with allogeneic pan T cells at a ratio of 1:10 
(104 DCs and 105 T cells). T cells were either used unstained or pre-treated 
with CFSE. Cultures were incubated at 37ºC in R10 PS media for 5 days and 
cell proliferation was determined via CFSE dilution by flow cytometry. 
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Supernatants from co-cultures were collected and cytokine production was 
determined by ELISA.   
 
2.9. Generation of pp65 T-cell lines 
PBMCs were suspended at 106 cells/ml in AIM V media (Invitrogen) 
supplemented with 2 % human Ab serum (Sigma-Aldrich), streptomycin 
sulphate at 50 g/ml, and gentamicin sulphate at 10 g/ml (AIMV 2Ab media). 
They were then stimulated with PepTivator pp65 spanning peptide pool (0.1 
g/ml per peptide; Miltenyi Biotec) for 9-10 days supplemented with IL-2 (10 
U/ml) added after 24 h to generate a peptide-derived pp65 T-cell line. To 
generate protein-derived pp65 T-cell line, 5 g/ml of pp65 recombinant 
protein (Miltenyi Biotec) was added instead. On day 9-10, >90 % and >95 % 
of cells were CD3+ in the protein-derived and peptide-derived T-cell lines, 
respectively. Cells were washed at least once with PBS and resuspended in 
fresh AIMV 2Ab media before they were used for further experiments.  
 
2.10. Restimulation of pp65 T-cell lines 
2.10.1. Restimulation of peptide-derived pp65 T-cell line 
After overnight maturation, CD137L-DCs or classical DCs were harvested 
and resuspended in AIM V media. Cells were pulsed with the pp65 peptide 
pool at various concentrations (0.01, 0.1 and 1 g/ml per peptide) for 2 h at 
37ºC. As a negative control, the pp65 peptide pool was not added into the 
culture. Cells were washed once and resuspended in AIMV 2Ab media. 
Pulsed DCs were co-cultured with autologous peptide-derived pp65 T-cell line 
at a ratio of 1:10 and was incubated for a total of 18 h. Brefeldin A at a 
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working concentration of 2 g/ml was added after the initial 2 h of co-culture. 
Samples were surface stained for CD3, CD4 and CD8 while intracellular 
staining was performed to detect IFN-, TNF and CD154 before being 
subjected to flow cytometric analysis. 
For the 5 day co-culture experiment, untreated/mature DCs were pulsed with 
the pp65 peptide pool at a concentration of 0.1 g/ml per peptide and were 
left in culture throughout. The autologous peptide-derived pp65 T-cell line was 
co-cultured with DCs at a ratio of 10:1 before supernatants were obtained 
after 5 days. Supernatants were kept at -20ºC until analysed by ELISA for 
IFN-, IL-10, IL-13, IL-17 and TNF.  
2.10.2. Restimulation of protein-derived pp65 T-cell line 
On day 6-7 of CD137L-DC or classical DC generation, cells were harvested, 
resuspended in AIMV 2Ab media and seeded onto culture plates. DCs were 
then activated with their respective optimised maturation cocktail for 18 h. 
Concurrently, DCs were pulsed with 0.385, 3.85 or 38.5 g/ml (0.1, 1 and 10 
×, respectively) of pp65 recombinant protein. As a negative control, the pp65 
recombinant protein was not added into the culture. After maturation and 
antigen-pulsing, cells were washed once and resuspended in AIMV 2Ab 
media. Pulsed DCs were co-cultured with autologous protein-derived pp65 T-
cell line at a ratio of 1:10 and were incubated for 18 h. Samples were surface 
stained for CD3, CD4, CD8 and CD137 before being subjected to flow 
cytometric analysis. 
 
2.11. Cytotoxic assay 
For the pp65-specific cytotoxic assay, the pp65 T-cell line was restimulated 
with the pp65 peptide pool (0.1 g/ml per peptide) pulsed DCs at a ratio of 
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10:1 for 5 days. Cells were harvested, resuspended in AIM V media 
supplemented with 2 % human Ab serum, 50 g/ml streptomycin sulphate, 10 
g/ml gentamicin sulphate, 2 mM probenecid and 50 M -mercaptoethanol 
(AIMV 2Ab PM media). T cells were surface stained for CD3 (> 95 %).  
Target HLA-matched EBV-transformed B lymphoblasts (clone CM371) were 
loaded with DELFIA® BATDA Reagent and a cytotoxicity assays was 
performed according to manufacturer’s instruction (DELFIA® EuTDA 
Cytotoxicity Reagents; Perkin Elmer). This assay has been described to be 
more sensitive than the conventional 51Cr release assay(von Zons et al., 
1997). In brief, target cells were harvested and washed once in R10 PS 
before they were resuspended in R10 PS media supplemented with 2 mM 
probenecid and 50 M -mercaptoethanol (R10 PS PM media) at a density of 
106 cells/ml. 5 l of fluorescence enhancing ligand (DELFIA® BATDA 
Reagent) was added to every 4 × 106 target cells followed by an incubation 
for 20 min at 37ºC. Labelled cells were washed for 3-4 times in R10 PS PM 
media and were then resuspended in AIMV 2Ab PM media. Loaded target 
cells were then pulsed with pp65 peptide pool (1 g/ml per peptide) for 1 h at 
37ºC. Following which, they were washed and seeded into ‘V’-bottom 96-well 
plates at 104 cells per well.  
To initiate the killing assay proper, pp65-specific effector T cells were co-
cultured with target cells at E:T ratios of 5:1, 10:1 and 20:1 for 3 h at 37ºC. 
The Europium solution was added to the harvested supernatants for 15 min 
before the fluorescence was measured using a time-resolved fluorometer 





2.12. Microarray processing and analysis 
2.12.1. RNA extraction and cRNA synthesis1 
Total RNA was extracted following the double extraction protocol:  RNA isolation 
by acid guanidinium thiocyanate-phenol-chloroform extraction (Trizol: Invitrogen) 
followed by a Qiagen RNeasy® clean-up procedure. RNA purity was assessed by 
spectrophotometry. Total RNA integrity was assessed by Agilent Bioanalyzer and 
only high quality RNAs, with an RNA Integrity Number (RIN) greater than 7, were 
considered for microarray analysis. Biotinylated cRNA was prepared according to 
the Epicentre TargetAmpTM Nano-gTM Biotin-aRNA Labelling kit for Illumina 
system. Very strict quality control measures were applied during the target 
preparation procedures. cRNA was analysed by Agilent Bioanalyzer. 1 This 
procedure was performed me and Ms. Josephine Lum from A*STAR (Singapore). 
 
2.12.2. Standard array hybridisation2 
Illumina Human HT12v4 Beadchips for whole-genome gene expression were 
used as the standard array. Labelled cRNAs were hybridized to the standard 
arrays for 16 hours at 58ºC; the arrays were then washed and stained base 
on Illumina Wash Protocol and then scanned using BeadArray Scanner 
500GX at BSF Microarray Facility. 2 This procedure was performed by Ms. 
Josephine Lum from A*STAR (Singapore).  
 
2.12.3. Expression data analysis and selection of differentially 
expressed genes3 
The expression data were background subtracted in Genome Studio and 
further processed with quantile normalisation and log2 transformation. 
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Differential expression analysis was done with the linear model for microarray 
data (limma) bioconductor package and the differentially expressed genes 
were selected with Benjamini-Hochberg multiple testing correction adjusted p-
value < 0.05. The cluster dendrogram and cMAP analysis were generated 
using a freeware program called R. The CD137L-DC signature probes were 
selected by obtaining the gene set that is found in the intersection of 
differentially expressed genes of CD137-Fc treatment vs monocytes and 
differentially expressed genes of CD137-Fc vs Fc (figure 34). This allowed the 
acquisition of differentially expressed genes which are contributed solely by 
CD137L reverse signalling into monocytes. A total of 974 probes, 
corresponding to 829 genes, were identified as CD137L-DC differentially 
expressed genes. 3This procedure was performed by me and Dr. Kaibo Duan 
from A*STAR (Singapore). 
 
2.12.4. DAVID analysis 
To determine the unique functional characteristics of CD137L-DCs against 
each of the subtypes, differentially expressed genes with >2 fold change in 
each group were subjected to Gene Ontology (GO) biologic process using 
Database for Annotation, Visualization and Integrated Discovery (DAVID) 
tools (Huang da et al., 2009). Categories with significant enrichment (p value 
< 0.05) were acquired and similar categories were grouped together. Refer to 
appendix II to view the complete list of genes used for DAVID analysis. 
 
2.13. Neutralisation assay 
Day 7 CD137L-DCs were harvested and resuspended in fresh R10 PS media 
at 2 × 105 cells/ml. 50 l of DC suspension was added into each well of a 96-
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well round bottom plate. Antagonistic anti-ALCAM Ab (R&D Systems) or 
control mouse IgG1 isotype (MOPC-21) was added into appropriate wells at 
10 g/ml. Plates were incubated for 1 h in 37ºC before allogeneic T cells was 
added to give a final DC:T-cell ratio of 1:10 in total volume of 100 l/well. 
Culture plates were incubated for a total of 4 days and 3H-thymidine was 
added for the final 18 h of culture.  
To generate supernatants for ELISA purposes, co-culture conditions were 
scaled-up to a total volume of 400 l/well in 48-well plates. Cultures were 
incubated for 7 days before supernatants were harvested and kept in -20ºC 
freezer until analysis.  
 
2.14. Attachment assay 
Day 7 generated CD137L-DCs and classical DCs were incubated with 10 mM 
EDTA/non-enzymatic  cell dissociation medium for 20 min followed by cell 
scraping for a complete harvest of cells. Cells were resuspended in R10 PS 
media and seeded into individual wells of a 48-well plate at 105 cells/well. The 
culture plate was centrifuged for 5 min at 1,500 rpm to allow cells to descend 
onto the bottom before incubation at 37ºC.  
At the time-points of 10, 45 and 90 min, supernatants containing suspended 
cells were gently collected and washed once with PBS without flushing. 
Supernatants and washing PBS were pooled and labelled as ‘unattached 
cells’. DCs that had adhered to the wells were harvested by treatment with 
trypsin-EDTA for 10 min followed by flushing with PBS to ensure complete 
dissociation of cells. These collected cells were labelled as ‘attached cells’. 
Absolute numbers of cells in each condition were counted using 
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CountBrightTM absolute counting beads. Propidium iodide (PI) was added for 
dead cell exclusion.  
 
2.15. Detachment assay 
Day 7 generated CD137L-DCs and classical DCs were incubated with 10 mM 
EDTA/non-enzymatic  cell dissociation medium for 20 min followed by cell 
scraping for a complete harvest of cells. Cells were resuspended in R10 PS 
media and seeded into individual wells of a 48-well plate at 105 cells/well. The 
culture plate was centrifuged for 5 min at 1,500 rpm before incubation at 37ºC 
for 18-20 h to allow for a complete attachment of DCs.  
Supernatants were harvested and wells were gently washed once with PBS. 
Cells were detached from the substratum by treatment with typsin-EDTA for 
5, 10 or 15 min at 37ºC. At the indicated time-points, cells were harvested 
followed a single gentle wash with PBS. Trypsin-EDTA and washing PBS 
were pooled and labelled as ‘detached cells’. The absolute number of cells in 
each condition was counted using CountBrightTM absolute counting beads. PI 
was added for dead cell exclusion. 
 
2.16. Cell counting 
Cell counting was performed either by using a haemocytometer or by flow 
cytometry with counting beads.  
 
2.16.1. Manual counting using a haemocytometer 
Cells were harvested upon incubation with trypsin-EDTA or 10 mM 
EDTA/non-enzymatic  cell dissociation medium (Sigma-Aldrich). Sterile cell 
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scrapers were used to facilitate complete detachment of cells from culture 
plates. Cells were then washed and resuspended in PBS or media following 
which they were mixed at 1:1 ratio with 0.4 % trypan blue solution (Sigma-
Aldrich T8154). Cells were counted on a haemocytometer (Neubauer) under 
a bright field microscope.  
 
2.16.2. Cell counting beads assay 
Harvested cells were resuspended in a known volume of staining buffer in 
flow cytometry tubes. 5-10 l of CountBrightTM absolute counting beads 
(Invitrogen) were added into each tube before the sample was ran on the flow 
cytometer. The absolute cell number in each sample was calculated using the 
following formula.  
(A/B) × (C/D) = concentration of sample as cells/l. 
Where A = number of cell events, B = number of bead events, C = assigned 
bead count of the lot (beads/5 or 10 l), D = volume of sample in l.  
 
2.17. Quantification of cell proliferation 
Two methods were used to determine cell proliferation; the tritium (3H)-
thymidine incorporation assay and the CFSE dilution assay. 
 
2.17.1. 3H-thymidine incorporation assay 
During the final 18 h of incubation, cells were pulsed with 0.5 Ci of 3H- 
thymidine (PerkinElmer) after which the culture plate was kept in a -20ºC 
freezer to disrupt cellular integrity. The culture plate was then thawed at room 
temperature and the content was transferred onto a Packard Unifilter Plate 
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using a MicroMate 196 Cell Harvester and counted using TopCount 
(PerkinElmer) liquid scintillation and luminescence counter. Each condition 
was assayed at least in triplicates. 
 
2.17.2. CFSE dilution assay 
For CFSE-based assays, CellTraceTM CFSE Cell Proliferation Kit (Invitrogen) 
was used. T cells were harvested, washed and were thoroughly resuspended 
in sterile PBS supplemented with 0.1 % BSA (CFSE buffer) to a density of  
106 cells/ml. The CFSE stock solution was made freshly prior to every 
experiment by dissolving lyophilised CFSE powder into 18 l of DMSO. 8 M 
of stock CFSE dye was added into the T-cell suspension and the mixture was 
incubated for 10 min at 37ºC water bath. Staining was then quenched by the 
addition of 5 volumes of ice-cold R10 PS media to the cells following which 
they were incubated for a further 5 min in ice. Cells were washed, 
resuspended in media and used for further experiments.  
 
2.18. Flow cytometry 
In order to determine surface marker expression, cells were harvested and 
had their Fc receptors blocked by incubating cells with FcR blocking reagent 
(Miltenyi Biotec) for 10 min at 4ºC. Cells were then stained with antibodies in 
PBS containing 0.5 % BSA and 0.1 % sodium azide (staining buffer) for 45 
min at 4ºC in the dark. Cells were washed twice and resuspended in 400 l of 
staining buffer. Unstained samples or samples stained with the indicated 
isotype antibody were used as controls.  
For intracellular cytokine staining, cells were cultured in the presence of 2 
g/ml brefeldin A (eBioscience) overnight and stained with anti-CD8 or anti-
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CD4 antibody. This was followed by cell fixation and permeabilisation using 
BD Cytofix/Cytoperm fixation/permeabilization kit (BD Biosciences). 
Flow cytometry was carried out with CyAn ADP Analyzer (Dako) or BD LSR 
Fortessa cell analyzer (BD Bioscience). Data were analysed using the 
Summit or FlowJo data acquisition and analysis software.  
 
2.19. Intracellular cytokine staining 
Brefeldin A (2 g/ml) was added 2 h after the start of co-culture between DCs 
and T cells to halt protein transport within the cells, thereby preventing 
secretion of cytokines and proteins. Cells were harvested and blocked for Fc 
receptors by incubating cells with FcR blocking reagent (Miltenyi Biotec) for 
10 min at 4ºC. Upon which, cells were surface stained for CD3, CD4 or CD8 
using the respective anti-human antibodies. To stain intracellular cytokines, 
cells were initially fixed and permeabilised using the BD Cytofix/CytopermTM 
fixation/permeabilisation kit (BD Bioscience) according to manufacturer’s 
protocol. Briefly, cells were fixed and permeabilised using the BD 
Cytofix/Cytoperm solution for 20 min at 4ºC. Next, cells were washed twice in 
1 × BD Perm/Wash solution. After fixation and permeabilisation, cells were 
stained intracellularly for IFN-, TNF or CD154 using the appropriate 
antibodies in BD Perm/Wash solution.  
 
2.20. ELISA 
The concentrations of CXCL8, IFN-, IL-1, IL-6, IL-10, IL-12p40, IL-12p70 
and IL-13 in cell supernatants were determined by human CXCL8, IFN-, IL-
1, IL-6, IL-10, IL-12p40, IL-12p70, IL-13 ELISA Duoset (R&D Systems), 
respectively. IL-17 and IL-23 were detected by human IL-17 and IL-23 Ready-
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SET-Go!® ELISA kits, respectively (eBioscience). All measurements were 
performed in triplicates. 
ELISAs were performed according to manufacturer’s protocol. In brief, 
samples were incubated for 2 h in wells of Nunc MaxiSorp® flat-bottom 96 
well plates pre-coated with the appropriate capture antibody. This was 
followed by further 1-2 h incubation with appropriate detection antibody, 30 
min with streptavidin-HRP and eventually 10-20 min with TMB substrate 
(eBioscience). In between each incubation step, the wells were thoroughly 
washed with PBS containing 0.05 % Tween®20. Upon development of the 
TMB substrate, the reaction was stopped with 2N H2SO4 before being 




The morphology of cells was documented using the Zeiss Axiovert 40 
inverted microscope (Zeiss, Gottingen, Germany) and Canon PowerShot G6 
digital camera. 
 
2.22. Statistical analysis 
Statistical significance was determined by a two-tailed unpaired Student’s t-
test unless specified otherwise. 
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CHAPTER 3: RESULTS 
3.1. CD137L is expressed and is functional in primary human monocytes 
3.1.1. Expression of CD137L on monocytes 
It was previously reported that CD137L is expressed constitutively on human 
peripheral monocytes and also on promyeloblastic cells lines such as HL-60 
(Ju et al., 2003; Laderach et al., 2003). To verify these previous findings, the 
expression of CD137L on several donor peripheral monocytes was 
determined by flow cytometry. Donor PBMCs were gated for the monocytic 
population using forward and side scatter and this was followed by CD14+ 
expression to confirm the monocyte population. In two representative donors, 
about 43-48% of CD14+ cells were positive for CD137L surface expression 
thus confirming the previous reports (figure 3). Such an expression profile is 
similar to that reported by Ju and colleagues on peripheral monocytes (Ju et 
al., 2003) 
 
Figure 3. CD137L is expressed on peripheral monocytes. PBMCs isolated 
from buffy coats of 2 individual healthy blood donors were immunostained for 
CD137L using the anti-CD137L primary antibody, clone 41B-436, followed by 
goat anti-mouse-PE conjugate antibody. Percentage of CD137L expressing 
cells in CD14+ population was determined by flow cytometry. Unshaded and 
grey histograms represent isotype control and anti-CD137L stained cells, 






3.1.2. CD137L reverse signalling induces pro-inflammatory cytokine 
secretion in monocytes 
Cross-linking CD137L on peripheral monocytes by CD137-Fc protein or 
agonistic antibodies induces expression of pro-inflammatory cytokines and 
factors such as M-CSF that are essential for prolonged monocyte survival 
(Laderach et al., 2003; Langstein et al., 2000; Langstein et al., 1998; 
Langstein and Schwarz, 1999). This was duly observed in the supernatants of 
monocytes treated with CD137-Fc proteins for 18 h. Upon stimulation through 
CD137L, monocytes produced large amounts of TNF, IL-1, IL-6 and CXCL8 
(454 ± 43, 92 ± 14, 421 ± 15 and 22678 ± 315 pg/ml, respectively) and were 
significantly higher than Fc-treated monocyte controls (figure 4). Similarly, 
when compared to GM-CSF plus IL-4 or M-CSF treated monocytes, which will 
skew their differentiation towards classical DCs and macrophages, 
respectively, CD137L reverse signalling induced an inflammatory condition as 
demonstrated by the significantly higher production of pro-inflammatory 
cytokines.  
These experiments confirmed that CD137L is indeed expressed on human 
peripheral monocytes and downstream reverse signalling is functional, 




Figure 4. CD137L reverse signalling activates monocytes. Isolated 
monocytes were cultured untreated (PBS), or with Fc or CD137-Fc 
treatments. Additionally, monocytes were also cultured in the presence of 100 
ng/ml M-CSF or 80 ng/ml GM-CSF + 100 ng/ml IL-4 to generate 
macrophages and classical DCs, respectively. After 18 h of culture, 
supernatants were harvested and levels of inflammatory cytokines, TNF, IL-
1, IL-6, and CXCL8 were determined by ELISA. Depicted are means ± 
standard deviations of triplicate measurements. *p<0.05; **p<0.01 using a 











3.2. Characterising CD137L-DCs for antigen recall capacity  
Two recent studies identified a new method for generating human DCs of 
enhanced potency. Activation of CD137L by crosslinking with CD137-Fc 
protein or agonistic anti-CD137L antibody was able to activate and 
differentiate monocytes into inflammatory DCs (Ju et al., 2009; Kwajah and 
Schwarz, 2010). These CD137L-generated DCs, henceforth referred to as 
CD137L-DCs, can potently activate T cells leading to a stronger proliferation 
and higher cytokine release in an allogeneic MLR than classical DCs. 
Preliminary results also point towards a more potent cytotoxic capacity by 
these CD137L-DC-activated T cells (personal communication by Dr. 
Shaqireen Kwajah). Although these earlier studies yielded very promising 
data they left open whether CD137L-DCs have superior potency in an 
autologous setting which is critical for their potential use in tumour 
immunotherapy. 
 
3.2.1. HLA-A2 haplotyping of donors 
To study the ability of CD137L-DCs in an autologous condition, donors of a 
specific haplotype and with the ability to respond to specific antigens have to 
be initially identified. Individuals with a positive haplotype for HLA-A2 were of 
interest due to the vast availability of antigens and HLA-matched cell lines 
which could be potentially used for recall studies and killing assays.  
A total of 8 potential donors were recruited and tested for HLA-A2 expression 
on their PBMCs. Flow cytometry analysis showed that donors 1-4 were HLA-
A2+ while donors 5-8 were HLA-A2- (figure 5). Despite being HLA-A2-, donors 
5-8 were also tested for their response to various antigen peptide pools, and 




Figure 5. Haplotyping HLA-A2+ donors. PBMCs isolated from whole blood 
of 8 individual healthy blood donors were immunostained for HLA-A2 using 
directly-conjugated anti-HLA-A2-PE antibody and analysed by flow cytometry. 
Unshaded and grey histograms represent unstained control and anti-HLA-A2 
stained cells, respectively. Values in histograms represent percentages of 
positive cells. 
 
3.2.2. Expression of surface CD137 corresponds to IFN- production by 
activated T cells 
Activation of T cells is often noticeable by degranulation or by detection of 
intracellular cytokines such as IFN-. However, surface expression of CD137 
has been well documented to be activation-dependent in both murine and 
human CD4+ and CD8+ T cells (Kwon and Weissman, 1989; Schwarz et al., 
1993). A study by Wolfl et al. also showed that CD137 has favourable 
characteristics as a surrogate T-cell activation marker as it is expressed on 
nearly all responding cells regardless of their cytokine secretion profile (Wolfl 
et al., 2007). This finding was reaffirmed using PBMCs from a donor who is 
CMV+ EBV-. PBMCs were gated for CD3+ cells and were analysed for the 
expression of intracellular IFN- or membrane-bound CD137 upon overnight 
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treatment with CMV-pp65 or EBV-LMP2A peptide-pools (figure 6). It is 
worthwhile to note that the peptides used in the experiment were commercial 
peptide-pools which consist mainly of 15-mer peptides with 11 amino acid 
overlaps, covering the complete sequence of the pp65 protein of human CMV 
or of the LPM2A protein of human EBV. Therefore, both antigen-specific 
CD4+ and CD8+ effector/memory T cells can be activated by the peptide-pool. 
T cells in unpulsed conditions or pulsed with LMP2A were in their resting 
state and therefore devoid of both IFN- and CD137 expression. The 
presence of positive-control CytoStim, an antibody-based reagent that acts 
similarly to a superantigen but independently of V domains of the TCR and 
only in the presence of APCs, induced both IFN- and CD137 expression in 
both the CD8+ and CD8- T-cell population. Similarly, in a pp65-pulsed 
condition, activation of antigen-specific T cells could be detected by using 
either IFN- or CD137 expression as a marker. More importantly, the degree 
of sensitivity was at least equal, if not higher when CD137 was used as an 
activation marker especially in the positive-control condition. Therefore, both 
IFN- and CD137 expression can be use as T-cell activation markers and will 





Figure 6. CD137 surface expression on T cells is an ideal surrogate 
marker of activation. PBMCs were isolated from a pp65+ LMP2A- donor and 
were pulsed with either CMV pp65 or EBV LMP2A peptide pool. Unpulsed 
and CytoStim conditions acted as negative and positive controls, respectively. 
After 18 h of culture, cells were immunostained intracellularly for IFN- (top 
panel) or surface CD137 (bottom panel) and counterstained for CD3 and 
CD8. Depicted are flow cytometry histograms gated on the CD3+ population. 

















3.2.3. Antigen recall capacity in donor PBMCs 
The ability of donors to respond to several different recall antigens was tested 
to determine the best candidates for subsequent studies involving CD137L-
DCs. The virus-based CMV-pp65 and EBV-LMP2A peptide pools were 
utilised as antigens since latent infection is prevalent in 50-85 % and 80-90 
%, respectively, in human adults thus significantly increasing the chance of 
acquiring a positive donor. Even though both viruses are not commonly 
considered as oncogenic viruses, barring the positive correlation of CMV with 
glioblastoma and EBV with nasopharyngeal carcinoma, utilising these viral-
based antigens would simplify the antigen-specific experimental model. This 
will allow for the verification of our ‘proof-of-concept’ question in which we 
propose that CD137L-DCs are more potent APCs. Donor response towards 
the major melanoma-associated antigen MelanA/MART-1 peptide pool was 
also performed as high frequencies of MelanA/MART-1-specific naive T cells 
have been found in a large proportion of healthy individuals especially those 
who are HLA-A2+ (Pittet et al., 1999).  
PBMCs were pulsed with the various peptide pools and CD137 expression on 
T cells was analysed. Out of a total of 8 donors, 3 individuals (donors 1, 2 and 
8) responded strongly to pp65 peptide pool restimulation while donor 4 was a 
weak responder (figure 7). Donor 2 was the only individual who responded 
strongly while donor 3 responded weakly to LMP2A antigen. None of the 
donors’ PBMC tested were able to restimulate MelanA/MART-1 T cells as 
evidenced by the lack on CD137+ T cells. As donors 1 and 2 were both HLA-
A2+ and could restimulate pp65 and/or LMP2A-specific T cells, they were 
recruited for further studies involving CD137L-DCs. Table 3 summarises the 





Figure 7. Antigen recall ability of donors. PBMCs isolated from whole 
blood of 8 individual healthy blood donors were pulsed with either CMV pp65, 
EBV LMP2A or melanoma MelanA/MART-1 peptide pool. Unpulsed and 
CytoStim conditions acted as negative and positive controls, respectively. 
After 18 h of culture, cells were immunostained for surface CD137 and 
counterstained for CD3 and CD8. Depicted are flow cytometry histograms 
gated on CD3+ population. Donors 2, 3 and 8 were not tested for recall 
towards MelanA/MART-1 and donor 8 was not tested for recall towards 
LMP2A. Values in histograms represent percentages of positive cells.   
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1     
2    NT 
3   ? NT 
4  ?   
5     
6     
7     
8   NT NT 
 : positive,  : negative, ? : weak/uncertain, NT : not tested 
 
3.2.4. Antigen recall assay using various DCs types (restimulation using 
CMV pp65 and EBV LMP2A peptide pools) 
Having established the donor haplotype and responses towards various 
peptide antigens, the capacity of CD137L-DCs to restimulate antigen-specific 
T cells could be tested. In this instance, donors 1 and 2 were ideal 
candidates. Classical DCs and CD137L-DCs were generated over a period of 
7 days and were pulsed with either the pp65 or the LMP2A peptide pool. 
Simultaneously, DCs were activated with either LPS or TNF overnight to 
induce further maturation followed by a co-culture with autologous pan T cells 
for 18 h. Fc-treated monocytes were not used as controls as the resultant 
cells are not able to survive well beyond 6 days and in fact, only less than 10 
% are viable at day 10 (Langstein and Schwarz, 1999). Thus, it is impractical 
to use these Fc-treated monocytes in our experimental setting. 
Despite restimulation by either classical DCs or CD137L-DCs, there were no 
significant differences in the percentages of activated pp65-specific T cells in 
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donor 1 (figure 8A). Additional maturation of DCs by either LPS or TNF was 
unable to heighten the activation of both CD8+ and CD8- T cells. As expected, 
DCs pulsed with LMP2A were unable to activate any T cells as the donor was 
EBV-. A different situation was observed in donor 2 where antigen-pulsed 
CD137L-DCs were slightly more potent than classical DCs (figure 8B). 
CD137L-DCs pulsed with pp65 were able to activate 2.7% of antigen-specific 
CD8+ T cells while only 2.2% were activated when they were co-cultured with 
pp65-pulsed classical DCs. When comparing the population of CD8- T cells, 
CD137L-DCs and classical DCs activated 2.7% and 2.3% of antigen-specific 
T cells, respectively. Similarly, CD137L-DCs were capable of activating 
LMP2A-specific CD8+ T cells (1.1%) and CD8- T cells (0.8%) whereas 
classical DCs could not activate them at all. Addition of LPS or TNF during 
the pulsing step failed to increase the capacity of CD137L-DCs to activate 















Figure 8. CD137L-DCs are able to activate antigen-specific T cells to a 
degree similar or slightly better than classical DCs. Classical DCs or 
CD137L-DCs generated from  donors 1 (A) and 2 (B) were pulsed with either 
the CMV pp65 or the EBV LMP2A peptide pool and simultaneously co-
cultured with autologous pan T cells at a ratio of 1:10. DCs pulsed with 
CytoStim condition acted as a positive control. In certain cases, DCs were 
treated with either LPS or TNF for 18 h prior to co-culture. After an 18 h co-
culture, cells were immunostained for surface CD137 and counterstained for 
CD3 and CD8. Depicted are line graphs gated on CD3+CD8+ population (top 
panel) and CD3+CD8- population (bottom panel).  
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Levels of IFN- secreted by activated T cells further support the notion of 
CD137L-DCs being potent APCs. Despite the absence of any differences in 
the expression levels of T-cell activation marker upon restimulation by 
classical DCs or CD137L-DCs in donor 1, there was a significant increase in 
IFN- production by T cells co-cultured with pp65 peptide pool-pulsed 
CD137L-DCs as compared to classical DCs. In this condition, there was a 2.5 
times increase in IFN- levels (figure 9A). A similar trend was observed when 
DCs were pre-treated with either LPS or TNF. However, maturation of DCs 
with these factors decreased the overall activation of pp65-specific T cells as 
IFN- levels were lower than in T cells co-cultured with untreated DCs. Given 
that the donor was HLA-A2+, the immunodominant NLVPMVATV (NLV) 
peptide derived from CMV pp65 protein was also utilised to evoke a 
response. Surprisingly, the absence of an increase in IFN- meant that the T 
cells were not activated by this particular peptide and perhaps the peptide-
pool provided a variety of other peptides which were more dominant in 
evoking an immune response. As expected, there were no changes in IFN- 
levels in LMP2A-pulsed co-cultures as compared to unpulsed co-culture 
controls. A similar observation was made with donor 2 (figure 9B). The 
increased expression of membrane CD137 on T cells activated by CD137L-
DCs corresponded to the higher IFN- secretion in their supernatant. These 
pp65 peptide pool-activated and LMP2A-activated T cells secreted 3.5 times 
and 1.5 times more IFN-, respectively, compared to their counterparts 
restimulated by classical DCs. As with donor 1, DCs matured with either LPS 
or TNF had an overall reduction in T-cell activation based on IFN- levels 
although CD137L-DCs were still more potent than their classical counterparts. 






Figure 9. Antigen-specific T cells activated by CD137L-DCs secrete high 
amounts of IFN-. Classical DCs or CD137L-DCs generated from donors 1 
(A) and 2 (B) were pulsed with either the CMV pp65 immunodominant peptide 
(NLV), CMV pp65 or the EBV LMP2A peptide pool, and simultaneously co-
cultured with autologous T cells at a ratio of 1:10. DCs pulsed with CytoStim 
condition acted as a positive control. In certain conditions, DCs were 
activated with either LPS or TNF for 18 h prior to co-culture. Supernatants 
were harvested after 18 h of co-culture and concentrations of IFN- were 
determined by ELISA. Depicted are fold-changes of IFN- concentrations in 
relation to corresponding unpulsed conditions. Bar charts depict means ± 
standard deviations of triplicate measurements. *p<0.05; **p<0.01 using a 
two-tailed unpaired Student’s t-test. 
 70 
 
To further support the observation that CD137L-DCs are more potent APCs, 
T-cell proliferation was measured upon co-culture with antigen-pulsed DCs. 
Enhanced IFN- secretion by activated pp65 T cells was accompanied with 
enhanced cell proliferation (figure 10). Both, the pp65 peptide-pool and the 
NLV peptide were able to induce pp65 specific-T-cell proliferation although 
the former was clearly much more competent. Essentially, both types of DCs 
were able to efficiently induce strong pp65 T-cell proliferation (using pp65 
peptide-pool) and there was no significant difference between them. The 
addition of LPS to further activate the DCs was not able to further enhance T-
cell proliferation thus indicating that LPS was not a suitable maturation factor 
for either type of DCs. In fact, LPS treatment on classical DCs led to an 
increase in background T-cell proliferation even in the absence of peptide 
antigens. Due to constrain in resources, DCs from donor 2 were not tested for 
their ability to activate T cells.  
Taken together, CD137L-DCs are able to present peptide antigens and 
activate autologous T cells in an antigen-specific manner. These T cells 
seemed to be more activated than those restimulated by classical DCs as 
evidenced by the slightly higher surface expression of the activation marker 
CD137 and profound elevation of IFN- secretion although there was no 




Figure 10. CD137L-DCs are not able to enhance the proliferative 
capacity of antigen-specific T cells. Classical DCs or CD137L-DCs 
generated from donor 1 were pulsed with either CMV pp65 immunodominant 
peptide (NLV) or the CMV pp65 peptide pool and simultaneously co-cultured 
with autologous T cells at a ratio of 1:10. DCs pulsed with CytoStim condition 
acted as a positive control. In indicated conditions, DCs were activated with 
either LPS for 18 h prior to co-culture. At day 5, proliferation was quantified by 
3H-thymidine incorporation. Proliferation was measured as counts per minute 










3.2.5. Antigen recall assay using various DC types (restimulation using 
tetanus toxoid) 
Besides using a peptide-based antigen, whole protein antigens from tumour 
lysates are also commonly used for DC-based immunotherapy (Cintolo et al., 
2012). It is therefore appropriate that the ability of CD137L-DCs to process 
and present such antigens be determined. To investigate this, a recall assay 
using tetanus toxoid as a model antigen was performed on donors 1 and 3 
who were recently immunized with tetanus vaccine (<3 years, personal 
communication with donors). As with the peptide-pool recall assay, the 
various DCs were pulsed with tetanus toxoid and simultaneously matured 
with LPS. After an overnight incubation, DCs were co-cultured with 
autologous pan T cells. The cytokine profile and proliferation rates were 
determined as a measure of tetanus toxoid-specific T-cell activation. 
T cells from both donors produced high levels of cytokines when challenged 
with tetanus toxoid and this is consistent with them being recently vaccinated 
with tenatus toxoid (figure 11). Although both DC subsets were able to 
activate tetanus toxoid-specific T cells, classical DCs were more potent than 
CD137L-DCs as observed by the higher expression of cytokines by classical 
DC activated T cells. This is especially pronounced for IFN- whereby tetanus 
toxoid-specific T cells activated by classical DCs produced at least 3 times 
more cytokine than T cells activated by CD137L-DCs in both donors. 
Interestingly, maturation of classical DCs with LPS drastically reduced IFN- 
but increased IL-10 production which indicates a shift towards an anti-
inflammatory profile. Such a response was not seen in LPS-treated CD137L-
DCs suggesting that different TLR ligands may be required to further 
manipulate these DCs. Another cytokine that has been reported to be 
produced by tetanus toxoid-specific T cells is IL-17 (Brenchley et al., 2008; 
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Lenarczyk et al., 2000). Indeed, there was a dose-dependent increase of IL-
17 by T cells from donor 1 but not from donor 3 and this could be contributed 
to donor variation. Nonetheless, CD137L-DCs were unable to cultivate a 
stronger antigen-specific response which is in contrast to the previous finding 
whereby these DCs were able to heighten IL-17 expression more potently 
than their classical counterparts (Kwajah and Schwarz, 2010).    
 
Figure 11. T cells restimulated by classical DCs secrete more cytokines 
in response to whole protein antigens. Classical DCs or CD137L-DCs 
generated from donors 1 (A) and 3 (B) were pulsed with increasing 
concentrations of tetanus toxoid and were co-cultured with autologous T cells 
at a ratio of 1:10. DCs pulsed with CytoStim condition acted as a positive 
control. In certain conditions, DCs were activated with LPS for 18 h prior to 
co-culture. Supernatants were harvested after 6 days co-culture and 
concentrations of IFN-, IL-10 and IL-17 were determined by ELISA. Bar 
charts are illustrated as means ± standard deviations of triplicate 




The proliferative capacity of tetanus toxoid-specific T cells ran in parallel with 
their IFN- production whereby it followed a dose-dependent trend with 
respect to the amount to pulsed tetanus toxoid (figure 12). When compared 
between the different types of DCs pulsed with 1 g/ml tetanus toxoid, 
classical DCs were more potent activators of antigen-specific T cells in both 
donors. However, with a higher concentration of pulsed antigen, both 
classical DCs and CD137L-DCs were able to induce similar rates of T-cell 
proliferation. LPS-treated DCs failed to further potentiate tetanus-toxoid T-cell 
proliferative capacity and this mirrors the previous finding when peptide 
antigens were utilised (section 3.2.4). Instead, these DCs and in particular 
classical DCs, were able to highly activate large numbers of non-specific T 
cells as evinced by the high T-cell proliferation in the unpulsed condition. 
Collectively, although the data demonstrates that CD137L-DCs are able to 
stimulate and activate autologous T cells in an antigen-specific manner, to 
claim that CD137L-DCs are more potent APCs than classical DCs may be 
premature due to a minimal increase in the T-cell activation marker and a 
similar potency to classical DCs in inducing T-cell proliferation in a peptide 
recall assay.  Furthermore, classical DCs seemed to be more efficient APCs 
in the presence of whole protein antigens. Disappointingly, the addition of 
either LPS or TNF to mature CD137L-DCs was unable to further enhance T-
cell activation, and this is in line with previous data from our laboratory 
(Kwajah and Schwarz, 2010). Thus, before embarking on further antigen-
specific experiments, improvements in terms of maturing CD137L-DCs has to 
be carried out to further increase the potency of CD137L-DCs to initiate 






Figure 12. T cells restimulated by classical DCs have a higher 
proliferative capacity in response to whole protein antigens. Classical 
DCs or CD137L-DCs generated from donors 1 (A) and 3 (B) were pulsed with 
tetanus toxoid at increasing concentrations and were co-cultured with 
autologous T cells at a ratio of 1:10. DCs pulsed with CytoStim condition 
acted as a positive control. In indicated conditions, DCs were activated with 
either LPS for 18 h prior to co-culture. At day 5, proliferation was quantified by 
3H-thymidine incorporation. *p<0.05 using a two-tailed unpaired Student’s t-
test. CPM = counts per minute.  
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3.3. Maturation of CD137L-DCs 
The recall assay experiments presented in the previous section showed that 
CD137L-DCs are indeed able to function as an APC and activate T cells in an 
antigen-specific manner. Nevertheless, the potential to further mature these 
DCs exist as it was previously shown that the expression of DC maturation 
markers such as CD83, CD86 and HLA-DR can be enhanced by LPS and 
IFN- although the capacity to elicit a T-cell response was not affected 
(Kwajah and Schwarz, 2010). Likewise, maturation with either LPS or TNF 
alone as discussed in the previous section, proved to be redundant or 
insufficient. Hence, in this section we discuss methods to mature CD137L-
DCs with the eventual aim of eliciting an even more potent activated T-cell 
status. 
In the previous study by Kwajah and Schwarz, they termed CD137L-DCs as 
already having a mature phenotype based on the presence of CD83 and their 
ability to activate allogeneic naive and memory T cells to levels superior than 
mature classical DCs (Kwajah and Schwarz, 2010). Due to this reason, we 
refrain from calling CD137L-DCs that are not treated with any exogenous 
maturation factors as ‘immature CD137L-DCs’ but rather as ‘untreated 
CD137L-DCs’.  
Several well-established maturation factor cocktails were tested for their 
ability to mature CD137L-DCs (table 4). These include the standard LPS plus 
IFN- and the gold standard Jonuleit cocktail for immunotherapy, comprising 
of TNF, IL-1, IL-6 and PGE2. CD137L-DCs were generated for 7 days, 





Table 4: Cytokine combinations employed for CD137L-DC maturation  
Cocktail Components (concentration) Remarks 
C0 - - Untreated CD137L-DCs 
C1 LPS  IFN-  
1 g/ml 
50 ng/ml 
IL-23 control for CD137L-DCs 























Zobywalski cocktail 1 (Zobywalski 














Zobywalski cocktail 2 (Zobywalski 
et al., 2007) 
C5 R848 Poly (I:C) 
3 g/ml 
100 ng/ml 
Boullart cocktail 1 (Boullart et al., 
2008) 
C6 Flagellin 25 ng/ml TLR5 agonist (low concentration) 
C7 Flagellin 50 ng/ml TLR5 agonist (high concentration) 
 
3.3.1. Effects of maturation cocktails on CD137L-DC phenotype 
Morphological differences were observed upon the treatment of CD137L-DCs 
with the various maturation cocktails (figure 13). C0 (untreated) CD137L-DCs 
is a mixed population of cells with fiber-like extensions and spindle-shaped 
cells which are strongly adhered to the culture plate, and floating cells with 
rounded morphologies. Upon 18 h treatment with either C3 or C4, most of the 
floating cells became adherent while those already attached became flatter 
and apparently even more strongly adherent. These cells also had more 
pronounced extension and spindles. This increase in adherence was made 
obvious when the cells were harvested. In the presence of trypsin-EDTA, 
twice the time was required to completely detach the C3 or C4-treated cells 
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from the culture plate as compared to the untreated CD137L-DCs (figure 14). 
Despite any clear morphological distinction between untreated CD137L-DCs 
and those treated with C1, C2, and C5, the adherent properties differed 
amongst these differentially treated DCs. C1 and C5-treated CD137L-DCs 
were more adherent than untreated CD137L-DCs while the opposite is true 
for C2-treated DCs. This reduced adherence is likely due to the presence of 
PGE2 in the cocktail which has been reported to reduce attachment 
properties and therefore favour migration (Boullart et al., 2008).  
 
Figure 13. Maturation cocktails C3 and C4 induced morphological 
changes in CD137L-DCs. Monocytes were treated with immobilised CD137-
Fc protein for 6 days to generate CD137L-DCs and were further treated with 
the indicated maturation cocktails for 18 h. Photographs were taken on day 7 
at magnification of 40 and 63 ×. Blue arrows refer to attached cells while red 






Figure 14. Maturation cocktails C1, C3, C4 and C5 are able to increase 
adhesion properties of CD137L-DCs. Monocytes were treated with 
immobilised CD137-Fc protein for 6 days to generate CD137L-DCs and were 
further treated with the indicated maturation cocktails for 18 h. Cells were 
washed and treated with trypsin-EDTA with constant agitation to allow cells to 
detach. Depicted are times taken for cells to completely detach from wells as 
observed by microscopy. Bar charts depict means ± standard deviations of 
triplicate measurements. **p<0.01 using a two-tailed unpaired Student’s t-
test. This experiment has been performed twice with comparable results. 
 
Further, the expression profile of DC surface protein markers was determined 
to gauge the level of DC maturation (figure 15). Basal levels of the DC 
maturation marker CD83 were expressed by 39 % of untreated CD137L-DCs, 
with a MFI of 66. This was significantly enhanced by C3 (64 %, MFI = 108) 
and C4 (58 %, MFI = 99) while C1 increased expression only modestly (58 %, 
MFI = 75). Treatment by cocktails C2, C5, C6 and C7 had no effect on CD83 
expression. A similar pattern was observed for the co-stimulatory molecule 
CD86 (B7-2). 43 % of untreated CD137L-DCs expressed CD86, with an MFI 
of 103. Treatment of CD137L-DCs with C1, C3 and C4 led to a considerable 
upregulation of CD86 (69 %, MFI = 179; 57 %, MFI = 165; 52 %, MFI = 139, 
respectively) while only a slight increase was observed with C2 (55 %, MFI = 
122). The expression of the other major member of the B7 family, CD80, was 
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also enhanced by cocktails C1, C3 and C4 albeit at much lower levels by 
cocktails C3 and C4 (figure 15).        
MHC class II is required for the presentation of antigen epitopes and the 
subsequent activation of antigen-specific autologous CD4+ T cells. It was 
therefore surprising that CD137L-DCs, despite being potent activators of 
CD4+ T cells, expressed low levels of MHC class II (Kwajah and Schwarz, 
2010). Thus, we hypothesised that an increase in surface MHC class II 
expression on CD137L-DCs would be one of the most likely events that can 
enhance the activation of CD4+ T cells by CD137L-DCs. Treatment with C1, 
C3 or C4 significantly enhanced levels of HLA-DR (70 %, MFI = 116; 79 %, 
MFI = 122; 77 %, MFI = 117, respectively) as compared to untreated 
CD137L-DCs (46%, MFI = 87), (figure 15). 
Maturation is associated with the increased expression of co-stimulatory 
molecules, surface MHC class II as well as the acquisition of chemokine 
receptors such as CCR7 which allows the migration of DCs into the draining 
lymph node where they interact with T cells (Trombetta and Mellman, 2005). 
Indeed, treatment of CD137L-DCs with C1, C3, C4 and C6 increased CCR7 
expression. However, treatment by C3 and C4 marginally reduced the 












Figure 15. Maturation cocktails C1, C3 and C4 upregulates maturation 
markers on CD137L-DCs. Monocytes were treated with immobilised CD137-
Fc protein for 6 days to generate CD137L-DCs and were further treated with 
the indicated maturation cocktails for 18 h. Cells were immunostained for 
CD80, CD83, CD86, HLA-DR, CCR7 and CXCR4 and analysed by flow 
cytometry. Unshaded and grey histograms represent unstained control and 
indicated surface markers, respectively. Values in histograms are 
percentages of positive cells and mean flourescence intensities (MFI), 
respectively. Bar charts on the bottom depict mean percentages and the 
mean MFI ± standard deviations of data from two independent donors, except 
for CCR7 and CXCR4, which are from a single donor. 
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DCs are the mediators between innate and adaptive immunity and often 
ensure the development of appropriate immune responses. The ability of DCs 
to polarise specific T-cell response is highly dependent on the cytokine profile 
of the DCs. Often critical for DC immunotherapy is the generation of Th1-
polarising DCs in which IL-12 is a key cytokine that defines this DC 
phenotype. C1-treated CD137L-DCs produced more IL-12p40 than its 
untreated counterpart whereas treatment with C2 cocktail caused a slight 
reduction in cytokine expression (figure 16). The rest of the maturation 
cocktails had no effects on IL-12p40 production. Disappointingly, expression 
of functional IL-12p70 was absent in all conditions. Despite the lack of Th1-
driving IL-12p70 cytokine, IL-23, which is a pro-inflammatory cytokine from 
the IL-12 family, was detected in supernatants from C1, C3, C4 and C5-











Figure 16. Maturation cocktails do not induce IL-12p70 while C1, C3, C4, 
and C5 promote IL-23 expression. Monocytes were treated with 
immobilised CD137-Fc protein for 6 days to generate CD137L-DCs and were 
further treated with the indicated maturation cocktails for 18 h. Supernatants 
were then harvested and concentrations of IL-12p40, IL-12p70 and IL-23 
were determined by ELISA. Bar charts depict means ± standard deviations of 







3.3.2. Effects of maturation cocktail treated CD137L-DCs on T-cell 
activities 
Morphological, surface marker and cytokine profiles point towards a positive 
influence of cocktails C1, C3 and C4 to mature CD137L-DCs. However, to 
ascertain whether these maturation cocktails not only enhance expression of 
T-cell activating molecules but also enhance their overall T-cell activating 
potency, the ability of cocktail-treated CD137L-DCs to induce T-cell 
proliferation in an allogeneic MLR was assessed.  
CFSE-stained allogeneic T cells were co-cultured with C1, C3 or C4-treated 
CD137L-DCs for 5 days and T-cell proliferation was determined by CFSE 
dilution. In the absence of CD137L-DCs, T cells remained resting as there 
was barely any proliferation (2 %, MFI = 1877), (figure 17A). Untreated 
CD137L-DCs were able to induce proliferation in 64 % of the T cells (MFI = 
733), while C1-treated CD137L-DCs, despite having enhanced CD83, CD86 
and HLA-DR expression, were not able to increase T-cell proliferation any 
further (68 % proliferation, MFI = 665). This confirmed the previous 
observation whereby the treatment of CD137L-DCs with LPS plus IFN- has 
no substantial effect on their ability to induce allogeneic T-cell responses 
(Kwajah and Schwarz, 2010). Nonetheless, CD137L-DCs treated with either 
C3 or C4 were more potent T-cell activators as evidenced by the enhanced T-
cell proliferation. 81 % (MFI = 444) and 80 % (MFI = 463) of the T cells had 
undergone proliferation when co-cultured with C3 and C4-treated CD137L-
DCs, respectively. 
As an additional measure of CD137L-DC potency and as an initial indication 
of the ability to induce Th1 response, levels of IFN- in day 5 co-culture 
supernatants were determined. IFN- secreted by T cells co-cultured with C3-
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treated CD137L-DCs were five times higher (1265 pg/ml ± 243 pg/ml) than 
those from control CD137L-DCs (241 pg/ml ± 74 pg/ml) while levels were 
three times higher (720 pg/ml ± 241 pg/ml) in supernatants of T cells co-
cultured with C4-treated CD137L-DCs (figure 17B). This observation 
suggests a correlation between IFN- secretion with enhanced proliferation 
rate of T cells. While maturation with cocktails C1, C3 and C4 augmented DC 
activation markers expression, only C3 and C4 were able to boost the ability 
of CD137L-DCs to enhance T-cell proliferation and IFN- secretion.  
Maturation cocktails C3 and C4 differ by the presence of poly (I:C) in C4 
(table 4). Poly (I:C) is a TLR3 agonist with the ability to induce production of 
IL-12p70 in classical DCs (Boullart et al., 2008). However, CD137L-DCs 
treated with C4 containing poly (I:C) were not able to produce detectable IL-
12p70 in the supernatants, nor were any of other maturation cocktails (figure 
16). Since the presence of poly (I:C) did not contribute to CD137L-DC 
maturation, the other components, i.e. cocktail C3, mediated the functional 





Figure 17. CD137L-DCs treated with either C3 or C4 are more potent T-
cell activators. Monocytes were treated with immobilised CD137-Fc protein 
for 6 days and were further treated with the indicated maturation cocktails for 
18 h. CD137L-DCs were then further co-cultured for 5 days with CFSE-
stained allogeneic T cells at a ratio of 1:10. (A) Levels of T-cell proliferation 
were quantified by flow cytometry based on CFSE dilution. Values in the 
histograms and bar charts represent mean percentages of T cells undergoing 
CFSE-dilution and corresponding MFI of duplicate measurements. (B)  
Supernatants of day 5 co-cultures of maturation cocktail-treated CD137L-DCs 
with allogeneic T cells were harvested and levels of IFN- were determined by 
ELISA. Depicted are means ± standard deviations of triplicate measurements. 
**p<0.01 using a two-tailed unpaired Student’s t-test. This experiment has 




3.3.3. R848 and IFN- are essential and sufficient to functionally mature 
CD137L-DCs 
Having identified C3 as the most potent and suitable cocktail for maturing 
CD137L-DCs, the next aim was to deduce the essential components of this 
cocktail. C3 consist of five factors; IL-1, TNF, IFN-, PGE2 and R848. Two of 
these inflammatory cytokines, IL-1 and TNF, were previously shown to be 
produced upon reverse signalling through CD137L in monocytes (figure 4). It 
is therefore reasoned that these components can be omitted from maturation 
cocktail C3. Additionally, we aim to systematically eliminate individual 
components of C3 in order to define a maturation cocktail that combines 
highest potency with the least components as it would aid future clinical use 
of CD137L-DCs (table 5).   
Table 5: Definition of essential factors for CD137L-DC maturation. 
Cocktail Components (concentration) Remarks 




















Without TNF and IL-1 which is 
endogenously produced by 
CD137L-DCs (figure 4) 
C3B IFN- R848 
250 ng/ml 
1 g/ml - 
C3C IFN- 250 ng/ml - 






As previously described, C3 induced a change in cellular morphology 
whereby CD137L-DCs became more attached and had more pronounced 
extension and spindles. In all but one derivatives of C3, such changes were 
similarly observed. The C3D cocktail, which only contained the TLR7/8 ligand 
R848, was unable to bring about a morphological change to CD137L-DCs, 
however, IFN- alone (C3C) was sufficient (figure 18). 
 
Figure 18. All derivatives of cocktail C3 induced morphological changes 
in CD137L-DCs except for C3D. Monocytes were treated with immobilised 
CD137-Fc protein for 6 days to generate CD137L-DCs and were further 
treated with the indicated maturation cocktails for 18 h. Photographs were 




As cocktail C3 was able to significantly upregulate the expression of CD83, 
CD86 and HLA-DR (figure 15), these DC maturation markers on CD137L-DC 
treated with C3-derived cocktails were also tested. The absence of IL-1 and 
TNF in cocktail C3A made no difference to the induction of CD83, CD86 and 
HLA-DR when compared to the parental C3 (figure 19). Similarly, production 
of IL-23 was equally upregulated with either C3 or C3A (figure 20). Besides, 
when T cells were co-cultured with C3 or C3A-treated CD137L-DCs, there 
were no differences in their proliferation rates and secretion of IFN- 
suggesting that the induction of endogeneous IL-1 and TNF by CD137L 
reverse signalling in monocytes and developing CD137L-DCs is sufficient to 
promote their maturation (figure 21).  
On top of promoting a morphological change in CD137L-DCs, IFN- alone 
(C3C) was sufficiently able to increase the expression of CD83, CD86 and 
HLA-DR, and it also enhanced T-cell proliferation to similar levels as C3 
(figures 19 and 21A). However, C3C-treated CD137L-DCs were unable to 
significantly raise IL-23 production and furthermore, it was inadequate to bring 
about a further increase in IFN- production by T cells in a co-culture 
condition (figures 20 and 21B).  The TLR7/8 ligand R848 alone (C3D) was not 
able to increase expression of the co-stimulatory molecules and IL-23 but it 
was mildly sufficient to activate CD137L-DCs to a level where they could 
enhance T-cell proliferation and IFN- production (figures 19-21). Yet, the 
combination of R848 and IFN- (C3B) was as potent as the parental C3 
cocktail in maturing CD137L-DCs as evidenced by the comparable 
phenotypic and functional competence of the DCs upon treatment by either 
maturation cocktails (figure 19-21). This demonstrates that R848 plus IFN- 









Figure 19. IFN- alone (C3C) is sufficient to upregulate expression of DC 
maturation markers. Monocytes were treated with immobilised CD137-Fc 
protein for 6 days to generate CD137L-DCs and were further treated with the 
indicated maturation cocktails for 18 h. Cells were immunostained for CD83, 
CD86, and HLA-DR and analysed by flow cytometry. Unshaded and grey 
histograms represent unstained control and indicated surface markers, 
respectively. Values in histograms are percentages of positive cells and MFI. 
Bar charts on the bottom depict mean percentages and the mean MFI ± 




Figure 20. IFN- and R848 (C3B) are both required for IL-23 production.  
Monocytes were treated with immobilised CD137-Fc protein for 6 days to 
generate CD137L-DCs and were further treated with the indicated maturation 
cocktails for 18 h. Supernatants were then harvested and concentrations of 
IL-12p40 and IL-23 were determined by ELISA. Bar charts illustrate means ± 
standard deviations of triplicate measurements. **p<0.01 using a two-tailed 





Figure 21. IFN- and R848 (C3B) are essential and sufficient for the 
optimal maturation of CD137L-DCs and subsequent T-cell activation. 
Monocytes were treated with immobilised CD137-Fc protein for 6 days and 
were further treated with the indicated maturation cocktails for 18 h. CD137L-
DCs were then further co-cultured for 5 days with CFSE-stained allogeneic T 
cells at a ratio of 1:10. (A) Levels of T-cell proliferation were quantified by flow 
cytometry based on CFSE dilution. Values in the histograms and bar charts 
represent mean percentages of T cells undergoing CFSE-dilution and 
corresponding MFI of duplicate measurements. (B) Supernatants of day 5 co-
cultures of mature CD137L-DCs with allogeneic T cells were harvested and 
levels of IFN- were determined by ELISA. Depicted are means ± standard 
deviations of triplicate measurements. *p<0.05; **p<0.01 using a two-tailed 
unpaired Student’s t-test. This experiment has been performed twice with 




3.3.4. Optimisation of R848 and IFN- concentrations in maturation 
cocktail C3B 
To facilitate the use of CD137L-DCs for future clinical settings, optimisation 
was performed to deduce the minimum concentration of R848 and IFN- 
required to mature CD137L-DCs without compromising on their resulting 
activity. To achieve this goal, R848 and IFN- were titrated in various 
combinations (table 6). Morphology and surface markers of treated CD137L-
DCs were then documented. 
Table 6: Optimising concentrations of IFN- and R848 for maturation of 
CD137L-DCs. 
Cocktail Components (concentration) 
 IFN- R848 
C0 - - 
C3B 250 ng/ml 1 g/ml 
C3B.1 50 ng/ml 1 g/ml 
C3B.2 10 ng/ml 1 g/ml 
C3B.3 250 ng/ml 200 ng/ml 
C3B.4 250 ng/ml 40 ng/ml 
 
Treatment with cocktail C3B.1, which contained a reduced IFN- 
concentration of 50 g/ml, on CD137L-DCs produced near identical 
morphology as when C3B was used (figure 22). Cells were highly attached 
and had defined protrusions and spindles. Further reduction of IFN- 
concentration (10 g/ml; C3B.2) abolished this effect and the CD137L-DCs 
were essentially morphologically similar to untreated CD137L-DCs. 
Decreased levels of R848 in both C3B.3 and C3B.4 yielded CD137L-DCs 
with attached morphology, however, there was clear reduction in spindle 
formation and cells were generally round and oval shaped. Likewise, only 
cocktail C3B.1 was able mature CD137L-DCs to the same degree as parental 
C3B, without compromising on the intensity of CD83, CD86 and HLA-DR 
 97 
 
surface expression (figure 23). Therefore, maturation cocktail C3B.1 
containing R848 at 1 g/ml and IFN- at 50 ng/ml are the optimised 
concentrations which are sufficient to induce full maturation of CD137L-DCs. 
Henceforth, CD137L-DCs activated by this cocktail is termed ‘mature 
CD137L-DCs’. 
 
Figure 22. IFN- at 50 ng/ml plus R848 at 1 g/ml (C3B.1) are required for 
morphological change of CD137L-DCs. Monocytes were treated with 
immobilised CD137-Fc protein for 6 days to generate CD137L-DCs and were 
further treated with the indicated maturation cocktails for 18 h. Photographs 





Figure 23. IFN- at 50 ng/ml plus R848 at 1 g/ml (C3B.1) are required for 
optimal induction of DC maturation markers. Monocytes were treated with 
immobilised CD137-Fc protein for 6 days to generate CD137L-DCs and were 
further treated with the indicated maturation cocktails for 18 h. Cells were 
immunostained for CD83, CD86 and HLA-DR and analysed by flow 
cytometry. Bar charts on the bottom are corresponding mean percentages 
and the mean MFI ± standard deviations of duplicate samples. Vertical dotted 
line refers to mean percentage or MFI of indicated markers for parental C3B-
treated CD137L-DCs. These data are representative of 2 independent 




3.4. CMV pp65 specific assay in an autologous system 
Having established an effective maturation cocktail for CD137L-DCs in an 
allogeneic system, the next question asked is whether these mature CD137L-
DCs are capable - and potentially more effective than classical DCs - of 
initiating an autologous antigen-specific response. For this purpose, CMV 
pp65 recombinant protein and peptide pool were employed as a model 
antigen of interest and we generated pp65-specific T-cell lines from a 
pp65+/HLA-A2+ donor.  
 
3.4.1. Generation of DCs 
Classical DCs and CD137L-DCs were generated from autologous peripheral 
monocytes for 7 days and during the final 18 h, matured with a cocktail 
containing TNF, IL-1, IL-6 and PGE2 (Jonuleit cocktail) or R848 plus IFN- 
(cocktail C3B.1 from 3.3.4), respectively. The Jonuleit cocktail is widely used 
in current clinical trials and is considered the gold standard for DC 
immunotherapy (Jonuleit et al., 1997). Therefore, classical DCs matured by 
the Jonuleit cocktail were used as a yardstick for the assessment of CD137L-
DC activities. Classical DCs and CD137L-DCs differed morphologically even 
prior to maturation. Classical DCs were generally suspension cells with veil-
like structures, and upon maturation developed many small dendrites while 
remaining non-adherent (figure 24A). CD137L-DCs on the other hand were 
mainly adherent and their maturation increased the frequency of more 
pronounced spindle protrusions and adherence, resulting in a distinct flatter 
morphology of the cells. Crucially, the expression of DC maturation markers 
CD83, CD86 and HLA-DR was upregulated in both mature classical DCs and 
mature CD137L-DCs with regards to their respective immature precursors 
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(figure 24B). Maturation also led to a reduction of the monocyte/macrophage 
marker CD14 and an increase in MHC class I (HLA-ABC) expression. These 
observations proved that the maturation cocktails for the respective DCs were 
indeed effective.  
The growth factor GM-CSF and the cytokine IL-4 are essential for the 
differentiation and survival of classical DCs. However, CD137L-DCs are not 
supplemented with any exogeneous factors or cytokines during their 
differentiation from monocytes, and are therefore solely dependent on the 
effects of CD137L reverse signalling. To show that indeed signalling through 
CD137L is sufficient, the final numbers of DCs generated on day 7 were 
quantified. This is also essential as it is important to know how many DCs can 
be generated using a particular protocol. Using cell counting by microscopy 
and also by counting beads, it was deduced that there was no significant 
difference between the absolute number of DCs generated by either the 
classical protocol or by induction of CD137L signalling (figure 24C). In each 
case, 55 – 70 % of the monocytes had differentiated into DCs, and this was 
not affected by their subsequent maturation. Hence, CD137L signalling in 
















Figure 24. Generation and maturation of classical DCs and CD137L-DCs. 
Monocytes were treated with immobilised CD137-Fc protein (CD137L-DCs) 
for 7 days, or with 80 ng/mL GM-CSF plus 100 ng/mL IL-4 (classical DCs). 
For the final 18 h of culture, TNF, IL-1, IL-6 and PGE2 were used to mature 
classical DCs, while IFN- (50 ng/ml) plus R848 (1 g/ml) were used to 
mature CD137L-DCs. (A) Photographs were taken on day 7 at a 
magnification of 40 and 63 ×. Scale bar: 20 m. (B) Cells were harvested and 
expression of CD14, CD83, CD86, HLA-DR, and HLA-ABC was determined 
by flow cytometry. These data are representative of at least 2-3 independent 
experiments with comparable results. (C) DC numbers were quantified by 
manual counting using microscopy or by counting beads using flow 
cytometry. Bar charts represent cell count per million cells seeded on day 0. 
Depicted are means ± standard deviations of triplicate countings. These data 












3.4.2. Classical DCs are superior to CD137L-DCs when whole protein 
antigen is used  
In this first approach, recombinant pp65 whole protein was utilised to 
comparatively assess the antigen-presenting capacity of classical DCs and 
CD137L-DCs. This would require the DCs to endocytose the antigen followed 
by its processing and subsequent expression of peptide antigen-MHC 
complex onto the cell surface. DCs were pulsed with pp65 protein at various 
concentrations, matured and then co-cultured with an autologous pp65-
specific T-cell line (generated with pp65 protein) for 18 h before surface 
expression of the T-cell activating marker, CD137, was determined to 
measure activation.   
To generate a pp65 T-cell line, PBMCs were pulsed with recombinant CMV 
pp65 protein. After 9-10 days, pulsed PBMCs were predominantly T cells 
based on their CD3 expression (figure 25). About 76 % of these T cells were 
CD4+ while the rest were CD8+.  
 
Figure 25. Phenotype of the pp65-specific T-cell line generated by 
recombinant pp65 protein. Donor PBMCs were stimulated with recombinant 
pp65 protein (10 g/ml) for 9-10 days, with rIL-2 (10 U/ml) added after 24 h. 
Cells were immunostained for CD3, CD4, and CD8 and analysed by flow 
cytometry. In the left panel, unshaded and grey histograms represent 
unstained control and indicated surface marker, respectively. The right panel 
shows a dot plot of the population gated for CD3+ cells. Values in the 
histogram and dot plot are percentages of positive cells from a single 
experiment. These data are representative of at least 2 independent 
experiments with comparable results. 
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Classical DCs are superior initiators of a pp65-specific CD4+ and CD8+ T-cell 
response. Although percentages of CD4+CD137+ T cells did not differ much 
amongst the various DC subsets, the MFI suggest that both immature and 
mature classical DCs are much more potent activators of CD4+ T cells than 
CD137L-DCs even at the lowest antigen concentration (figure 26A). The 
CD4+ T-cell activating ability of classical DCs reached a maximum at 0.1-1 × 
pp65 protein concentration and increasing antigen levels led to a reduction in 
T-cell activation. CD137L-DCs on the other hand, were able to increase, in an 
antigen dose-dependent manner, their capacity to activate CD4+ T cells.  
However, both untreated and mature CD137L-DCs pulsed with even 10 × 
concentration of pp65 protein were not able to activate CD4+ T cells more 
potently than mature classical DCs.  
A similar response was noticed in the CD8+ T-cell population. The lowest 
amount of pp65 antigen used (0.1 ×) was able to induce a maximum number 
of activated CD8+ T cells by classical DCs while a further increase of pulsed-
antigen was unable to supplement T-cell activation as the percentage of 
CD137+ T cells had plateaued (figure 26B). CD137L-DCs were substantially 
less able to activate CD8+ T cells although their capacity could be increased 
by pulsing with higher amounts of protein antigens. Altogether, these data 
shows that even though CD137L-DCs can perform cross-presentation, they 







Figure 26. CD137L-DCs pulsed with whole pp65 proteins are weak T-cell 
activators. Day 7 DCs were pulsed with recombinant pp65 protein at the 
indicated concentrations (1× = 3.85 g/ml) overnight with simultaneous 
maturation with either Jonuleit cocktail for classical DCs or R848 plus IFN- 
for CD137L-DCs. Day 9/10 pp65 T-cell line generated by pp65 proteins was 
harvested and co-cultured with protein-pulsed DCs at a ratio of 10:1 for 18 h. 
T cells were immunostained for the T-cell activation marker CD137, and co-
stained for either CD4 (A) or CD8 (B) followed by analysis by flow cytometry. 
The line-graph represents the quantitative evaluation of all protein 
concentrations against various DC subsets. Depicted are means ± standard 




3.4.3. Mature CD137L-DCs potently activate autologous, peptide pool-
generated, antigen-specific T cells within 18 h  
Besides using whole protein antigens, peptides are also commonly used in 
DC immunotherapy to stimulate an antigen-specific T-cell response. In this 
second approach, DCs were pulsed with pp65 peptides and were co-cultured 
with the autologous pp65-specific T-cell line for 18 h before expression of 
intracellular cytokines were measured to quantify T-cell activation.  
To generate a pp65 T-cell line, PBMCs were pulsed with a CMV pp65 peptide 
pool. After 9-10 days, pulsed PBMCs were predominantly T cells based on 
their CD3 expression (figure 27). About 68-70 % of these T cells were CD8+ 
while the rest were CD4+.  
 
 
Figure 27. Phenotype of the pp65-specific T-cell line generated by the 
pp65 peptide pool. Donor PBMCs were stimulated with PepTivator pp65 
spanning peptide pool (0.1 g/ml per peptide) for 9-10 days, with rIL-2 (10 
U/ml) added after 24 h. Cells were immunostained for CD3, CD4, and CD8 
and analysed by flow cytometry. In the left panel, unshaded and grey 
histograms represent unstained control and indicated surface marker, 
respectively. The right panel shows a dot plot of the population gated for 
CD3+ cells. Values in the histogram and dot plot are percentages of positive 
cells from a single experiment. These data are representative of at least 3 





In the absence of pp65 peptides, T cells remained unactivated and did not 
produce any of the cytokines tested (figure 28). The different types of DCs 
were equally able to activate CD8+ T cells in an antigen- and dose- 
dependent manner, however at 1 g/ml per peptide concentration, T-cell 
activation was significantly potentiated by mature CD137L-DCs as denoted by 
the IFN- expression (46.2 % of T cells), (figure 28A). Untreated CD137L-DCs 
were least able to activate pp65-specific T cells at this high antigen 
concentration (19.2 % of T cells). About 29-33 % of CD8+ T cells were 
activated by immature/mature classical DCs. Besides IFN-, TNF is also 
produced by pp65-specific CD8+ T cells (Shin et al., 2013). Despite the ability 
of mature CD137L-DCs to induce a high percentage of IFN--producing CD8+ 
T cells, they were unable to initiate potent TNF production by these T cells 
(5.9 % of T cells). On the other side, both immature and mature classical DCs 
were much more potent in promoting TNF production (9.8 % and 8.3 % of T 
cells, respectively). Untreated CD137L-DCs were only able to promote a 
maximum TNF production in 4.1 % of CD8+ T cells. Regardless of the 
capacity to induce TNF production in T cells, mature CD137L-DCs were 
potent activators of CD8+ T cells as IFN- production is considered a key 
cytokine that signifies functional activation of cytotoxic T cells. 
A similar pattern was observed for the priming of CD4+ T cells by the different 
DC populations (figure 28B). CD4+ T cells remained inactive in the absence of 
pp65 peptides and only a small population was minimally activated in the 
presence of pp65 peptide at a concentration of 0.01 g/ml. Maximal T-cell 
activation was achieved at a peptide concentration of 0.1 g/ml while a further 
increase in loaded peptides (1 g/ml) led to a slight reduction in T-cell 
activation and this trend was observed in all DC types. More importantly, the 
mature form of classical DCs and CD137L-DCs were more potent activators 
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of CD4+ T cells than their immature counterpart. At 0.1 g/ml per peptide 
concentration, 25-26 % of T cells produced IFN- when co-cultured with the 
mature form the DCs while only 18.3 % and 12.4 % were IFN-+ when 
restimulated by immature classical DCs and untreated CD137L-DCs, 
respectively. Unlike their effects on CD8+ T cells, mature CD137L-DCs were 
able to activate CD4+ T cells to not only produce IFN- but also TNF. In fact, 
mature CD137L-DCs and mature classical DCs were the strongest activators 
of TNF-producing CD4+ T cells. A similar pattern was also observed for the 
expression of CD154; a CD4+ activation marker. Untreated CD137L-DCs 
were the least effective APCs in instilling a CD4+ T-cell response. 
Collated data from four independent experiments validated that mature 
CD137L-DCs are indeed more potent activators of both antigen-specific CD8+ 















Figure 28. Mature CD137L-DCs pulsed with a pp65 peptide pool are 
potent T-cell activators. Day 7 DCs were left untreated or matured with 
either the Jonuleit cocktail for classical DCs, or R848 plus IFN- for CD137L-
DCs for 18 h. Upon maturation, DCs were pulsed with the pp65 peptide pool 
at 0.01 g/ml, 0.1 g/ml or 1 g/ml of each peptide or no peptides as a control 
for 2 h at 37ºC. Day 9/10 pp65 T-cell line generated by pp65 peptide pool was 
harvested and co-cultured with protein-pulsed DCs at a ratio of 10:1 in the 
presence of 2 g/ml Brefeldin A for a further 18 h. T cells were 
immunostained intracellularly for IFN-, TNF, and CD154 (only for CD4+ T 
cells) and co-stained for either CD8 (A) or CD4(B) followed by analysis by 
flow cytometry. Line-graphs represent the quantitative evaluation of all 
peptide concentrations against the various DC subsets. Depicted are means 
± standard deviations of percentages of duplicate measurements. **p<0.01 





Figure 29. Mature CD137L-DCs potently induce IFN- but not TNF 
production in both CD8+ and CD4+ T cells. Scatter plot depicting collated 
data of IFN--secreting or TNF-secreting CD8+ or CD4+ pp65-specific T cells 
from 3-4 independent experiments. Day 7 DCs were left untreated or matured 
with either the Jonuleit cocktail for classical DCs, or R848 plus IFN- for 
CD137L-DCs for 18 h. Upon maturation, DCs were pulsed with the pp65 
peptide pool at 1 g/ml of each peptide for 2 h at 37ºC. Day 9/10 pp65 T-cell 
line generated by pp65 peptide pool was harvested and co-cultured with 
protein-pulsed DCs at a ratio of 10:1 in the presence of 2 g/ml Brefeldin A 
for a further 18 h. T cells were immunostained intracellularly for IFN- and 
TNF, and co-stained for either CD8  or CD4 followed by analysis by flow 
cytometry. Depicted are percentage and MFI means ± standard deviation. 







3.4.4. Both untreated and mature CD137L-DCs are able to potently 
activate autologous, peptide pool-generated, antigen-specific T 
cells in 5 days 
Having demonstrated that mature CD137L-DCs are superior antigen-specific 
T-cell activators, the next logical step was to characterise the T cells 
restimulated by the various DCs. Rather than investigating the T cells after a 
short reactivation period, T cells were co-culture with the various pp65 
peptides-pulsed DCs for 5 days prior to further analysis. This mimics the 
physiological situation where DC interaction with T cells is dynamic and 
occurs in three distinct phases over a period of 48 h or more (Mempel et al., 
2004). 
 
3.4.4.1. Morphology of DC-T-cell co-culture 
Photographs of the co-culture were acquired on day 5, and in the absence of 
pp65 peptides, a small number of T-cell clumps were observed in all co-
culture conditions (figure 30). These clumps could be due to the presence of 
residual activated T cells and not due to their restimulation by the DCs. T cells 
co-cultured with antigen pulsed untreated or mature CD137L-DCs formed not 
only more aggregates but ones that were also larger in size and grew in 
clonal suspension in an apparent homotypic aggregate. When observed at a 
higher magnification, co-cultures with either pulsed immature or mature 
classical DCs were able to drive T cells to form larger aggregates than in their 
respective unpulsed condition. Nevertheless, T-cell aggregates were 
markedly smaller than those cultured with CD137L-DCs implying that 
CD137L-DCs, whether untreated or matured, are better T-cell restimulators 




Figure 30. pp65 T cells cultured with CD137L-DCs form large 
aggregates. DCs were either used unpulsed or pulsed with pp65 peptide 
pool (at 0.1 g/ml per peptide) and co-cultured with day 9/10 pp65-specific T 
cells at a ratio of 1:10. Photographs were taken on day 5 at magnifications of 
40 and 63 ×. 
 
3.4.4.2. Cytokine production and T-cell phenotype 
DCs can not only present antigens but also determine the outcome of an 
immune response by inducing T-cell activation and polarisation. Hence, T-cell 
function is more often than not directly influenced by the stimulating DCs, and 
their cytokine production is a good phenotypic indicator of the T cells 
generated.  
Pro-inflammatory T cells can be divided into 3 main subsets, namely Th1, Th2 
and Th17, and are distinguishable by the type of cytokines they produce. Th1 
cells generally secrete IFN- and TNF, Th2 cells secrete IL-4 and IL-13 while 
Th17 cells produce IL-17 (Kadowaki, 2007; Kurts, 2008). Anti-inflammatory 
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Tregs can be characterised by the production of IL-10. Activated CMV pp65 T 
cells predominantly produce the inflammatory cytokines IFN- and TNF and 
therefore skew towards a Th1 response (Kiecker et al., 2004; Shin et al., 
2013). Indeed, in all DC conditions, day 5 reactivated T cells were able to 
secrete IFN- and TNF in response to pp65 peptide presentation. This is in 
line with the previous data in section 3.4.3 which shows that IFN- was 
produced by pp65-specific T cells within a short time span especially when 
there were reactivated by mature CD137L-DCs (figure 29). Nonetheless, 
longer periods of restimulation by either untreated or mature CD137L-DCs 
rendered higher overall IFN- and TNF production by T cells compared to 
those restimulated by the classical DCs. Untreated CD137L-DCs induced 2 
times more IFN- (14.6 ± 0.6 ng/ml vs 7.2 ± 0.2 ng/ml) and 2.5 times more 
TNF (301 ± 8 pg/ml vs 120 ± 2 pg/ml) compared to mature classical DCs 
(figure 31). Mature CD137L-DCs were most effective and T cells restimulated 
by them produced by far the highest amount of IFN- (25.7 ± 1 ng/ml) and 
TNF (324 ± 6 pg/ml). Collectively, despite the inefficiency of CD137L-DCs to 
strongly activate pp65 T cells within 18 h (figure 29), it is clear that a longer 
period of T-cell-DC interaction is required for untreated CD137L-DCs to exert 
their potent T-cell activating function.  
CD137L-DCs have been shown to activate not only Th1 but also Th2 and 
Th17 subsets of CD4+ T cells (Kwajah and Schwarz, 2010). Thus, production 
of IL-13 and IL-17 were also analysed. Basal levels of IL-13 were produced (< 
3 ng/ml) in the absence of stimulation which were heightened upon 
restimulation with peptide-pulsed DCs (figure 31). Co-culture of T cells with 
untreated CD137L-DCs was more effective than classical DCs in elevating 
production of IL-13 (4.4 ± 0.1 ng/ml vs 2.7 ± 0.1 ng/ml) and even more so by 
mature CD137L-DCs (5.4 ± 0.1 ng/ml). Although CD137L-DCs are capable of 
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polarising CD4+ T cells towards a Th2 phenotype, this is surprising, in the 
context of CMV, as pp65 is not known to induce IL-13 production in T cells. 
Instead, CMV infection induces an inflammatory response with a distinct type 
1 cytokine signature (van de Berg et al., 2010). The other cytokines tested, IL-
17 and IL-10, were not detected in the co-culture supernatants suggesting 
that Th17 cells and Tregs are not activated by CMV infection (data not 
shown).   
 
 
Figure 31. T cells stimulated by CD137L-DCs for 5 days induce high Th1 
and Th2 cytokine secretion. DCs were pulsed with a pp65 peptide pool or 
were used unpulsed. T cells specific for pp65 were co-cultured with the 
peptide-pulsed DCs at a ratio of 10:1. IL-2, IL-7 and IL-15 were added on day 
3 of restimulation. Concentrations of IFN-, TNF and IL-13 in day 5 
supernatants were determined by ELISA. Depicted are means ± standard 
deviations of percentages of triplicate measurements. These data are 
representative of at least two independent experiments with comparable 





IL-13, TNF and IFN- are cytokines that are predominantly synthesised by 
CD4+ T cells, although the latter is also produced by cytotoxic CD8+ T cells. 
Since CD137L-DCs, especially in the mature form, were able to strongly 
initiate the production of these cytokines by T cells, we speculated that there 
may be a shift in the CD8/CD4 T-cell ratio towards a CD4+ T-cell bias when 
pp65 T cells are primed by CD137L-DCs. Day 5 co-cultures attained were 
predominantly T cells as more than 96 % were CD3+ (figure 32A). More 
notably, pp65-specific T cells restimulated with all types of DCs, with the 
exception of mature CD137L-DCs, had maintained or slightly reduced 
(collated data from 3 independent experiments) their CD4/CD8 population 
phenotype as compared to their initial phenotype before reactivation (figure 
27 and 32B, respectively). On the other hand, mature CD137L-DCs shifted 
the T-cell ratio towards a CD4 phenotype as evidenced by the increased 
percentage of CD4+ T cells (29.9 % vs 37.1 %) and the simultaneous 
percentage reduction of the CD8+ T cells (67.9 % vs 60.7 %) with respect to 
their phenotype prior to restimulation (figure 32A). Such a shift towards a CD4 
phenotype upon restimulation by mature CD137L-DCs was validated from 
collated data of three independent experiments (figure 32B).  
In this regard, we suggest that untreated CD137L-DCs are indeed more 
potent activators of CD4+ T cells than classical DCs as there was no 
significant shift in the CD8/CD4 ratio when restimulated by either DCs, and 
therefore the stark increase in IL-13, TNF and IFN- is likely contributed solely 
to the robust function of CD137L-DCs to drive a strong CD4+ T-cell response 
(and perhaps also CD8+ T-cell response as IFN- is also highly produced by 
these cells). On the other hand, it is likely that mature CD137L-DCs have a 
similar potency as untreated CD137L-DCs in inducing a CD4+ T-cell 
response, however, the shift of the ratio towards the CD4+ T-cell population 
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would mean that there are more CD4+ T cells that can contribute to an even 
higher production of IL-13, TNF and IFN-. 
 
Figure 32. Mature CD137L-DCs alter the CD4/CD8 T-cell ratio towards a 
CD4+ T-cell bias. DCs were pulsed with a pp65 peptide pool or were used 
unpulsed. T cells specific for pp65 were co-cultured with the peptide-pulsed 
DCs at a ratio of 10:1. IL-2, IL-7 and IL-15 were added on day 3 of 
restimulation. Cells were immunostained for CD3, CD4 and CD8, and were 
analysed by flow cytometry. (A) Bottom panel shows cells gated on the CD3+ 
population. Values in histograms depict percentages of a single experiment. 
(B) Bar chart depicts percentage difference of CD4+ T cells (left panel) and 
CD8+ T cells (right panel) with respect to the initial pre-restimulated pp65 T-




3.4.5. Both untreated and mature CD137L-DCs induce superior killing 
activity in antigen-specific autologous T cells 
Both untreated and mature forms of CD137L-DCs are able to prime pp65-
specific T cells and this leads to a large production of TNF and IFN- in a 5 
day restimulatory condition. Additionally, mature CD137L-DCs were able to 
potently activate antigen-specific CD8+ T cells within 18 h as evidenced by 
the IFN- production. Altogether, this profile suggests that mature CD137L-
DCs are able to initiate a powerful Th1 and CTL response towards specific 
antigens. To prove this hypothesis, the killing activity of T cells restimulated 
by the different DCs was determined by assessing their potency to lyse pp65 
peptides-pulsed target cells in a cytotoxicity assay.  
To ensure that target cell lysis is due to recognition of peptide-antigens and 
not HLA mismatch, it was crucial that the donor and target cells were HLA-
matched. Haplotyping of donor monocytes and the target lymphoblastoid B 
cell line (clone CM371) confirmed that they were indeed HLA-matched as 
both were HLA-A2+ (figure 33A). 
Dose-dependent killing of target cells was observed at increasing 
effector/target (E:T) ratios in all conditions (figure 33B). Notably, maturation of 
classical DCs or CD137L-DCs had no or little effect, respectively, on their 
ability to induce cytotoxic activity in the T cells. In the absence of pp65 
peptides, immature or mature classical DCs restimulated T cells had no 
cytotoxic activity while T cells restimulated by CD137L-DCs, with or without 
maturation, killed 4 – 20% of the target cells. Regardless of the restimulatory 
DC, pulsing of target cells with pp65 peptides enhanced in each case the 
capacity to induce the T-cell killing activity. 
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T cells primed by CD137L-DCs were at least twice as effective as T cells 
primed by classical DCs in lysing target cells at all E:T ratios tested. The 
percentages of specific lysis of target cells by T cells restimulated by 
untreated CD137L-DCs were 49 %, 63 % and 75 %, respectively, at E:T 
ratios of 5:1, 10:1 and 20:1, while the percentages were 16 %, 23 % and 35 
%, respectively, for T cells primed by mature classical DCs. Taken together, 
these data demonstrate that autologous, antigen-specific T cells that have 
been restimulated by CD137L-DCs are functionally superior to T cells 













Figure 33. pp65 T cells restimulated by CD137L-DCs are more cytotoxic 
than T cells restimulated by classical DCs. (A) Monocytes were isolated 
from a HLA-A2+ donor, and the EBV-lymphoblastic cell line CM371 was 
immunostained for CD20 and HLA-A2 and analysed by flow cytometry. (B) 
CM371 cells were loaded with DELFIA® BATDA reagent, pulsed with the 
pp65 peptide pool and used as target cells. As a control, unpulsed cells were 
used. T cells restimulated by the different DCs for 5 days were added at the 
indicated effector/target ratios, and were incubated for 3 h. Depicted are 
mean ± standard deviation of percentages of specific lysis from triplicate 
measurements. **p<0.01 using a two-tailed unpaired Student’s t-test. These 
data are representative of at least two independent experiments with 





3.5. Transcriptional profiling of CD137L-DCs reveals a closer 
relationship with classical DCs rather than macrophages 
To better understand the biological and functional properties of CD137L-DCs, 
we analysed their transcriptional profile and compared it to those of 
macrophages and classical DCs which are cellular subtypes representing 
terminal differentiation of monocytes.  
Using monoytes from 4 healthy individuals, the various cellular subtypes; 
immature and mature classical DCs, macrophages, CD137L-DCs and Fc-
treated monocytes, were generated over a period of 8 days. Gene expression 
profiles of these populations, together with that of a day 0 monocyte control, 
were obtained using Illumina Expression BeadChip arrays. Gene profiling of 
mature CD137L-DCs were not obtained as at that point of study, the 
optimised maturation factors (i.e. R848 plus IFN-) had not been deciphered. 
However, they were later used for protein expression verification studies and 
also functional assays. 
To obtain differentially expressed genes, linear model for microarray data 
(limma) package with paired sample analysis was applied on the dataset 
(Smyth, 2004). Gene probes with p-values < 0.01 with respect to control 
monocytes were of interest. The CD137L-DC signature probes were selected 
by obtaining the gene set that was found in the intersection of differentially 
expressed genes of CD137-Fc treatment vs monocytes and differentially 
expressed genes of CD137-Fc vs Fc (figure 34). This allowed for the 
acquisition of differentially expressed genes which are contributed solely by 
CD137L reverse signalling into monocytes. A total of 974 probes, 





Figure 34. Methodology for the acquisition of CD137L-DC differentially 
expressed genes. The CD137L-DC signature probes were selected by 
obtaining the gene set that was found in the intersection of differentially 
expressed genes of CD137-Fc treatment vs monocytes and differentially 
expressed genes of CD137-Fc vs Fc. This allowed for the acquisition of 
differentially expressed genes which are contributed solely due to CD137L 
reverse signalling into monocytes.  
 
To determine the relationship of CD137L-DCs with the other cell populations, 
the CD137L-DC differentially expressed genes dataset was subjected to 
hierarchical clustering and cMAP analysis (figure 35). The closer the cMAP 
score is to the value 1 the closer is the linkage to CD137L-DCs, while a larger 
cluster distance refers to a weaker linkage to CD137L-DCs. Both analyses 
unravelled that CD137L-DCs are more closely clustered to mature and 
immature classical DC than to macrophages. This reiterates the previous 









Figure 35. Transcriptional profiling shows that CD137L-DCs are more 
similar to classical DCs than macrophages. Indicated DCs and APCs were 
generated from 4 healthy donors. RNA was obtained and gene expression 
profiling was performed using Illumina Human HT12-V4 BeadChip arrays. 
Gene expression profiles of differentially expressed genes were subjected to 
(A) hierarchical clustering and (B) cluster distance analysis (Pearson 
correlation, average linkage between sample groups) using R package and 
also (C) cMAP analysis. The length of lines is proportional to the 
transcriptional similarity between CD137L-DCs and the respective DCs or 
APCs. 
 
3.6. Characteristics of CD137L-DCs revealed by in silico analysis  
The transcriptional fold-changes of the 829 signature CD137L-DC 
differentially expressed genes were compared alongside monocytes, 
macrophage, immature and mature classical DCs to acquire a list of genes 
which were highly expressed in CD137L-DCs with respect to the different cell 
population subtypes. The top 25 differentially expressed genes by CD137L-
DCs in each group are shown in tables 7-10. To determine the unique 
functional characteristics of CD137L-DCs against each of the cell population, 
CD137L-DC differentially expressed genes with >2 fold change in each group 
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were subjected to Gene Ontology (GO) biologic process using DAVID tools 
(Huang da et al., 2009). Categories with significant enrichment (p value < 
0.05) were acquired and similar categories were grouped together (table 11).  
When compared to control monocytes, CD137L reverse signalling initiate 
functional responses that are distinctively involved in lipid processes, immune 
responses and adhesion (table 11). However, as CD137L-DCs are highly 
potent DCs, it was of interest to discover the key biologic functions that 
makes CD137L-DCs a stronger T-cell activator than classical DCs. To answer 
this, a GO comparison between CD137L-DCs with classical DCs was 
performed. GO enrichment of highly expressed differentially expressed genes 
in CD137L-DCs compared to mature classical DCs showed that CD137L-DCs 
participates greatly in cell adhesion, locomotion and activation of immune 
responses while functions of lipid processes, adhesion and immune 
responses are increased when compared to immature classical DCs. The 
representative genes involved in several of these GO enrichment categories 
are shown in figure 36. Hence, these biologic processes may be essential to 
unravel the reasons behind the heighten potency of CD137L-DCs compared 









Table 7: Top 25 differentially expressed genes in CD137L-DCs as compared 
to monocytes 
GeneSymbol Gene Name Fold change 
CCL22 Chemokine (C-C Motif) Ligand 22 2841 
SPP1 Secreted Phosphoprotein 1 1575 
MMP7 Matrix Metallopeptidase 7 (Matrilysin, Uterine) 841 
GPNMB Glycoprotein (Transmembrane) Nmb 547 
CXCL5 Chemokine (C-X-C Motif) Ligand 5 545 
LAMP3 Lysosomal-Associated Membrane Protein 3 458 
TM4SF19 Transmembrane 4 L Six Family Member 19 419 
MMP7 Matrix Metallopeptidase 7 (Matrilysin, Uterine) 392 
INDO Indoleamine 2,3-Dioxygenase 1 283 
TM7SF4 Transmembrane 7 Superfamily Member 4 257 
CYP27B1 Cytochrome P450, Family 27, Subfamily B, Polypeptide 1 196 
SCG5 Secretogranin V (7B2 Protein) 192 
LPL Lipoprotein Lipase 191 
FXYD2 Fxyd Domain Containing Ion Transport Regulator 2 185 
CCL17 Chemokine (C-C Motif) Ligand 17 180 
IDO1 Indoleamine 2,3-Dioxygenase 1 178 
PLTP Phospholipid Transfer Protein 159 
SLCO2B1 Solute Carrier Organic Anion Transporter Family, Member 
2B1 
153 
NDP Norrie Disease (Pseudoglioma) 142 
CCR7 Chemokine (C-C Motif) Receptor 7 124 
TM4SF19 Transmembrane 4 L Six Family Member 19 119 
PDPN Podoplanin 118 
DHCR24 24-Dehydrocholesterol Reductase 104 
EBI3 Epstein-Barr Virus Induced 3 94 
 
Table 8: Top 25 differentially expressed genes in CD137L-DCs as compared 
to mature classical DCs 
GeneSymbol GeneName Fold change 
CXCL5 Chemokine (C-X-C Motif) Ligand 5 392 
CLEC5A C-Type Lectin Domain Family 5, Member A 237 
SCG5 Secretogranin V (7B2 Protein) 142 
TNFRSF21 Tumor Necrosis Factor Receptor Superfamily, Member 21 142 
C19orf59 Chromosome 19 Open Reading Frame 59 65 
AOX1 Aldehyde Oxidase 1 53 
GPC4 Glypican 4 43 
MTMR11 Myotubularin Related Protein 11 35 
NDRG2 Ndrg Family Member 2 33 
SEZ6L2 Seizure Related 6 Homolog (Mouse)-Like 2 32 
TPM2 Tropomyosin 2 (Beta) 30 
FOS V-Fos Fbj Murine Osteosarcoma Viral Oncogene Homolog 28 
DBN1 Drebrin 1 26 
PTPRF Protein Tyrosine Phosphatase, Receptor Type, F 26 
CA2 Carbonic Anhydrase Ii 25 
MYO1B Myosin Ib 25 
PITPNC1 Phosphatidylinositol Transfer Protein, Cytoplasmic 1 24 
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HOPX Hop Homeobox 24 
NRGN Neurogranin (Protein Kinase C Substrate, Rc3) 24 
TACSTD2 Tumor-Associated Calcium Signal Transducer 2 22 
GREM1 Gremlin 1, Cysteine Knot Superfamily, Homolog (Xenopus 
Laevis) 
21 
PTPN13 Protein Tyrosine Phosphatase, Non-Receptor Type 13 (Apo-
1/Cd95 (Fas)-Associated Phosphatase) 
20 
IGFBP6 Insulin-Like Growth Factor Binding Protein 6 19 
FYN Fyn Oncogene Related To Src, Fgr, Yes 18 
COL22A1 Collagen, Type Xxii, Alpha 1 18 
 
Table 9: Top 25 differentially expressed genes in CD137L-DCs as compared 
to immature classical DCs 
GeneSymbol GeneName Fold change 
CXCL5 Chemokine (C-X-C Motif) Ligand 5 842 
INDO Indoleamine 2,3-Dioxygenase 1 461 
MMP7 Matrix Metallopeptidase 7 (Matrilysin, Uterine) 294 
CLEC5A C-Type Lectin Domain Family 5, Member A 175 
SCG5 Secretogranin V (7B2 Protein) 155 
CCR7 Chemokine (C-C Motif) Receptor 7 114 
CLLU1OS Chronic Lymphocytic Leukemia Up-Regulated 1 Opposite 
Strand 
65 
EBI3 Epstein-Barr Virus Induced 3 61 
GPC4 Glypican 4 55 
AOX1 Aldehyde Oxidase 1 53 
TMEM132A Transmembrane Protein 132A 41 
PTPRF Protein Tyrosine Phosphatase, Receptor Type, F 38 
GLDN Gliomedin 36 
PMAIP1 Phorbol-12-Myristate-13-Acetate-Induced Protein 1 36 
SLC1A2 Solute Carrier Family 1 (Glial High Affinity Glutamate 
Transporter), Member 2 
33 
SEZ6L2 Seizure Related 6 Homolog (Mouse)-Like 2 28 
FPR2 Formyl Peptide Receptor 2 28 
MYO1B Myosin Ib 26 
DBN1 Drebrin 1 25 
LAT Linker For Activation Of T cells 23 
PDPN Podoplanin 23 
FSTL1 Follistatin-Like 1 22 
TM4SF1 Transmembrane 4 L Six Family Member 1 22 
MTMR11 Myotubularin Related Protein 11 21 
BIRC3 Baculoviral Iap Repeat-Containing 3 21 
 
Table 10: Top 25 differentially expressed genes in CD137L-DCs as 
compared to macrophages 
GeneSymbol GeneName Fold change 
CCL22 Chemokine (C-C Motif) Ligand 22 2727 
INDO Indoleamine 2,3-Dioxygenase 1 413 
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LAMP3 Lysosomal-Associated Membrane Protein 3 333 
TACSTD2 Tumor-Associated Calcium Signal Transducer 2 277 
MMP7 Matrix Metallopeptidase 7 (Matrilysin, Uterine) 275 
GPC4 Glypican 4 213 
CYP27B1 Cytochrome P450, Family 27, Subfamily B, Polypeptide 1 203 
LPL Lipoprotein Lipase 177 
CCL17 Chemokine (C-C Motif) Ligand 17 176 
CCR7 Chemokine (C-C Motif) Receptor 7 144 
NDP Norrie Disease (Pseudoglioma) 139 
NDRG2 Ndrg Family Member 2 99 
SPOCD1 Spoc Domain Containing 1 93 
EBI3 Epstein-Barr Virus Induced 3 73 
CCND1 Cyclin D1 64 
ALDH1A2 Aldehyde Dehydrogenase 1 Family, Member A2 45 
SLC1A2 Solute Carrier Family 1 (Glial High Affinity Glutamate 
Transporter), Member 2 
44 
CLLU1OS Chronic Lymphocytic Leukemia Up-Regulated 1 Opposite 
Strand 
42 
SERPINE1 Serpin Peptidase Inhibitor, Clade E (Nexin, Plasminogen 
Activator Inhibitor Type 1), Member 1 
38 
CXCL5 Chemokine (C-X-C Motif) Ligand 5 36 
PHLDA3 Pleckstrin Homology-Like Domain, Family A, Member 3 31 
PSD3 Pleckstrin And Sec7 Domain Containing 3 30 
MATK Megakaryocyte-Associated Tyrosine Kinase 29 
TMEM132A Transmembrane Protein 132A 28 
ZNF366 Zinc Finger Protein 366 27 
 
Table 11: GO enrichment of biologic processes of CD137L-DCs compared to 
other DCs/APCs. 
Term Count p 
CD137L-DC differentially expressed genes which are ≥ 2× fold-change compared to 
monocytes 
    Lipid processes   
        GO:0016126: sterol biosynthetic process 14 2.4E-12 
        GO:0006694: steroid biosynthetic process 19 7.0E-12 
        GO:0006695: cholesterol biosynthetic process 11 5.7E-10 
        GO:0008610: lipid biosynthetic process 32 6.2E-10 
        GO:0008202: steroid metabolic process 24 4.3E-9 
        GO:0016125: sterol metabolic process 17 9.3E-9 
        GO:0008203: cholesterol metabolic process 16 1.8E-8 
    Immune response   
        GO:0009611: response to wounding 34 5.1E-6 
        GO:0006954: inflammatory response 19 2.8E-3 
        GO:0006952: defense response 26 2.3E-2 
    Adhesion   
        GO:0045785: positive regulation of cell adhesion 6 2.1E-2 
        GO:0022407: regulation of cell adhesion 9 3.0E-2 
        GO:0010810: regulation of cell-substrate adhesion 5 3.3E-2 
        GO:0010811: positive regulation of cell-substrate 
adhesion 
4 3.7E-2 
        GO:0022610: biological adhesion 29 2.1E-2 
        GO:0007155: cell adhesion 29 2.1E-2 




CD137L-DC differentially expressed genes which are ≥ 2× fold-change compared to 
mature classical DC 
    Adhesion   
        GO:0007155: cell adhesion 24 2.0E-5 
        GO:0022610: biological adhesion 24 2.1E-5 
    Locomotion   
        GO:0042330: taxis 9 9.0E-4 
        GO:0006935: chemotaxis 9 9.0E-4 
        GO:0007610: behavior 15 2.3E-3 
        GO:0007626: locomotory behavior 10 7.5E-3 
    Immune response   
        GO:0009611: response to wounding 20 3.5E-5 
        GO:0006954: inflammatory response 10 2.1E-2 
        GO:0006952: defense response 13 8.4E-2 
   
CD137L-DC differentially expressed genes which are ≥ 2× fold-change compared to 
immature classical DC 
    Lipid processes   
        GO:0010743: regulation of foam cell differentiation 5 2.7E-4 
        GO:0010885: regulation of cholesterol storage 4 3.2E-4 
        GO:0010883: regulation of lipid storage 4 2.3E-3 
    Adhesion   
        GO:0007155: cell adhesion 21 6.8E-4 
        GO:0022610: biological adhesion 21 6.9E-4 
    Immune response   
        GO:0009611: response to wounding 22 4.5E-6 
        GO:0006954: inflammatory response 12 3.2E-3 
        GO:0006952: defense response 15 2.7E-2 
   
CD137L-DC differentially expressed genes which are ≥ 2× fold-change compared to 
macrophage 
    Lipid processes   
        GO:0016126: sterol biosynthetic process 10 1.5E-10 
        GO:0006694: steroid biosynthetic process 12 3.2E-9 
        GO:0006695: cholesterol biosynthetic process 8 1.2E-8 
        GO:0016125: sterol metabolic process 10 2.3E-6 
        GO:0008202: steroid metabolic process 13 3.6E-6 
        GO:0008610: lipid biosynthetic process 16 4.5E-6 
        GO:0008203: cholesterol metabolic process 9 1.0E-5 
        GO:0008299: isoprenoid biosynthetic process 5 7.0E-5 
        GO:0055114: oxidation reduction 20 1.3E-4 
        GO:0006720: isoprenoid metabolic process 5 1.6E-3 
        GO:0010743: regulation of foam cell differentiation 4 2.8E-3 
        GO:0010885: regulation of cholesterol storage 3 6.7E-3 
        GO:0010883: regulation of lipid storage 3 2.4E-2 
Immune response   
        GO:0009611: response to wounding 16 1.1E-3 
        GO:0006952: defense response 14 2.4E-2 
        GO:0006954: inflammatory response 9 3.4E-2 
        GO:0070663: regulation of leukocyte proliferation 5 1.6E-2 
        GO:0032944: regulation of mononuclear cell proliferation 5 1.6E-2 
        GO:0051249: regulation of lymphocyte activation 6 2.8E-2 
        GO:0019955: cytokine binding 5 3.7E-2 
        GO:0002694: regulation of leukocyte activation 6 4.2E-2 
Growth   
        GO:0040007: growth 7 1.9E-2 
        GO:0031099: regeneration 4 4.5E-2 





Figure 36. Representative GO categories associated with the 
differentially expressed genes most highly expressed by CD137L-DCs. 
The log 2 levels of genes associated with various GO categories deemed to 
be functionally upregulated by CD137L-DCs using DAVID tools. Fold change 









3.6.1 Flow cytometric analysis of surface markers expressed by 
CD137L-DCs  
GO enrichment analysis revealed that CD137L-DCs have several enhanced 
biological functions that may in turn positively influence their interaction and 
activation of T cells. Of primary interest were their adhesion properties. 
In order for T cells to mount a successful response, it is essential that these 
cells interact with APCs, form stable immune synapses and are subjected to 
appropriate MHC-peptide complexes and co-stimulatory molecules (Thauland 
and Parker, 2010). Structural durability of the immune synapse is key and it 
has been shown that stable and longer-lasting synapses correlate with the 
development of stronger immune responses (Hugues et al., 2004). 
Correlating effective formation of the immune synapse with the superior 
adhesion properties of CD137L-DCs, it is hypothesised that perhaps this 
could lead to a more stable immune synapse and therefore their superior T-
cell activation ability.   
Intracellular adhesion molecule 1 (ICAM-1) forms a ring on the outer part of 
the immune synapse and is necessary for the initial contact with T cells via 
interaction with LFA-1 (Davis, 2009). Although not considered as a CD137L-
DC signature gene, the surface expression of ICAM-1 was determined. 
Virtually all CD137L-DCs expressed ICAM-1 at similar levels with immature 
classical DCs and macrophages while mature CD137L-DCs expressed 3.5 
times and mature classical DCs expressed 7 times more ICAM-1 (figure 37B). 
This corresponded to the mRNA transcriptional profile (figure 37A). Another 
cell adhesion molecule, ALCAM, not only interacts with T cells to maintain a 
stable contact but also acts as a ligand to the co-stimulatory molecule CD6 on 
T cells (Zimmerman et al., 2006). ALCAM is a CD137L-DC signature gene 
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(figures 36 and 37A) and correspondingly, it is highly expressed on CD137L-
DCs (99 %, MFI= 962) while maturation with R848 plus IFN- only slightly 
increased its expression (98 %, MFI= 1151), (figure 37B). Expression is also 
high in classical DCs but only upon their maturation (97 %, MFI= 943). Other 
adhesion molecules such as PDPN and CLEC5A are expressed on CD137L-
DCs but are significantly less on both mature and immature classical DCs 
(PDPN; 33 % vs 16 % vs 1 %, respectively, and CLEC5A; 72 % vs 18 % vs 2 
%, respectively).  
In addition, surface markers which are involved in inflammatory responses, 
and in particular co-stimulation, were also investigated. OX40L and CD70 are 
members of the TNF superfamily and are important co-stimulatory molecules 
commonly found on mature classical DCs (Kober et al., 2008; Krause et al., 
2009). Based on the transcriptional profile, untreated CD137L-DCs express 
these genes at a higher levels than mature classical DCs, however, this was 
not the case when their surface expression was determined (figure 37). 
Untreated CD137L-DCs did not express both OX40L and CD70 while the 
latter was expressed only upon their maturation (42 %, MFI= 273). Similarly, 
39 % of mature classical DCs expressed CD70 (MFI= 300) but not OX40L. 
CD83, a mature DC marker, was detected on 38 % of untreated CD137L-DCs 
while only 12 % of immature DCs expressed this protein. 
The co-stimulatory molecule profiles are similar between immature classical 
DCs and untreated CD137L-DCs (with the exception of heightened CD83 in 
the latter) and also between mature classical DCs and mature CD137L-DCs. 
Taken together, it is plausible to propose that CD137L-DCs exert their 
superior T-cell activation ability due to their heighten adhesion properties 





Figure 37. Transcriptional expression and corresponding flow 
cytometric analysis of selected adhesion and co-stimulatory molecules. 
(A) Fold change of transcriptional expression of various adhesion and co-
stimulatory genes as compared to baseline monocyte expression levels. The 
horizontal dotted line refers to transcriptional levels of monocytes. Mature 
CD137L-DCs were not available for transcriptional analysis. (B) DCs and 
APCs were generated for 6 days and were further treated with LPS plus IFN-
to generate mature classical DCs or R848 plus IFN- to generate mature 
CD137L-DCs for 18 h. Cells were harvested, immunostained for the 
described corresponding markers, and analysed by flow cytometry. Values in 
histograms depict percentages and MFI of a single experiment. These data 




3.7. The biological contributions of various CD137L-DC differentially 
expressed genes 
CD137L-DCs express certain proteins such as ALCAM and other adhesion 
molecules that may contribute towards their general biological function and 
also T-cell activating potential. To test this hypothesis, we performed several 
functional assays namely to quantify adherence ability of CD137L-DCs and 
the requirement of ALCAM for T-cell activation.  
 
3.7.1. Attachment/detachment assay 
As many as 24 genes involved in adhesion were more highly transcriptionally 
expressed on untreated CD137L-DCs than their classical counterparts (figure 
36). To verify if this upregulation indeed translates to a stronger adhesion 
capacity, CD137L-DCs were tested for their ability to re-adhere onto cell 
culture plates within a short period. Day 7 DCs were harvested and re-seeded 
onto culture plates before suspended cells and adhered cells were counted 
using flow cytometric analysis at various time-points. 
As expected, CD137L-DCs were able to adhere effectively even within a short 
time span of 10 min upon inoculation. Maximal adherence had already been 
achieved within this period as there was virtually no time-dependent increase 
in the percentage of CD137L-DCs adhered (10 min: 94 %, 45 min: 95 %, 90 
min: 97 %), (figure 38A). Mature CD137L-DCs were however, slightly less 
adherent than untreated CD137L-DCs within the stipulated time-points tested. 
Immature classical DCs were the least adherent cells as only 53 % adhered 
within 10 min while mature classical DCs had intermediate adherent 
properties with 65 % of cells being adherent. Interestingly, both immature and 
mature classical DCs were less attached at 45 min (38 % and 58 %, 
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respectively) but regained adherence at 90 min (43 % and 66 %, 
respectively).  
Having shown that CD137L-DCs do adhere to culture plates at a faster pace 
than the classical DCs, we next tested the strength of adherence. Equal 
numbers of various types of DCs were plated onto culture wells before being 
incubated overnight to allow for complete attachment. DCs were then 
detached by trypsin-EDTA treatment for various time periods and counted. 
Concurring with the abovementioned observations, CD137L-DCs, both 
untreated and matured, do indeed have strong adherent properties. Only 
about 5 % of the total CD137L-DCs were detached from the culture plate at 
10 min, and prolonged periods of trypsin-EDTA treatment failed to further 
detach the DCs (figure 38B). Despite having an initial intermediate adhesion 
characteristic, mature classical DCs were most easily detached by trypsin-
EDTA (32-34 % detachment). On the other hand, 19-22 % of immature 
classical DCs were detached upon treatment. Taken together, the functional 
observations are consistent with the GO enrichment data regarding heighten 





Figure 38. CD137L-DCs are highly adherent cells.  DCs were generated 
for a period of 7 days with classical DCs matured by LPS plus IFN- while 
CD137L-DCs by R848 plus IFN- for the final 18 h. DCs were harvested and 
seeded at equal density on culture plate wells. (A) DCs were incubated at 
37ºC and at various time-points, suspended (unattached) and adhered 
(attached) cells were harvested and counted using counting beads. Depicted 
are means ± standard deviations of percentages of unattached and attached 
DC from duplicate samples. (B) DCs were incubated at 37ºC overnight before 
cells were treated with trypsin-EDTA for 5, 10, and 15 min. Detached DCs 
were harvested and counted using counting beads. Depicted are mean 
percentages ± standard deviations of detached DCs from duplicate samples. 




















3.7.2. ALCAM neutralising assay 
Amongst the genes involved in adhesion, ALCAM was a prime candidate for 
further studies as it has been described to not only play a role in DC-T-cell 
adhesion but also in lasting T-cell activation via its interaction with CD6 on T 
cells (Zimmerman et al., 2006). Since CD137L-DCs were able to strongly 
activate antigen-specific T cells even after 5 days of co-culture (figures 30 
and 31), it was speculated that ALCAM may be an important factor that 
contributes to long-term T-cell activation.  
To elucidate the contribution of DC-expressing ALCAM on T-cell activities, 
neutralising studies were performed. Noteworthy, ALCAM has been reported 
to be expressed also on activated lymphocytes (Bowen et al., 2000) and 
therefore we confirmed this by flow cytometry prior to initiating blocking 
studies. In the absence of mitogens, resting T cells are devoid of ALCAM 
expression even after 48 h of culture (figure 39). Nonetheless, activation of T 
cells by PMA plus ionomycin was able induce low expression of ALCAM on 
11 % of T cells although the MFI remained very low at 32. As a whole, 
activated T cells do not express high amounts of ALCAM, thus subsequent 
blocking of ALCAM with antagonistic anti-ALCAM antibodies in co-culture 
studies should predominantly affect ALCAM on CD137L-DCs. 
Neutralisation of ALCAM on untreated CD137L-DCs led to modest reduction 
in T-cell proliferation (12 % reduction), (figure 40). This effect was more 
pronounced when ALCAM on mature CD137L-DCs were neutralised. In this 
case, T-cell proliferation was reduced by nearly 40 %. Interestingly, despite 
the presence of ALCAM on immature and mature classical DCs, there were 
no effects on T-cell proliferation even after the blockade of ALCAM with 
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antagonistic antibody. These evidences suggest that ALCAM may play a role 
in the ability of CD137L-DCs to promote potent T-cell activation and function. 
 
 
Figure 39. Activated T cells express low levels of ALCAM. T cells were 
isolated from PBMCs by positive selection and treated with PMA plus 
ionomycin for 24 and 48 h to induce activation. Resting T cells were used as 
controls. Cells were immunostained for surface ALCAM and analysed by flow 
cytometry. Unshaded and grey histograms represent unstained control and 
ALCAM, respectively. Values in histograms are percentages of positive cells 







Figure 40. Neutralising ALCAM on CD137L-DCs reduces T-cell 
activation. DCs were generated for a period of 7 days with classical DCs 
matured by LPS plus IFN- while CD137L-DCs by R848 plus IFN- for the 
final 18 h. DCs were then further co-cultured with allogeneic T cells at a ratio 
of 1:10. At day 4, proliferation was quantified by 3H-thymidine incorporation. 
Proliferations are expressed as the percentage of PBS control and are means 
± standard deviations of triplicate measurements. *p<0.05; **p<0.01 using a 
two-tailed unpaired Student’s t-test. This experiment has been performed 






















CHAPTER 4: DISCUSSION 
4.1. Discovery of a new form of DC for immunotherapy: CD137L-DCs 
The traditional oncologic treatment modalities – surgery, chemotherapy and 
radiotherapy – are the status quo regimes for the combat against cancer. 
More recently, biologic therapies utilising the immune system are gaining 
acceptance as a complementary approach towards a more holistic form of 
anti-cancer treatment. Specifically, immunotherapeutic procedures such as 
infusing immune modulating antibodies, NK and T-cell adoptive transfer, and 
DC-based vaccines are some avenues in which scientists are probing to 
develop (Childs and Berg, 2013; Kalos and June, 2013; Palucka and 
Banchereau, 2013; Sliwkowski and Mellman, 2013). Though much insights 
and progress have been gained, it is still early days in the immunotherapeutic 
field and much research is required to understand and optimise the protocols 
for treatment. 
In this project, we aimed to further develop DC-based vaccines by 
characterising a novel type of DC that was previously described to be 
biologically potent in instilling allogeneic T-cell responses (Ju et al., 2009; 
Kwajah and Schwarz, 2010). Nonetheless, these CD137L-stimulated DCs 
(CD137L-DCs) had not been tested for their ability to stimulate autologous T 
cells. Therefore, it is paramount that these CD137L-DCs be further defined in 
an autologous system in order to determine their potential use as an 
immunological tool for therapy. Through the use to cytomegalovirus (CMV)-
derived protein pp65 as a model antigen, we demonstrated that CD137L-DCs 
induce an abundant secretion of IFN-, TNF and IL-13 from autologous pp65-
specific T cells, endowing them with a robust cytotoxic potential towards HLA-
matched, pp65-pulsed target cells. Furthermore, transcriptional profiling of 
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CD137L-DCs corroborated with their biological phenotype in which they are 
more similar to classical DCs than to macrophages. In this section, we will 
discuss the functional biology of CD137L-DCs in addition to their 
requirements for maturation and activation. Next, we will evaluate the 
potential of CD137L-DCs as a means for DC-based immunotherapy and 
consider further clarifications required before any application in the clinical 
setting can be envisaged. 
 
4.2. Ex vivo generated DC-based vaccines: A challenge 
Appreciable effort has been made to develop strategies for using ex-vivo 
generated DCs to mount a proficient anti-tumour immune response. Many 
clinical studies from the past decade have concluded that such vaccines are 
safe and generally have a low toxicity profile thus making the procedure an 
enticing option for cancer treatment (Alatrash et al., 2013). Conventional GM-
CSF plus IL-4 generated DCs (classical DCs) are intensively researched 
upon and have been successful in the clinic although the response rates of 
patients to DC-based therapies remain low (Figdor et al., 2004; Osada et al., 
2006; Thomas-Kaskel and Veelken, 2007; Tuyaerts et al., 2007). More 
recently, further developments have implemented new innovations in DC 
preparations such as by inducing the differentiation of DCs within three days 
and those matured by TLR agonists to facilitate production of IL-12 
(Frankenberger and Schendel, 2012). Although many current protocols are 
able to stimulate tumour-specific CD4+ and/or CD8+ T cells, most responses 
are neither robust nor long lasting owing to inadequate T-cell activation and 
maintenance coupled with a highly immunosuppressive tumour 
microenvironment (Hadrup et al., 2013). Further, a major regulatory obstacle 
for immunotherapy is the requirement of good manufacturing production 
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(GMP). In addition to the need to use GMP-grade media and antigens 
(peptide/proteins or RNA), the majority of current DC production and 
maturation protocols require the application of a large amount of recombinant 
cytokines including GM-CSF, IL-4, IL-1, IL-6, IFN-, TNF and PGE2 which in 
turn adds to the complexity of the protocol and an increase in production 
costs (Cintolo et al., 2012; Erdmann and Schuler-Thurner, 2010). Thus, there 
is presently an immense interest in the aspects of modulating DCs in terms of 
their development, maturation, antigen delivery and mode of vaccine 
inoculation (Cintolo et al., 2012; Palucka and Banchereau, 2013; Schuler, 
2010). Against a backdrop of intensive exploration for optimised DC-based 
vaccine protocols, our identification and characterisation of this novel yet 
potent CD137L-DCs is particularly pertinent.  
 
4.3. Activation of CD137L-DCs by exogenous cytokines 
As reviewed in the introductory section, T cells can be polarised towards 
various phenotypes (i.e. Th1, Th2, Th17, Treg, etc) and this is dependent on 
the activation status of the stimulating DCs. Such differentially activated DCs 
are developed in the presence of inflammatory cytokines and mediating 
factors. 
Before proceeding to the maturation experiments, preliminary findings 
suggested that CD137L-DCs are more potent than classical DCs when 
peptides are used. Although IFN- production by T cells restimulated by 
CD137L-DCs was higher than those restimulated by classical DCs, there was 
also no difference in their ability to promote stronger antigen-specific T-cell 
proliferation (figures 8-10). It is, however, important to note that the detection 
of IFN- production by T cells and their proliferation were performed at a 
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different time-points (18 h for IFN- production and 5 days for proliferation). 
Such a discrepancy could be due to the difference in kinetics between the 
onset of cytokine production and proliferation. Additionally, CD137L-DCs 
were weaker T-cell activators compared to classical DCs when whole protein 
antigens, in this case tetanus toxoid, were used as an antigen of interest 
(figures 11 and 12). Even the addition of LPS or TNF which are commonly 
used to induce type-1 DC maturation failed to further activate CD137L-DCs 
(figures 11 and 12), (Kalinski et al., 2009). In fact, pre-treatment of CD137L-
DCs with either LPS or TNF rendered the peptide-restimulated T cells less 
able to secrete IFN-(figure 9). These initial findings prompted us to search 
for maturation factors that may be able to potentiate the T-cell activating 
effects of CD137L-DCs.  
It was previously described that CD137L-DCs are able to induce a stronger T-
cell response than mature classical DCs (Ju et al., 2009; Kwajah and 
Schwarz, 2010). In order to further boost T-cell activation, Kwajah and 
Schwarz further treated CD137L-DCs with a combination of LPS (a TLR4 
agonist) and IFN-a commonly used DC maturation cocktail. Although this 
concoction led to a substantial increase in the expression of CD80, CD86, 
HLA-DR and CCR7 on CD137L-DCs, therefore prompting a matured identity, 
the resultant mature CD137L-DCs were unable to potentiate allogeneic T-cell 
activation, and were essentially similar to untreated CD137L-DCs (Kwajah 
and Schwarz, 2010). Nevertheless, the fact that the expression of DC 
maturation markers could be upregulated implied that CD137L-DCs can be 
enhanced by maturation, but it was unclear whether factors other than, or in 
addition to, LPS and IFN- would be required. Accordingly, we explored the 
possibility to augment the T-cell activating potency of CD137L-DCs by using 
an array of published maturation cocktails (table 4), (Boullart et al., 2008; 
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Jonuleit et al., 1997; Zobywalski et al., 2007). These cytokine cocktails were 
carefully selected for their ability to promote potent Th1 and CD8+ CTL 
responses which are desirable for anti-tumour therapy. 
Amongst the 7 different types of maturation cocktails used, cocktails C3 and 
C4 were able to promote further morphological differences as compared to 
the untreated CD137L-DCs (figure 13). In either C3 or C4 matured conditions, 
CD137L-DCs were much more adhered and had more pronounced dendrite 
and spindle formation. Such morphological changes were the first evidence to 
propose that these maturation cocktails were able to further activate CD137L-
DCs. Also, the concomitant increase in cellular adhesion was suggestive of a 
more activated phenotype as the adherent CD137L-DCs, rather than those in 
suspension, were defined to be the population that contributes significantly to 
the T-cell activation (personal communication with Dr. Shaqireen Kwajah).  
Furthermore, CD137L-DCs in the presence of maturation cocktails C3 and C4 
had significantly higher expression of DC maturation marker CD83, co-
stimulatory molecule CD86, and HLA-DR while CD80 and CCR7, an essential 
chemokine receptor required to guide DC migration to the lymph nodes, were 
slightly upregulated (figure 15), (Gunn, 2003; Randolph et al., 2005). These 
results supplemented the morphological changes observed in C3 and C4- 
treated CD137L-DCs. A salient observation was that the abovementioned 
surface molecules were also upregulated in C1 (LPS and IFN-)-treated 
CD137L-DCs (figure 15) and as previously discussed, these maturation 
factors were not able to potentiate T-cell stimulation despite the apparent 
maturation state of CD137L-DCs (Kwajah and Schwarz, 2010). Indeed, our 
data supports this view as C1-treated CD137L-DCs have a similar capacity as 
their untreated counterparts to induce T-cell activation (figure 17). Thus, a 
supposed mature DC phenotype based on the expression of surface 
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molecules may not necessarily translate to a more biologically potent activity. 
It is therefore essential that the DCs’ functional potential be ascertained by 
their ability to activate T cells rather than solely relying on maturation 
markers. 
That said, the effects of maturing CD137L-DCs by C3 or C4 was determined 
to be biologically functional as either cocktail was able to potentiate their T-
cell stimulation ability as evidenced by an increase in T-cell proliferation and 
expression of IFN- (figure 17). Such a gain in the DC potency is highly 
desirable as DC-based vaccines rely tremendously on the ability to promote 
strong antigen-specific T-cell expansion in the tumour-bearing individual 
(Kalinski et al., 2009). Quantity apart, the generated vaccine-elicited T cells 
must support anti-tumour activities and a major criterion is for the T cells to be 
able to secrete high amounts of IFN-. The production of this cytokine can 
bolster a Th1 response and concurrently promote effector CD8+ CTL function 
(Smeltz et al., 2002). As expected, culturing allogeneic T cells with either C3 
or C4-treated CD137L-DCs drove substantial production of IFN- by more 
than 2-fold compared to untreated CD137L-DCs, and this supports the notion 
of a more mature and active anti-tumour DC phenotype (figure 17). 
More often than not, a potent Th1 response and the associated IFN- 
secretion by T cells are due to the release of soluble factors such as 
cytokines by DCs. This contributes to signal 3 which instigates the 
polarisation of T cells towards various subsets including Th1, Th2, and Th17 
(de Jong et al., 2005; Kalinski et al., 1999). Among the most well studied DC-
derived pro-inflammatory cytokine is IL-12 whose most acclaimed function is 
to induce the transcription factor T-bet in naive CD4+ T cells thereby directing 
their differentiation into IFN--producing Th1 cells (Afkarian et al., 2002; 
Gately et al., 1998; Hsieh et al., 1993; O'Garra et al., 1995). On this account, 
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it was surprising that CD137L-DCs pre-treated with either C3 or C4 were able 
to upregulate T-cell production of IFN- even though active heterodimeric IL-
12p70 was absent (figure 16). Therefore, the presence of R848 (a TLR7/8 
agonist) and/or poly (I:C) (a TLR3 agonist) in maturation cocktails C3 and C4, 
which were documented to greatly enhance IL-12p70 production in 
classically-derived DCs, failed to promote IL-12p70 production in CD137L-
DCs (figure 16), (Boullart et al., 2008).  
So how do mature CD137L-DCs propel IFN- production in stimulated T cells 
despite the absence of IL-12p70? This observation is not unheard-of as 
Schuler et al. previously reported that in a metastatic melanoma clinical trial, 
IFN--producing CD4+ T cells were detectable even though IL-12p70 
secretion by mature classical DCs was miniscule (Schuler, 2010). A possible 
explanation is that T cells receive pro-Th1 stimulatory signals via a different 
route; for example by CD70 expressed on APCs (Krause et al., 2009; Soares 
et al., 2007). Indeed, untreated CD137L-DCs expressed a low amount of 
CD70 which was highly upregulated upon their maturation using the 
optimised maturation cocktail which will be discussed in the next section 
(section 4.4), (figure 37). Expression of CD70 may therefore contribute 
towards a pro-Th1 immune response. 
Alternatively, the production of a different member of the IL-12 cytokine family 
IL-23, which was upregulated in CD137L-DCs pre-treated with maturation 
cocktails containing poly (I:C) and/or R848 (C3, C4 or C5), may play a role in 
the induction of IFN--producing CD4+ T cells (figure 16). This heterodimeric 
cytokine, which shares a common p40 subunit with IL-12p70, has been 
described to skew T cells towards an IL-17 producing phenotype dubbed as 
Th17. However, it was recently shown that IL-23 are able to activate group 1 
innate lymphoid cells (ILCs) to co-express IFN- together with IL-17 via 
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downstream IL-23 receptor (IL-23R) signalling (van der Fits et al., 2009). In 
our experimental context, it is tempting to hypothesise that IL-23 secreted by 
activated CD137L-DCs may drive IFN- synthesis in IL-17 producing T cells, 
or perhaps also in all IL-23R expressing T cells, thus contributing to the 
heighten IFN- levels observed in the co-culture system (figure 17). In 
addition, murine data by Codarri et al. showed that IL-23 is also capable of 
inducing secretion of GM-CSF in activated T cells via the transcription of 
RORt (Codarri et al., 2011). Given the importance of GM-CSF in vaccination 
approaches during subcutaneous tumour growth, IL-23-dependent synthesis 
of GM-CSF by CD4+ T cells may be another potential mechanism that can 
contribute to anti-tumour response (van Elsas et al., 1999).  
It is worthwhile to note that IL-23 production is also induced by CD137L-DCs 
activated by LPS plus IFN-, although this cocktail does not contribute to the 
subsequent enhancement of T-cell activation (figures 16 and 17). This may 
be explained by the fact that in certain cases, IL-23 functions in synergy with 
other factors such as IL-18 in order to bring about an enhanced IFN- 
production by CD4+ T cells (Lalor et al., 2011). Hence, it is possible to 
speculate that perhaps R848 plus IFN-matured CD137L-DCs, but not LPS 
plus IFN- matured CD137L-DCs, secrete other soluble factors that may work 
in tandem with IL-23 to potentiate IFN- production in T cells.  
 
4.4. A TLR7/8 agonist and IFN- are essential and sufficient to 
functionally mature CD137L-DCs 
Maturation cocktails C3 and C4 differ in the presence of poly (I:C), which is 
only included in the latter (table 4). Since there was no observable biological 
and functional difference between the CD137L-DCs treated with either 
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cocktail, we surmised that maturation cocktail C3 contains the components 
that are key to mediating CD137L-DC activation.  
Maturation cocktail C3 consists of five factors namely IL-1, TNF, IFN-, R848 
and PGE2. To minimise the need of using large amounts of GMP-grade 
materials, and to create a simpler protocol for future clinical use, we next 
aimed to systematically eliminate superfluous components without 
compromising on functional potency. In the process of generating CD137L-
DCs, reverse signalling through CD137L activates the monocytes to produce 
pro-inflammatory cytokines including IL-1 and TNF (figure 4), (Langstein et 
al., 1998). These two conceivably autocrine signalling components of C3 
together with PGE2 were subsequently removed without any deleterious 
effects (figures 19-21). Thus, the resultant cocktail containing only R848 and 
IFN- was deduced to be essential and sufficient to mature CD137L-DCs. 
CD137L-DCs exposed to LPS plus IFN- and R848 plus IFN- were able to 
heighten the expression of maturation markers however, only the latter 
treatment induced a comparatively more intense T-cell stimulation as 
compared to untreated CD137L-DCs (figures 15-17 and 19-21). Such an 
enhanced co-stimulatory activity of CD137L-DCs treated with R848 and IFN- 
is presumably due to a synergistic effect. A possible underlying mechanism 
might be related to the fact that IFN- increases TLR8 expression in human 
classical DCs (Xu et al., 2006; Zannetti et al., 2010). Considering that R848 is 
a TLR7/8 agonist, the upregulation of TLR8 by IFN- would naturally increase 
the sensitivity of CD137L-DCs to R848. This agonist has also been reported 
to trigger immunostimulatory properties in 6-sulfo LacNAc (slan) DCs, a major 
subpopulation of pro-inflammatory myeloid blood DCs and monocyte-derived 
DCs (Hackstein et al., 2011; Jahnisch et al., 2013). Both authors describe that 
DCs pre-treated with R848 had potent T-cell stimulatory potential as evinced 
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by stronger allogeneic proliferation and IFN- release in both CD4+ and CD8+ 
subsets. It is worth to note that imiquimod, an agonist to TLR7 but not TLR8, 
failed to deliver a similar outcome (Jahnisch et al., 2013). Thus, it is highly 
plausible that the functional effects of R848 observed upon maturation of 
CD137L-DCs are due to agonistic effects solely onto TLR8. 
A question of particular interest is why the combination of LPS and IFN- 
does not contribute towards an enhanced potency of CD137L-DCs even 
though this cocktail has been widely reported to be a potent activator of APCs 
(Czerniecki et al., 2007; Dohnal et al., 2007). Firstly, we have to understand 
the biology of CD137L reverse signalling. In the human system, engagement 
of CD137L leads to activation of the Src family of protein tyrosine kinases and 
perhaps NF-B, although there is much debate on the latter due to conflicting 
published data (Ju et al., 2009; Kwajah and Schwarz, 2010; Sollner et al., 
2007). In the murine system however, it has been shown that CD137L 
physically interacts with TLR4, a receptor for LPS, and associates directly 
with TLR4 downstream signalling entities consisting of Toll-interleukin-1 
receptor domain-containing adaptor protein (TIRAP). This event essentially 
produces a signalling cascade which is similar to that of the TLR4 pathway 
(Kang et al., 2007). If such signal transduction also occurs in the human 
system, then CD137L-DCs would be refractory to the activating effects of LPS 
via the TIRAP cascade as the engagement of CD137L with CD137-Fc protein 
would have likely activated this TIRAP-dependent signalling cascade. The 
production of IL-23 observed upon LPS plus IFN- treatment of CD137L-DCs 
is probably contributed by the alternative signalling cascade by TLR4. 
Besides the TIRAP-dependent cascade, TLR4 can also activate the TIR-
domain-containing adapter-inducing interferon-/ TRIF-related adaptor 
molecule (TRIF/TRAM) signalling cascade which is not reported to be 
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associated with CD137L (Kang et al., 2007). This signalling cascade 
promotes activation of interferon regulatory factor 3 (IRF3), a key 
transcriptional factor for the IL-23p19 promoter (Smith et al., 2012). 
Therefore, in CD137L-DCs, the presence of LPS may only contribute to the 
activation of TRIF/TRAM signalling cascade but not the TIRAP-dependent 
pathway thereby bringing about only a suboptimal DC activation. On the other 
hand, R848 is an agonist for endogenous TLR7/8 which has a contrasting 
downstream signalling pathway compared to TLR4. Signalling through 
TLR7/8 activates interferon regulatory factor 7 (IRF7) which has been 
described to induce type-1 interferon and in mice, plays a role in governing 
induction of CD8+ T-cell responses (Honda et al., 2005).  
The triggering of R848-dependent receptors in CD137L-DCs may hence 
contribute towards greater maturation resulting in a potent enhancement of 
their biological activities. 
 
4.5. Peptide-pulsed CD137L-DCs potently activate autologous, antigen-
specific T cells 
Having delineated an optimised maturation cocktail for CD137L-DCs in an 
allogeneic system, we next strived to investigate the capability of CD137L-
DCs as compared to classical DCs, to initiate an antigen-specific response in 
an autologous setting. To this aim, we utilised a pool of peptides derived from 
the CMV-encoded protein pp65 as an antigenic stimulus. The advantage of 
using a peptide pool is that both the CD4+ and CD8+ T-cell population can 
potentially be activated thus allowing for a more complete characterisation of 
CD137L-DCs (Zandvliet et al., 2010). 
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We first tested the capability of CD137L-DCs to activate the pp65 T-cell line 
within a short period of 18 h. Co-culture within this time frame was insufficient 
for untreated CD137L-DCs to strongly activate the T-cell line (figure 28). In 
fact, potency was weaker than even that of the immature classical DCs. On 
the other hand, brisk restimulation by mature CD137L-DCs enabled CD4+ T 
cells to potently express IFN- to a level higher than mature classical DC. 
Such enhanced potency of mature CD137L-DCs was not restricted to only the 
CD4+ T cell subset as a similar trend was also observed in CD8+ T cells 
(figure 28B). From these data, it was considered that maturation of CD137L-
DCs was indeed functional and more importantly, required for the induction of 
a potent T-cell response.  
In the lymph node, however, DC interaction with T cells is dynamic and 
occurs in three distinct phases (Mempel et al., 2004). This progression from 
transient serial interaction to the formation of stable contacts with cytokine 
production and finally rapid T-cell proliferation requires more than 48 h and 
therefore it was suggested that a longer interaction of CD137L-DCs with pp65 
T cells would be physiologically more relevant than an overnight co-culture 
system.  
Longer T-cell restimulation resulted in an altered T-cell activation status. 
Consistently, the pp65-specific T cells restimulated by autologous CD137L-
DCs, be it matured by R848 plus IFN- or otherwise, were more activated 
than those restimulated by mature classical DCs in a 5 day co-culture. This is 
in contrast to the 18 h co-culture in which only mature CD137L-DCs, but not 
untreated CD137L-DCs, were effective pp65-specific T-cell activators. The 
first evidence came about by the examination of T-cell morphology in the co-
culture. pp65-specific T cells in the presence of peptide-pulsed CD137L-DCs 
grew in apparent homotypic aggregates suggesting clonal expansion (figure 
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30). These aggregates were larger than those formed in the presence of 
classical DCs signifying greater T-cell growth. Furthermore, by comparing the 
cytokine profile of IFN-, TNF and IL-13, it is clear that CD137L-DCs poise T 
cells towards activation, and that the restimulation by mature CD137L-DCs 
further potentiates T-cell activities (figure 31) Nevertheless, quantification of 
proliferative capacity of these T cells should be resolved in both in vitro and in 
vivo conditions in order to determine if CD137L-DCs are capable in 
expanding functional antigen-specific T cells. 
Accumulated findings suggest that regardless of the maturation status, 
CD137L-DCs are able to activate pp65-specific T cells more potently than 
mature classical DCs, albeit there is a more robust activation by mature 
CD137L-DCs. This indicates that untreated CD137L-DCs are already 
biologically equipped and sufficient to stimulate T cells in an antigen-specific 
manner while maturation further propels this function. Besides affecting the 
quality of T-cell activation, maturation also imparts CD137L-DCs with the 
ability to activate T cells at an earlier time. Maturation of CD137L-DCs prior to 
co-culture is vital for the induction of a quick response by both the CD4+ and 
CD8+ antigen-specific T cells but is not entirely necessary if these T cells are 
restimulated for a longer period (figures 28-31). From these set of data, we 
conclude that maturation bestows CD137L-DCs with the enhanced capacity 
to quickly yet effectively activate both CD4+ and CD8+ subsets of antigen-
specific T cells although untreated CD137L-DCs themselves are functional 
APCs.  
Examination of the co-culture cytokine profiles suggest that CD137L-DCs 
support predominantly a Th1 response as evidenced by the multiple-fold 
increase in both IFN- and TNF in the presence of pp65 peptides. Frequently, 
the levels of Th1 cytokines inversely correlate with those of Th2 cytokines. It 
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was therefore surprising to detect a profile of IL-13, a cytokine associated with 
Th2 activation, in response to CD137L-DCs that was similar to that observed 
for IFN- and TNF, albeit to a lower degree in terms of fold change (figure 31). 
A possible explanation for this profile is that IL-13 may have been upregulated 
to function as an immunoregulator. Although often labelled as a cytokine 
mediating allergic inflammation, IL-13 has also been described to dampen 
inflammatory effects of APCs such as monocytes and macrophages (Doherty 
et al., 1993; Gordon and Martinez, 2010). In fact, in a viral infection model, 
Shin et al. concluded that IL-13 is necessary to limit polarised Th1 mediated 
inflammation, which otherwise would cause severe liver inflammation and 
pathology (Shin et al., 2007). Thus, IL-13 production may be a negative 
feedback mechanism as a consequence of the pronounced pro-inflammatory 
environment that was generated in the presence of CD137L-DCs.  
It should be noted that in this assay, bulk supernatants were measured and 
therefore does not necessarily reflect the exact phenotype of T cells that are 
highly activated; i.e. CD4+ or CD8+ T cells. For example, high levels of IFN- 
in the supernatant could be contributed by either subset of antigen-specific T 
cells and the usage of ELISA would not be able to indicate the specific type of 
T-cell that is predominantly activated. Thus, for improved characterisation of 
the type of T-cell being activated, it would be beneficial that the application of 
high resolution read-outs such as by ELISPOT be utilised. Such assays would 
allow us to enumerate the amount of antigen-specific T cells and also the 
level of activation based on the amount of cytokines produced per T-cell.     
Nevertheless, since CD137L-DCs induced effective production of cytokines 
associated with CD4+ Th cells, we inferred that perhaps these DCs, on top of 
their potent activation capacity, are also able to propagate the CD4+ T-cell 
population. At least in conditions where T cells were restimulated by mature 
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CD137L-DCs, we noted a shift in the balance of CD4+/CD8+ T-cell ratio tilting 
towards the CD4+ population (figure 32). This is in parallel to the observation 
of a stark increase in expression of MHC class II molecules on the surface of 
mature CD137L-DCs (figure 24). The subset identities of these CD4+ T cells, 
however, are yet to be characterised but it is not too far-fetched to suggest 
that CD137L-DCs are more prone towards a Th1 response. This is evidenced 
by a multiple fold-increase in Th1 cytokines (IFN- and TNF) and in contrast, 
only a less than 2 fold increase in Th2 cytokine (IL-13) when pp65-specific T 
cells were restimulated in the presence of peptide antigens (figure 31). 
Further profiling of the CD4+ T cells by determining the expression of lineage-
specific master regulator such as T-bet (Th1-specific), GATA3 (Th2-specific) 
and RORT (Th17-specific), and also the expression of other Th cell 
cytokines such as IL-2, IL-4, IL-5 using ELISPOT assay can be performed to 
further verify the T-cell subsets that are preferentially activated upon 
restimulation by CD137L-DCs. 
 
4.6. CD137L-DCs promote a superior killing activity in antigen-specific 
autologous T cells 
Using an allogeneic system, our laboratory previously described the potency 
of CD137L-DCs in activating CD8+ T cells as evidenced by high perforin and 
IFN- expression (Kwajah and Schwarz, 2010). More recently, we 
demonstrated that these CD8+ T cells are functionally superior to their 
counterparts stimulated by mature classical DCs in exerting cytotoxicity 
against an erythroleukemia cell line (Harfuddin et al., 2013).   
In order to further evaluate the immunotherapeutic potential of CD137L-DCs, 
we addressed their competency to induce anti-tumour functions in an antigen-
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specific manner. In line with what we observed in an allogeneic setting, pp65-
specific T cells primed by autologous CD137L-DCs, either untreated or 
mature, had a superior cytotoxic ability as compared to T cells co-cultured 
with classical DCs. Indeed, T cells stimulated by CD137L-DCs were 2-3 times 
more potent than T cells primed by classical DCs in inducing the lysis of HLA-
matched, antigen-pulsed transformed target cells (figure 33). Remarkably, the 
difference in T-cell effector potency was miniscule between those stimulated 
by untreated and mature CD137L-DCs which indicate that CD137L-DCs may 
actually not require additional exogenous factors to permit potent T-cell 
activation. 
A notable quality of CD137L-DC-activated T cells is their ability to not only 
instil potent killing of antigen-pulsed targets but also to function effectively 
with a small number of effector cells as evinced by the strong killing potential 
at a low E:T ratio. Because the neoplastic microenvironment is often hostile 
and therefore greatly limits the access of anti-tumour effector T cells, having 
such highly potent antigen-specific T cells will undoubtedly be beneficial as 
even a small number of effector cells may be sufficient to control a tumour 
(Hadrup et al., 2013).       
A potential explanation for the enhanced killing activity of CD137L-DCs may 
be found in the fact that CD137L-DCs stimulate not only CD8+ but also CD4+ 
T cells, as evidenced by the increase in IFN- expression detected in both T-
cell populations (figures 28 and 29). CD4+ T cells are essential helper cells 
that play a role in assisting CD8+ CTLs in their effector activities and also in 
maintaining them. Indeed, the interactions between CD4+ and CD8+ T cells 
via CD40 and its ligand (CD40L) results in the downregulation of programmed 
cell death 1 (PDCD1, an immunosuppressive receptor best known as PD-1) 
and tumour necrosis factor (ligand) superfamily, member 10 (TNFSF10, an 
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inducer of apoptosis, best known as TRAIL) on the surface of CD8+ T cells 
(Bourgeois et al., 2002; Fuse et al., 2009; Janssen et al., 2005). These 
phenotypic changes dramatically enhance the cytotoxicity of CD8+ T cells and 
limit their susceptibility to TRAIL-induced apoptosis. Also, soluble factors such 
as IL-2 that are secreted by CD4+ T cells further act onto CD8+ T cells, thus 
improving recall responses such as those that occur in the course of 
lymphocytic choriomeningitis virus (LCMV) infections (Williams et al., 2006).  
More recently, the discovery of cytotoxic CD4+ T cells has cast doubt on the 
dogma that CD4+ T cells merely operate as helpers for CD8+ CTLs. Cytotoxic 
CD4+ T cells were observed in response to infection or vaccination against 
viruses such as West-Nile virus, herpes virus, and dengue virus (Brien et al., 
2008; Stuller et al., 2010; Yauch et al., 2010). Besides, melanoma-reactive 
CD4+ T cells have been shown to exert a cytotoxic activity, leading to tumour 
rejection via MHC class II-restricted interactions (Quezada et al., 2010). 
These cytotoxic CD4+ T cells appear to exhibit a Th1 phenotype, and the 
enhanced level of Th1 cytokine IFN- by CD137L-DC-primed CD4+ T cells is 
suggestive of such a cytotoxic activity (figure 28 and 29). It is plausible to infer 
that perhaps both untreated and mature CD137L-DCs are equipotent in their 
ability to stimulate CD8+ and CD4+ T cells, and thereby induce an optimal, 
combined cytotoxic potential in the overall T-cell population. Nevertheless, 
further investigation of the phenotypic cellular subsets is certainly required in 
order to verify this possibility.   
 
4.7. Whole protein antigens are not well utilised by CD137L-DCs 
The bulk of current DC-based vaccines employ peptides as an antigen of 
choice (Cintolo et al., 2012). However, this procedure has several shortfalls. 
Firstly, there are many possible target peptides that can be derived from a 
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single protein and therefore it is logistically laborious to systematically test all 
possible peptides for immunogenicity (Gok and Ozcerit, 2012). Secondly, 
individual immunogenic peptides are specific and will only bind to either MHC 
class I or class II, partly depending on the number and sequence of amino 
acid residues. This means that only a single and specific T-cell subtype, 
either CD8+ or CD4+, will be sensitised at any one point, effectively preventing 
the development of synergistic T-cell cooperation needed for effective anti-
tumour response (Gonzalez-Martin et al., 2011; Takemoto et al., 2010). 
Thirdly, peptide binding is specific to particular HLA alleles, and hence will 
only benefit the population expressing that allele. To circumvent these 
limitations, researchers have devised an alternative strategy by using tumour 
cell lysates as a source of antigen (Alfaro et al., 2011; Reyes et al., 2013; Wu 
et al., 2010). TAAs in their native protein form, including as yet undefined 
ones, are taken-up by the DCs and subsequently processed and presented 
onto MHC molecules. Thus, a desired immune response should be directed. 
Major advantages of this procedure include the utilisation of multiple tumour 
antigens that can be presented on both MHC class I and class II, thereby 
activating both CD4+ and CD8+ T-cell subsets, and also the presentation on 
different HLA alleles. Since tumour lysates are essentially a concoction of 
tumour-associated proteins, we simplified this model by using a native CMV-
pp65 protein as a surrogate for tumour lysate.  
We clearly demonstrated the dominance of conventional monocyte-derived 
DCs over both untreated and mature CD137L-DCs in processing and 
presenting soluble antigens as reaffirmed by the degree of T-cell activation of 
both subsets (figure 26). This observation may be explained by the lower 
endocytic capacity of CD137L-DCs than their immature classical counterparts 
(Ju et al., 2009; Kwajah and Schwarz, 2010). Taking into account the 
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significance of endocytosis and micropinocytosis in governing the uptake of 
soluble proteins into APCs, it is likely that CD137L-DCs would have acquired 
fewer antigens translating to a reduced likelihood of effective antigen 
presentation (Burgdorf and Kurts, 2008).  
Such reduced endocytic capacity is a typical feature of a mature DC 
phenotype which is suggestive of untreated CD137L-DCs being already 
relatively mature (Hopkins and Connolly, 2012). Indeed, previously work from 
our laboratory and current data showed that expression levels of CD83, which 
is a distinctive marker of mature DCs, hovers in between immature and 
mature classical DCs, and further activation by R848 and IFN- brings about 
an even further maturation (figure 24B), (Kwajah and Schwarz, 2010). Also, 
transcriptional profiling analysis, which will be discussed in detail in the next 
section, concur with this hypothesis as untreated CD137L-DCs are shown to 
be more closely related to mature classical DCs than immature classical DCs 
(figures 35B and 35C). CD137L-DCs’ character of not possessing any 
genuine immature form and being already comparatively matured from the 
onset is a double-edged sword. On the one hand, having a mature phenotype 
enables CD137L-DCs to be effective T-cell activators as we have 
demonstrated using CMV pp65 peptides. On the other hand, being already 
mature would hamper the process of effective engulfment of large quantities 
of protein for the purpose of antigen acquisition and also prolonged antigen 
preservation; traits that are unique to the immature forms of DCs (Mellman 
and Steinman, 2001). This is unlike classical DCs which are endowed with 
temporal-dependent immature and mature forms; each of which plays crucial 
roles in the coordinated process of antigen presentation (Hopkins and 
Connolly, 2012).  
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In the previous section, it was discussed that peptide-loaded mature CD137L-
DCs were competent T-cell activators at both early (18 h) and late (5 days) 
time-points. However, untreated CD137L-DCs were capable APCs only at the 
late time-point. Such a similar temporal-dependent event may also occur 
when protein antigens are use and perhaps CD137L-DCs may be able to 
instil potent T-cell activation only when the cells are co-cultured for a longer 
period of time. Nonetheless, such a hypothesis needs to be tested.  
In view of the collective data from both peptide-dependent and protein-
dependent experiments, we propose that CD137L-DCs are more competent 
antigen-specific T-cell activators than classical DCs provided that the 
eventual immunogenic antigen residues are effectively loaded onto MHC 
molecules. This should be the case for the former assay as exogeneous 
peptides can directly bind onto the groove of membrane MHCs without the 
need to undergo internalisation and processing (Blum, 2005). Nevertheless, 
further investigations are required to identify the most advantageous method 
for antigen-delivery and presentation. Alternative modes of antigen delivery 
such as transfection of antigen-coding RNA, DC transduction using viral 
vectors containing antigen-cassettes, and fusion of DCs with autologous 
tumour cells can also be looked upon (Koido et al., 2013; Nair et al., 2002; 
Palucka and Banchereau, 2013).  
In addition, we cannot disregard the importance of effective cross-
presentation in mounting protective CD8+ T-cell responses, a process critical 
for anti-tumour immunity (Joffre et al., 2012). Several factors have emerged 
as important for the modulation of cross-presentation in DCs (Nierkens et al., 
2013). This includes the type of antigen encountered and the timing and 
phase of the immune response. The propensity of CD137L-DCs to undergo 
this activity has yet to be deciphered, and it is of great interest to further 
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characterise this feature of CD137L-DCs. Its appreciation will bring us closer 
to better designed and optimised protocols for future clinical applications. 
  
4.8. In silico characterisation of CD137L-DCs 
Our aforementioned work on CD137L reverse signalling into monocytes 
clearly points towards their differentiation into cells with DC-like features. To 
supplement these in vitro information, we conducted gene expression profiling 
of CD137L-DCs and compared them with the profiles of monocyte-derived 
DCs (i.e. classical DCs) and macrophages; two cell types known to be 
derived from peripheral monocytes during inflammation (Geissmann et al., 
2010). Essentially, this in silico study aimed to identify hitherto unknown 
functions and/or molecules that are crucial in imparting the biological 
functions observed in CD137L-DCs. We did not acquire a transcriptional 
profile for mature CD137L-DCs as these experiments were performed prior to 
the identification of the optimised maturation factors. However, mature 
CD137L-DCs were used in subsequent functional assays. 
We identified 829 genes which were differentially expressed by CD137L-DCs 
as a result of CD137 ligand reverse signalling. It is worthwhile to note that any 
gene expression contributed due the engagement of Fc receptor by the Fc 
domain of CD137-Fc protein was excluded from our analysis. This was done 
by eliminating the list of genes expressed by the Fc control monocytes. Thus, 
the differentially expressed genes of interest are specifically due to signalling 
via CD137 ligand and its downstream effects.  
As anticipated, CD137L-DCs were more closely clustered to classical DCs 
than any other subsets (figure 35A). In fact, deeper enquiry by cluster 
distance and cMAP analyses indicated that CD137L-DCs’ transcriptional 
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profile is more similar to mature rather than immature classical DCs (figures 
35B and 35C). This reiterates our previous conclusion that described CD137L 
reverse signalling as a factor driving monocyte differentiation to DCs with a 
somewhat mature phenotype.  
Gene ontology (GO) analysis revealed several biologic categories that are 
overrepresented upon CD137L reverse signalling in monocytes. Not 
surprisingly, categories involving immune responses and adhesion were 
highly enriched (table 11). However, the most enriched category involved 
regulation of lipids which include biosynthesis as well as metabolic processes 
of sterols and cholesterols. The implications of lipid regulation in CD137L-DC 
development are still unknown and studies are currently being engaged in our 
laboratory. 
To decipher the unique qualities that make CD137L-DCs more potent than 
classical DCs, we derived a set of genes which were highly upregulated by 
CD137L-DCs with respect to mature classical DCs (tables 8 and 11). GO 
analysis revealed categories involved in adhesion processes, locomotion 
behaviour and immune responses to be the most enriched. As CD137L-DCs 
are adherent cells, it was expected that transcription of adhesion-associated 
genes would be upregulated (figure 24A). This said, the discovery of this 
process being highly significant in CD137L-DCs as compared to mature 
classical DCs is novel. Functional studies comparing CD137L-DCs with 
classical DCs correlated with GO analysis since the former were much more 
prone to attachment than the latter upon being re-cultured (figure 38). With 
this observation, we deduce that the adhesion processes may possibly be an 
important contributing factor that confers CD137L-DCs with a greater T-cell 
activation capacity.  
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A probable benefit of possessing such adhesion properties is the ability to 
form strong cell-cell interaction via stable immune synapses. Although this 
hypothesis has not been tested in CD137L-DCs, DC-associated adhesion 
molecules such as ICAM-1, LFA-3 and several integrins are prerequisites for 
supramolecular activating complex (SMAC) formation, essential for the 
initiation of the immune synapse with T cells (Rodriguez-Fernandez et al., 
2010; Sims and Dustin, 2002). In fact, ICAM-1-deficient DCs did not form 
long-lasting interaction with CD8+ T cells which resulted in inadequate CTL 
priming and therefore reduced production of IFN- both in vitro and in vivo 
situations (Scholer et al., 2008). 
Surface expression of ICAM-1 was indeed detected on CD137L-DCs and was 
further increased upon their maturation (figure 37B). Yet mature classical DCs 
expressed more ICAM-1 suggesting that this molecule is not a main factor 
contributing to CD137L-DCs’ superior ability to activate T cells. Two other 
molecules CLEC5A and PDPN which are associated with viral attachment 
and cellular migration, respectively, are likewise highly expressed by 
CD137L-DCs (figure 37), (Acton et al., 2012; Chen et al., 2008). Interestingly, 
both molecules are also expressed on macrophages but not classical DCs 
implying that CD137L-DCs are phenotypically unique DCs. Efforts to study 
the impact of CLEC5A and PDPN on T-cell activation by CD137L-DCs were, 
however, hampered due to the lack of commercially available antagonists.  
The adhesion molecule, ALCAM also known as CD166, was found to be 
highly upregulated in CD137L-DCs and classical DCs although it is more 
prominent in the former (figure 37). Several studies have described ALCAM 
interaction with CD6 on T cells to be essential for immunological synapse 
stabilisation and optimal T-cell activation and proliferation (Gimferrer et al., 
2004; Hassan et al., 2004; Zimmerman et al., 2006). Our studies 
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demonstrated that the blocking of ALCAM on CD137L-DCs, but not on 
classical DCs, reduced their capacity to activate T cells as evidence by the 
reduction in T-cell proliferation (figure 40). Interestingly, while the effect of 
ALCAM blockade is more prominent on mature CD137L-DCs rather than 
untreated CD137L-DCs, expression of ALCAM is essentially similar between 
these two populations (figure 37). An obvious question would be why ALCAM 
appears to be more crucial for mature CD137L-DCs rather than untreated 
CD137L-DCs? This might be explained by an observation by Zimmerman and 
colleagues which illustrates a more robust binding of ALCAM to its ligand in 
mature rather than immature DCs, possibly due to avidity regulation; a 
process where molecules are redistributed into clusters on the cell membrane 
(Nelissen et al., 2000; Zimmerman et al., 2006). Thus, the biological 
contribution of ALCAM is naturally more impactful in mature DCs and any 
functional abrogation will result in a more severe consequence. In our hands, 
blocking of ALCAM on classical DCs did not impose any inhibitory effects on 
their potential to activate T cells suggesting that ALCAM function is 
dispensable for classical DCs. Collectively, we surmise the significance of 
ALCAM as a valuable contributor in augmenting CD137L-DCs’ biological 
capacity to stimulate T cells. 
Once a stable immune synapse is formed, MHC-TCR interactions as well as 
co-stimulatory interactions dictate the quality of the resulting T-cell response 
(Thauland and Parker, 2010). Hence, we studied the co-stimulatory 
molecules that may be necessary to confer a T-cell activating potency in 
CD137L-DCs. Transcription profiling data suggest that OX40L and CD70, 
which are respective ligands for OX40 and CD27 found on T cells, may be 
such co-stimulatory molecules (figure 37A). OX40L protein was not detected 
but CD70 was found to be expressed on the surface membrane of CD137L-
 166 
 
DCs although this only occurred upon their maturation implying that CD70 
may have been pre-synthesised and stored in intracellular compartments 
prior to maturation (figure 37B). Moreover, CD70 is delivered to the immune 
synapse by shared intracellular trafficking with MHC class II; a molecule 
which is only highly expressed by CD137L-DCs as a consequence of 
maturation (figure 24B), (Keller et al., 2007). CD70 is a member of the 
TNFRSF and its upregulation by DCs is a crucial component of CD40-
mediated licensing since blockade of CD70 abrogates pro-stimulatory effects 
by CD40 (Taraban et al., 2004). CD70 also directly stimulates T cells by 
interacting with T-cell-bound CD27 which is required for CD8+ T-cell priming 
and also maintaining their survival (Hendriks et al., 2003; Keller et al., 2008). 
Albeit not unique in mature CD137L-DCs, as a similar CD70 expression is 
observed in mature classical DCs, it is reasonable to speculate that the 
likelihood of stronger immune synapse formation by mature CD137L-DCs will 
provide a platform for a more sustained CD70-CD27 interaction which is 
essential for priming of T cells (Keller et al., 2007; Keller et al., 2008).  
Another membrane-bound molecule which is associated with mature DCs is 
CD83 (Lechmann et al., 2002). Ample lines of evidence have suggested the 
significance of human CD83 as a co-stimulator for the induction of stronger T-
cell activation including naive CD8+ T cells, although this is not the case in the 
murine system. (Hirano et al., 2006; Kretschmer et al., 2008; Prazma et al., 
2007; Prechtel et al., 2007; Scholler et al., 2001). Expression of CD83 on 
CD137L-DCs has been previously reported by our laboratory and this was 
one of the early indications denoting that CD137L reverse signalling in 
monocytes led to differentiation of a DC-like phenotype (Kwajah and 
Schwarz, 2010). Intriguingly, transcriptional expression data did not point 
towards a high CD83 expression on untreated CD137L-DCs although flow 
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cytometric analysis proved otherwise (figure 37). Such seemingly 
contradictory observations can be explained by the fact that CD83 is actually 
preformed and stored in perinuclear regions of monocytes and immature 
DCs, and only gets stably expressed on the cell surface upon maturation 
such as by LPS (Cao et al., 2005). Thus, CD137L reverse signalling in 
monocytes may induce events that drive the trafficking of intracellular CD83 
onto the cell membrane rather than initiating CD83 gene transcription. This 
event is likely to be potentiated by pre-treatment of CD137L-DCs with R848 
and IFN- resulting in the heightened surface protein expression (figure 37B). 
Just like with CD70, CD83 is not unique in CD137L-DCs and the proposed 
stronger immune synapse formation may be the deciding factor that drives 
potent T-cell responses. The abovementioned co-stimulatory molecules are 
nonetheless vital players in the overall commitment to mount an effective 
immune response.  
 
4.9. CD137L-DCs: Towards their use as therapeutic cancer vaccines 
These encouraging in vitro findings pave the way for future requisite work 
focused on developing this novel form of DCs for their use in anti-tumour 
immunotherapy. Various key features make CD137L-DCs an attractive 
alternative to the current protocols for DC development. These include (1) the 
requirement of fewer exogenous proteins and cytokines for DC generation, 
(2) the ability to potently stimulate antigen-specific effector T cells of high 
cytotoxic potential and (3) the capacity to activate IFN--producing CD4+ Th 
cells. Significantly, our novel form of DC is functionally more potent than 
classically-generated DCs in activating antigen-specific T cells and this 
warrants the need to look upon developing CD137L-DC-base vaccine 
protocols. As the ultimate goal is to use CD137L-DCs in DC-based 
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immunotherapy, further characterisation of their development and potential in 
vivo effects is required.   
 
4.9.1. Production and in vivo character of CD137L-DCs 
An advantage of producing CD137L-DCs is that they only require CD137-Fc 
protein as a prerequisite, making it the simplest protocol for DC generation. 
On the other hand, the current protocol requires two exogenous factors, 
namely GM-CSF and IL-4, although it was recently described that GM-CSF is 
actually dispensable for in vivo differentiation of inflammatory DCs (Greter et 
al., 2012). This provides evidence of the possibility of alternative methods of 
DC generation. Also, several additional factors (generally ranging from 4-6 
factors) are then needed to ensure maturation thus inflating production costs 
(Erdmann and Schuler-Thurner, 2010). The simplicity of developing CD137L-
DCs may be an effective strategy to reduce overall costs of therapy.    
Our current procedure for CD137L-DC generation requires CD137-Fc 
proteins to be coated onto culture plates before freshly isolated monocytes 
are seeded. This action allows cross-linking of homotrimeric CD137L and the 
subsequent downstream reverse signalling to be initiated; a process which 
cannot occur if CD137-Fc proteins are added solubly. Such stringent 
requirement for cross-linking would curb the production of CD137L-DCs using 
commonly used cell culture bags. Fortunately, alternative GMP-grade close-
system such as the Cell Factory is available and can be used for propagation 
of adherent cells (Erdmann and Schuler-Thurner, 2010). We also showed that 
the generation of CD137L-DCs is comparable to the protocol of classical DCs 
in terms of the final quantity of DCs acquired, and therefore does not impede 
the process of large-scale production (figure 24C).  
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As earlier presented, maturation of CD137L-DCs is required for early antigen-
specific T-cell activation but is dispensable if T cells are stimulated for a 
longer period. Whether or not DC maturation prior to infusion is a necessity 
for in vivo initiation of an anti-tumour response has yet to be determined. 
Nevertheless, maturing CD137L-DCs may boost their tendency to migrate to 
the lymph nodes and induce competent T-cell activation due to the increase 
in CCR7 expression (figure 15). The migratory potential of CD137L-DCs is 
currently being explored in the laboratory via in vitro techniques such as the 
utilisation of Boyden chambers (trans-chambers). 
Additionally, the ability to generate CD137L-DCs from cancer patient-derived 
peripheral monocytes should be attempted especially since monocytes from 
such individuals are often functionally aberrant as described in introduction 
(section 1.1.1.3).  
 
4.9.2. Improving antigen-loading and processing in CD137L-DCs 
A limitation of CD137L-DCs is their inefficiency to utilise whole protein 
antigens which poses a huge technical drawback. Confining to peptides alone 
would benefit only an HLA-specific population and this is inadequate since the 
goal is to expand the use of CD137L-DCs as a first approach for anti-tumour 
therapy.  
To circumvent this issue, several alternatives can be explored including the 
transfection of antigen-coding RNA and fusion of DCs with autologous tumour 
cells (Koido et al., 2013; Nair et al., 2002). Another approach that combines 
CD137L-DC development with antigen loading can also be used in our 
context. Here, CD137-Fc proteins can be physically conjugated with protein 
antigens to create a complex which is subsequently used to differentiate 
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monocytes into CD137L-DCs. Engagement of this complex with CD137L will 
activate monocytes towards CD137L-DC differentiation, and subsequently the 
complex will be internalised by endocytosis; a process that occurs in the 
natural CD137-CD137L system (Ho et al., 2013). This mechanism may assist 
CD137L-DCs with antigen uptake allowing for improved antigen processing 
and presentation onto MHC molecules which we reckon will beget greater T-
cell activation. We are, in the laboratory, currently studying this approach and 
it is hoped that it will be a feasible option for the loading of antigens into 
CD137L-DCs.  
 
4.9.3. Quality of vaccine-induced T cells 
Cancer immunotherapy has focused primarily on engaging tumour-reactive 
CD8+ CTLs with the capacity to directly kill tumour cells and also differentiate 
into long-lived memory cells (Dudley et al., 2002; Palucka and Banchereau, 
2013). Recently, specific phenotypes of CD8+ T cells with superior anti-
tumour effects have been defined. For example, CD8+ T cells expressing 
CD103 (E7) integrin facilitates their adherence to tumour expressing E-
cadherin, bringing about their demise and eventual rejection (Le Floc'h et al., 
2007). Also, CD8+ T cells with characteristics of central memory cells, i.e. 
CCR7+, CD27+, CD28+ and CD62L+, have more profound anti-tumour effects 
than highly differentiated cells that have lost these makers (Gattinoni et al., 
2005). Such detailed phenotyping of CD137L-DC-stimulated T cells have not 
been performed and should be looked into.  
The importance of tumour-specific CD4+ T cells cannot be ignored as they 
play critical supporting roles for CD8+ T cells, and are by themselves able to 
evoke direct cytotoxicity (Quezada et al., 2010). CD137L-DCs are able to 
promote CD4+ T cells to produce high levels of IFN-, a cytokine signifying a 
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Th1 response. However, the phenotype status remains to be investigated in 
detail, especially considering that IL-13, a prototypic Th2 cytokine, was found 
to be secreted by CD137L-DC-primed T cells. Whether or not CD137L-DCs 
also activate cytotoxic CD4+ T cells is unknown.  
An undesirable feature that may compromise anti-tumour effects is T-cell 
exhaustion. Although CD137L-DC stimulated T cells are able to secrete high 
amounts of IFN- and to induce effective antigen-specific killing of target cells, 
their ability to undergo additional rounds of re-stimulation has not be defined. 
It is paramount that T cells primed by CD137L-DCs are not exhausted and 
are able to mount effective anti-tumour reactions. This is especially so since T 
cells found in the vicinity of tumours often display higher markers of T-cell 
exhaustion such as PD-1 and CTLA-4 than T cells in blood or normal 
adjacent tissues (Ahmadzadeh et al., 2009; Wang et al., 2012).  
Such T-cell features should be ascertained before attempting to embark on 
clinical trials. 
 
4.9.4. Additional future work 
In this project, we employed CMV-derived pp65 peptides as a model antigen 
to describe the antigen-specific T-cell activation ability by CD137L-DCs. A 
further advance and a logical next step to develop CD137L-DCs for clinical 
use would be testing whether CD137L-DCs can also induce potent immune 
responses against human tumours. A candidate antigen of choice is MART-
1/MelanA, an immunogenic melanosomal-derived antigen expressed in more 
than 90 % of melanomas (Coulie et al., 1994; Kawakami et al., 1994). Highly 
immunogenic modified short peptides with optimised HLA anchor residues 
can be loaded onto CD137L-DCs to test for their ability to activate autologous 
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MART-1/MelanA-specific T cells, and can also be followed-up with cytotoxic 
assays. Many TAAs are self-derived, therefore, the T cells that are directed 
towards TAAs are often in a naive state. Accordingly, determining the ability 
of CD137L-DCs to prime naive, tumour-specific T cells is of upmost 
importance and can be performed using the MART-1/MelanA system 
(Chauvin et al., 2012). Other potential antigens that should be tested are the 
EBV-derived LMP1 and LMP2A that are commonly detected in 
nasopharyngeal carcinoma (NPC) samples (Lo et al., 2004; Young and 
Murray, 2003). T-cell clones specific to LMP1 and/or LMP2A can be 
generated and the capacity of CD137L-DCs to restimulate these clones in an 
antigen-specific manner should be performed. 
Gene expression profiling analysis identifies CD137L-DCs as being 
transcriptionally similar to classical DCs (figure 35). Yet, several macrophage-
like features such as high PDPN and CLEC5A are also prominent in these 
cells (figure 37). Further characterisation to ascertain whether such molecules 
are implicated in conferring T-cell activation ability may also be looked upon 
to better understand the activities of CD137L-DCs. Thorough scrutiny of the 
vast microarray data may also hold crucial clues that may help to decipher the 
mechanisms that define the potency of CD137L-DCs. For example, inhibitory 
PD-L1 and PD-L2 which bind to PD-1 on T cells to attenuate immune 
responses are transcriptionally highly expressed in mature classical DCs but 
not in CD137L-DCs (appendix I), (Keir et al., 2007). The absence of this 
inhibitory mechanism may explain why CD137L-DC-primed T cells become 
more activated with time (figure 31). Thus, a more detailed investigation of the 






Immunotherapeutics are currently used primarily to supplement traditional 
treatment approaches in anti-cancer regimes. With more robust and vigorous 
biologic therapy protocols in the pipeline, we predict a potential shift in clinical 
acceptance for cancer vaccines from a complementary procedure to a first-
line treatment.  
To aid in this vision, we have discovered a novel method of generating DCs 
with superior ability to activate both CD4+ Th cells and CD8+ CTLs in an 
antigen-specific manner using pulsed peptides as a source of antigen. More 
importantly, the resultant T cells are exceptional in inducing the killing of 
peptide-loaded target cell line thus displaying properties that are desired of an 
anti-tumour response. Through in silico analysis, we were able to show that 
CD137L-DCs are transcriptionally similar to classical DCs but are unique in 
their own right as they express several shared molecules defining both DCs 
and macrophages. In combination with functional analysis, ALCAM was 
identified as a possible contributor towards CD137L-DCs’ biological functions 
though it is likely that many other yet unknown factors are also involved.   
This current study presents the unparallel prowess of CD137L-DCs as potent 
APCs in a viral model, and it is our desire to apply these DCs onto a tumour 
setting. Granted, CD137L-DCs may yet be developed into a ‘next-generation’ 
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Appendix II: Gene lists for DAVID analysis 
Table A1: CD137L-DC DEG which are ≥ 2x fold-change compared to monocytes 
Probe_ID Gene_Symbol Probe_ID Gene_Symbol 
ILMN_2160476 CCL22 ILMN_2092441 LRP12 
ILMN_2374449 SPP1 ILMN_1656904 SLC1A4 
ILMN_1651354 SPP1 ILMN_1691539 LAT 
ILMN_2192072 MMP7 ILMN_1701195 PLA2G7 
ILMN_1801205 GPNMB ILMN_1709043 C9orf46 
ILMN_1752562 CXCL5 ILMN_1806434 PAQR5 
ILMN_2170814 LAMP3 ILMN_2407824 ATP1B1 
ILMN_2413644 TM4SF19 ILMN_2089329 SPRY2 
ILMN_1685403 MMP7 ILMN_1730291 ATP1B1 
ILMN_1656310 INDO ILMN_2188862 GDF15 
ILMN_2171384 CXCL5 ILMN_1758057 TOR1AIP2 
ILMN_2407389 GPNMB ILMN_1704985 CYP27A1 
ILMN_1793730 TM7SF4 ILMN_2199439 CA2 
ILMN_1740418 CYP27B1 ILMN_1670325 SLC47A1 
ILMN_2065773 SCG5 ILMN_2081883 IQCK 
ILMN_1786444 LPL ILMN_1701483 SYP 
ILMN_2289593 FXYD2 ILMN_1726230 CD1B 
ILMN_1710186 CCL17 ILMN_1700690 VAT1 
ILMN_3239965 IDO1 ILMN_1721623 APOO 
ILMN_1773389 PLTP ILMN_1803647 FAM162A 
ILMN_2087656 SLCO2B1 ILMN_1786469 FBXO22 
ILMN_1794803 NDP ILMN_3277905 LOC645313 
ILMN_1867119  ILMN_1758827 RTN4IP1 
ILMN_1715131 CCR7 ILMN_1725518 ANGPTL6 
ILMN_1808325 TM4SF19 ILMN_2408796 C19orf28 
ILMN_1670490 PDPN ILMN_2102330 COL8A2 
ILMN_1725510 DHCR24 ILMN_1743620 RARRES1 
ILMN_1802653 EBI3 ILMN_2077905 PTGFRN 
ILMN_1705750 TGM2 ILMN_1806249 IL1RN 
ILMN_3247139 C17orf96 ILMN_1674050 COL8A2 
ILMN_2316236 HOPX ILMN_1662795 CA2 
ILMN_1789502 GPC4 ILMN_1659801 ATP6V1C1 
ILMN_1754538 C10orf58 ILMN_1782635 YARS2 
ILMN_2124221 CLLU1OS ILMN_1682781 TEAD2 
ILMN_1761199 SLCO2B1 ILMN_1772964 CCL8 
ILMN_2223903 PPIC ILMN_1691339 CLEC1A 
ILMN_1689842 SC4MOL ILMN_1742853 LOC652184 
ILMN_1688480 CCND1 ILMN_1708743 NT5DC2 
ILMN_1690170 CRABP2 ILMN_1708041 PLEKHF1 
ILMN_1669032 PPIC ILMN_1683273 SNAPC5 
ILMN_2319000 MATK ILMN_1786108 TUT1 
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ILMN_3250257 ACVRL1 ILMN_1810267 DNHD1 
ILMN_1767113 AOX1 ILMN_1762713 C19orf59 
ILMN_2329927 ABCG1 ILMN_1851547  
ILMN_1785380 SLC1A2 ILMN_1783712 LOC400506 
ILMN_1787657 CLDN12 ILMN_1724699 ACAD8 
ILMN_1748538 ALDH1A2 ILMN_1804568 HOMER1 
ILMN_1704369 LIMA1 ILMN_1740875 FPR2 
ILMN_1843198  ILMN_3300358 ZNF84 
ILMN_1814022 NR1H3 ILMN_1774806 SLC9A7 
ILMN_1765557 OLFML2B ILMN_1664718 CYP51A1 
ILMN_1784553 SDC2 ILMN_1693664 POMGNT1 
ILMN_2317923 TMEM132A ILMN_2134974 RAB38 
ILMN_1694400 MSR1 ILMN_1788810 C12orf30 
ILMN_1705849 SPR ILMN_2085236 SNX24 
ILMN_1720889 SC4MOL ILMN_1738147 NES 
ILMN_2227248 SLAMF9 ILMN_2128770 CDR2L 
ILMN_2413779 SEZ6L2 ILMN_2406410 RHBDD2 
ILMN_3307791 FAM69A ILMN_1737561 LOC88523 
ILMN_1704376 GLDN ILMN_1769383 GIMAP5 
ILMN_1784532 COL22A1 ILMN_1751898 C12orf4 
ILMN_1717477 PSD3 ILMN_1769926 DBN1 
ILMN_1659106 PHLDA3 ILMN_2225595 ACAD8 
ILMN_2165867 DHCR7 ILMN_1743199 EGR2 
ILMN_1689329 SCD ILMN_1724946 SPINT1 
ILMN_1738578 FILIP1L ILMN_1702168 HSD17B12 
ILMN_1704753 EPAS1 ILMN_1758895 CTSK 
ILMN_2365307 CD276 ILMN_1680805 IL28RA 
ILMN_1696302 FABP5 ILMN_2049766 NFE2L3 
ILMN_2093027 MYO1B ILMN_1770911 NRSN2 
ILMN_1797822 SEL1L3 ILMN_1796335 LPCAT2 
ILMN_1717262 PROCR ILMN_1751328 FAM83H 
ILMN_1794782 ABCG1 ILMN_1781819 PAPSS1 
ILMN_2188722 GLS ILMN_3236135 FAM86D 
ILMN_1761247 PIR ILMN_2100287 CCDC147 
ILMN_2212909 MELK ILMN_3210914 LOC344887 
ILMN_1785170 ARMCX2 ILMN_3197097 TSTD1 
ILMN_1770338 TM4SF1 ILMN_2099277 HTRA4 
ILMN_2398572 FXYD2 ILMN_1670322 FCHO2 
ILMN_3245458 SNORA61 ILMN_1751228 C20orf46 
ILMN_1808404 RHBDF1 ILMN_3235853 S1PR1 
ILMN_1763638 BCAR3 ILMN_1805916 NIPSNAP1 
ILMN_1780831 SLC6A12 ILMN_1783909 COL6A2 
ILMN_2380163 PTPRF ILMN_2095133 SPTAN1 
ILMN_1732151 COL6A1 ILMN_1764861 ISOC1 
ILMN_1690040 TM7SF2 ILMN_1756992 MUC1 
ILMN_1809483 HSD17B14 ILMN_1729167 EFTUD1 
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ILMN_1669362 IGFBP6 ILMN_3193306 C14orf109 
ILMN_1805807 SLC30A3 ILMN_1715068 AQP9 
ILMN_1666546 DUSP14 ILMN_1809437 RHBDD2 
ILMN_2383707 ALDH1A2 ILMN_1799024 VAC14 
ILMN_3246538 LOC100133866 ILMN_1786273 C1orf122 
ILMN_1800091 RARRES1 ILMN_2051867 PTCD2 
ILMN_1911721  ILMN_1699139 CYP19A1 
ILMN_1733535 ZNF366 ILMN_2094106 HSD17B12 
ILMN_1739001 TACSTD2 ILMN_2119774 CYP2R1 
ILMN_1784005 LOC644615 ILMN_2125374 CMAS 
ILMN_1764723 SH3PXD2B ILMN_1785405 SLC17A9 
ILMN_1735157 GALNT12 ILMN_2121816 GPR137B 
ILMN_1779257 CD40 ILMN_1660031 P2RY6 
ILMN_1744381 SERPINE1 ILMN_1795507 ABCA6 
ILMN_1815190 METTL1 ILMN_1794386 IL2RG 
ILMN_1752965 GREM1 ILMN_1666665 COL23A1 
ILMN_2374683 PTPN13 ILMN_1666902 GPR114 
ILMN_3178258 FABP5L2 ILMN_1714082 CMAS 
ILMN_1678841 UBD ILMN_1673892 GK5 
ILMN_3306997 METTL1 ILMN_1796508 TOP1MT 
ILMN_1739222 ETV5 ILMN_1813338 LAG3 
ILMN_3210741 LOC642956 ILMN_2183216 TTRAP 
ILMN_2405324 IL28RA ILMN_1745152 UQCC 
ILMN_1780465 CLEC5A ILMN_1805371 HNRPM 
ILMN_1788180 RAB13 ILMN_2413064 ST6GALNAC4 
ILMN_2170813 LAMP3 ILMN_2073604 EBP 
ILMN_1776519 RAP1GAP ILMN_2049536 TRPV2 
ILMN_1685397 ITGA3 ILMN_2397954 PARP3 
ILMN_1775486 SSPN ILMN_1651800 GSTM4 
ILMN_1682015 GAL ILMN_1680659 C11orf63 
ILMN_2064725 METTL7B ILMN_1810996 COL24A1 
ILMN_1728799 FBP1 ILMN_1733562 TFB1M 
ILMN_1742547 NRP1 ILMN_2399392 SIL1 
ILMN_1699695 TNFRSF21 ILMN_2224103 PAPSS1 
ILMN_2332250 ACOT7 ILMN_1800787 RFTN1 
ILMN_1779852 LOC387934 ILMN_2077733 C12orf30 
ILMN_1707124 TFPI ILMN_1662390 ASPHD1 
ILMN_1726624 YPEL4 ILMN_1862521  
ILMN_1658926 NOTCH3 ILMN_3236756 ACSF2 
ILMN_1677441 C20orf123 ILMN_1695246 KLHDC8B 
ILMN_2370976 FER1L3 ILMN_1717677 ZFHX2 
ILMN_2146761 FABP5 ILMN_1808354 SLC4A7 
ILMN_1805930 CSF1 ILMN_1800412 BMP1 
ILMN_1670535 NDRG2 ILMN_1711928 FLJ20920 
ILMN_1782015 FCRLB ILMN_1657550 MVD 
ILMN_2381899 OPTN ILMN_1808769 C1orf97 
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ILMN_1653766 CCL24 ILMN_1712088 CLYBL 
ILMN_1811736 ENTHD1 ILMN_1745130 RBM9 
ILMN_1815626 DHCR7 ILMN_1678423 SPA17 
ILMN_1696028 ETNK1 ILMN_1790971 LOC652324 
ILMN_1815057 PDGFRB ILMN_1743275 SH3RF3 
ILMN_3251672 DSG2 ILMN_1693685 LOC205251 
ILMN_1658071 ATP1B1 ILMN_1655614 DSP 
ILMN_1701551 ABCA6 ILMN_1759453 UQCRB 
ILMN_3266606 FABP5L2 ILMN_1683755 SOX13 
ILMN_2078592 C6orf105 ILMN_1710209 MFSD6 
ILMN_2361603 NDRG2 ILMN_2407346 LDHD 
ILMN_2340347 PC ILMN_1804248 FDPS 
ILMN_1770641 KLHL3 ILMN_1770922 TMEM45A 
ILMN_1735231 ZSWIM4 ILMN_1691736 ST6GALNAC6 
ILMN_1784948 SPOCD1 ILMN_1755281 FBXO15 
ILMN_1801043 GSN ILMN_1796682 PARP3 
ILMN_1781045 FXYD2 ILMN_1659953 37865 
ILMN_1701914 CD274 ILMN_2359742 CTSB 
ILMN_1662619 TFPI ILMN_3217276 LOC644517 
ILMN_1695290 FERMT2 ILMN_1719392 FH 
ILMN_3248591 LTBP2 ILMN_2386355 CSNK2A1 
ILMN_1660806 CSRP2 ILMN_1653283 APP 
ILMN_1733402 CSF1 ILMN_1704656 PPP2R1B 
ILMN_1730906 FILIP1L ILMN_1689274 NIPA1 
ILMN_3245630 ECSCR ILMN_2086105 SPRY4 
ILMN_1784871 FASN ILMN_2069128 EPB41L2 
ILMN_1769615 FLRT2 ILMN_3223798 ZNF84 
ILMN_1722855 VEGFB ILMN_1656399 TCEAL8 
ILMN_2078599 ACP5 ILMN_2222651 MAK10 
ILMN_1779965 AK1 ILMN_1724612 SLC25A35 
ILMN_1704353 IGSF3 ILMN_2052335 MYOC 
ILMN_1807177 KIAA1797 ILMN_1668822 BATF 
ILMN_2200917 SLC4A7 ILMN_2195482 CACNB3 
ILMN_1772241 SQLE ILMN_1813701 RASAL2 
ILMN_3205353 LOC100131294 ILMN_2144088 FDFT1 
ILMN_1698218 TRAF1 ILMN_2355168 MGST1 
ILMN_1660871 NEK6 ILMN_1784709 GNPDA1 
ILMN_1677396 NDFIP2 ILMN_2352953 CPM 
ILMN_3248091 C6orf223 ILMN_1687743 BTBD7 
ILMN_1741014 SLC28A3 ILMN_1741096 FDFT1 
ILMN_2068104 TFPI2 ILMN_1657395 HMGCR 
ILMN_1712352 DOCK3 ILMN_1730032 BOK 
ILMN_2391150 FILIP1L ILMN_3240524 MFSD6 
ILMN_1801443 TSKU ILMN_2183409 SCARB1 
ILMN_1680856 MAMLD1 ILMN_1667748 ANKRD33 
ILMN_1776181 BIRC3 ILMN_1835017  
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ILMN_1678904 ENO3 ILMN_1803945 HCP5 
ILMN_2201678 FSTL1 ILMN_2305225 NDRG4 
ILMN_1680110 C10orf116 ILMN_2349393 MDK 
ILMN_1757604 TPM2 ILMN_1770412 AHCYL1 
ILMN_1808226 RGS16 ILMN_2064132 NANP 
ILMN_1684210 NPAL3 ILMN_1785821 TTRAP 
ILMN_1659352 KCNK13 ILMN_3239500 FAM135B 
ILMN_2112256 TNFRSF4 ILMN_1736704 DIXDC1 
ILMN_1690101 FAIM ILMN_1779076 HINT3 
ILMN_1781791 PRRG1 ILMN_1653319 MC1R 
ILMN_1654398 RGL1 ILMN_1758281 CALCRL 
ILMN_2047618 KCNE1 ILMN_1665571 LOC644869 
ILMN_1781867 FOXD4L1 ILMN_1760890 SEPN1 
ILMN_1711439 EMILIN1 ILMN_1746819 C5 
ILMN_1680364 CD109 ILMN_1726693 GTF2H1 
ILMN_2359287 ITGA6 ILMN_1657955 FMNL3 
ILMN_1770031 ABHD10 ILMN_1678729 SIL1 
ILMN_1707591 TNIP3 ILMN_1813911 HEXA 
ILMN_2100437 HBB ILMN_1684755 KAZALD1 
ILMN_1720282 NQO1 ILMN_2399036 SEPN1 
ILMN_2401927 TTC8 ILMN_1757845 SPIRE1 
ILMN_1808707 FSCN1 ILMN_3181411 ATL1 
ILMN_2373285 MSR1 ILMN_1745623 EFCAB4A 
ILMN_2395214 FMNL3 ILMN_1810864 PMP22 
ILMN_1715024 LSS ILMN_1667199 SQRDL 
ILMN_1797933 MRPL17 ILMN_1693513 LOC644143 
ILMN_2375992 SPINT1 ILMN_2157957 GTF2H1 
ILMN_1747673 RASL10A ILMN_1675542 LOC729148 
ILMN_1740265 ACOT7 ILMN_1793002 C20orf196 
ILMN_1731374 CPE ILMN_1751793 PCNXL2 
ILMN_1713679 MREG ILMN_1807719 CTNS 
ILMN_1788778 40787 ILMN_1798061 ZFYVE26 
ILMN_1802894 VKORC1L1 ILMN_1703228 AGFG2 
ILMN_1663257 ATP6V1C1 ILMN_2148469 RASL11B 
ILMN_1726981 VEGFB ILMN_1781626 C1S 
ILMN_1741632 RAB3IL1 ILMN_1731783 ATP1A1 
ILMN_1682099 TNFAIP8L3 ILMN_3179620 LOC100129673 
ILMN_1663538 CLYBL ILMN_1741727 QPCT 
ILMN_1741021 CH25H ILMN_1725314 GBP3 
ILMN_1717727 LOC284293 ILMN_1680727 GLRX2 
ILMN_1719649 TMEM63A ILMN_1652163 DVL2 
ILMN_1670134 FADS1 ILMN_1737089 CAPN5 
ILMN_2347592 NMB ILMN_1816342  
ILMN_1681644 BIRC3 ILMN_2128741 RDH11 
ILMN_1804735 CBS ILMN_1747759 WSB1 
ILMN_1914249  ILMN_1915188  
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ILMN_1809859 PCGF2 ILMN_1794825 ALDH3A2 
ILMN_1913060  ILMN_2229261 SIGLEC16 
ILMN_1655469 TSPAN3 ILMN_1699737 TRAP1 
ILMN_1774874 IL1RN ILMN_1751901 TMEM163 
ILMN_1772821 KIAA1671 ILMN_1689001 CDK4 
ILMN_1759023 WFS1 ILMN_1736127 KIAA0773 
ILMN_1815690 TIE1 ILMN_3209232 LOC644496 
ILMN_3243682 C1orf93 ILMN_1702124 LNX2 
ILMN_1716006 C18orf54 ILMN_1671568 ECHDC2 
ILMN_1723962 LXN ILMN_1784238 SEC22B 
ILMN_1765459 S100A13 ILMN_1698243 C1orf85 
ILMN_1898723  ILMN_1789436 C1orf218 
ILMN_1768273 POP1 ILMN_1760849 NETO2 
ILMN_2075643 ANKRD29 ILMN_1730622 EVL 
ILMN_1746673 37865 ILMN_1736539 ALDH1L2 
ILMN_2041293 SQLE ILMN_1775566 ATP1A1 
ILMN_3235176 C2orf89 ILMN_3292082 LOC642367 
ILMN_1747395 SLC24A1 ILMN_1658759 PEX19 
ILMN_1652237 CBR3 ILMN_1704383 TRIM37 
ILMN_1679460 PPFIBP1 ILMN_1719627 SLC27A3 
ILMN_1793476 PRKCDBP ILMN_2362974 CASP7 
ILMN_2381121 UQCC ILMN_1670302 HK3 
ILMN_1789196 TPM2 ILMN_2364072 CLCNKA 
ILMN_2365383 ENO3 ILMN_1800889 FIG4 
ILMN_1811470 PLEK2 ILMN_1674038 CTSD 
ILMN_1687857 ST6GALNAC4 ILMN_1788387 UGCGL2 
ILMN_1666819 PHLDB1 ILMN_2164081 KLHL12 
ILMN_1724941 CDCP1 ILMN_2117171 LMO4 
ILMN_3302919 MYOF ILMN_2357577 PRKAA1 
ILMN_1701052 TUBG2 ILMN_1704084 CMAH 
ILMN_2387860 CYP19A1 ILMN_1756572 COQ2 
ILMN_2124585 GREM1 ILMN_2375830 DIXDC1 
ILMN_1723971 SLC29A1 ILMN_1697115 FLJ12355 
ILMN_1702501 RPS6KA2 ILMN_1703487 LMO4 
ILMN_2143685 CLDN7 ILMN_2373763 CASP7 
ILMN_1698666 CST6 ILMN_2378696 GFM2 
ILMN_1677765 LRP8 ILMN_2242463 CTSC 
ILMN_2090802 TMEM79 ILMN_1653496 GLUL 
ILMN_2374687 PTPN13 ILMN_1803813 ASTE1 
ILMN_1783593 CCL13 ILMN_1688152 IL27RA 
ILMN_3305849 LOC728431 ILMN_1788547 GCLM 
ILMN_1694798 C5orf28 ILMN_1682399 CLOCK 
ILMN_1765274 CAPN11 ILMN_2353697 HINFP 
ILMN_1810289 FER1L3 ILMN_3289508 LOC339192 
ILMN_1786658 BOLA3 ILMN_1815264 RHBDD3 
ILMN_1719696 PLD1 ILMN_1800276 RCN1 
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ILMN_1670561 TCEAL8 ILMN_1728049 S100A16 
ILMN_1708672 ACAT2 ILMN_1672743 ZNF334 
ILMN_1670870 ALCAM ILMN_1779855 HSD17B6 
ILMN_3248786 LOC647588 ILMN_2382648 MID2 
ILMN_1709937 KCNN4 ILMN_1684289 PNPO 
ILMN_1728581 C3orf18 ILMN_1678353 FARP1 
ILMN_1655796 37681 ILMN_1737580 PPPDE2 
ILMN_1758750 EARS2 ILMN_1705297 MYBPH 
ILMN_1656378 NMT2 ILMN_1688089 PEBP1 
ILMN_1655100 LOC644680 ILMN_1738010 CTNS 
ILMN_1668283 HYAL2 ILMN_1680781 C14orf135 
ILMN_1718972 MFSD3 ILMN_1699772 RRAGD 
ILMN_1696031 C15orf21 ILMN_1770020 PPIL3 
ILMN_1654411 CCL18 ILMN_1659888 PPP1R14B 
ILMN_2131381 PDE3B ILMN_1690099 ITGB1BP1 
ILMN_3298511 LOC728537 ILMN_1663512 COX5B 
ILMN_1770466 ATP5G3 ILMN_3219631 LOC647081 
ILMN_1749792 SORBS1 ILMN_2106167 RAP1GDS1 
ILMN_1697220 NT5E ILMN_2413780 SEZ6L2 
ILMN_1724789 CD59 ILMN_1736103 ITPR2 
ILMN_1885771  ILMN_1807515 CSTF2T 
ILMN_1771261 SYNC1 ILMN_2372136 P4HTM 
ILMN_3234089 N4BP2L2 ILMN_1761031 PTPDC1 
ILMN_1797585 MYO1B ILMN_3236928 ROBLD3 
ILMN_2383349 STEAP3 ILMN_1726306 HMBS 
ILMN_1685703 ACOX2 ILMN_2245305 ABHD12 
ILMN_1700047 ALAS1 ILMN_1791306 C9orf103 
ILMN_1702231 C1orf54 ILMN_1803392 TAX1BP3 
ILMN_1774739 MMP14 ILMN_1712291 MICALL2 
ILMN_1677814 ABCC3 ILMN_2208495 LASS5 
ILMN_2338963 SLC29A1 ILMN_3243705 PDXDC1 




Table A2: CD137L-DC DEG which are ≥ 2x fold-change compared to mature cDCs 
Probe_ID Gene_Symbol Probe_ID Gene_Symbol 
ILMN_1752562 CXCL5 ILMN_1731745 NINJ2 
ILMN_2171384 CXCL5 ILMN_2413064 ST6GALNAC4 
ILMN_1780465 CLEC5A ILMN_2224103 PAPSS1 
ILMN_2065773 SCG5 ILMN_1756572 COQ2 
ILMN_1699695 TNFRSF21 ILMN_1674050 COL8A2 
ILMN_1762713 C19orf59 ILMN_1742547 NRP1 
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ILMN_1767113 AOX1 ILMN_1808354 SLC4A7 
ILMN_1789502 GPC4 ILMN_1781867 FOXD4L1 
ILMN_1769299 MTMR11 ILMN_1767253 RRP12 
ILMN_2361603 NDRG2 ILMN_3251155 PCBP2 
ILMN_2413779 SEZ6L2 ILMN_1732151 COL6A1 
ILMN_1789196 TPM2 ILMN_1666546 DUSP14 
ILMN_1669523 FOS ILMN_1805371 HNRPM 
ILMN_1769926 DBN1 ILMN_2347592 NMB 
ILMN_2380163 PTPRF ILMN_1781819 PAPSS1 
ILMN_2199439 CA2 ILMN_1725518 ANGPTL6 
ILMN_2093027 MYO1B ILMN_1735231 ZSWIM4 
ILMN_1757604 TPM2 ILMN_1758806 C21orf2 
ILMN_1670638 PITPNC1 ILMN_2102330 COL8A2 
ILMN_2316236 HOPX ILMN_1680364 CD109 
ILMN_1705686 NRGN ILMN_1660806 CSRP2 
ILMN_1739001 TACSTD2 ILMN_1689160 DPEP2 
ILMN_1670535 NDRG2 ILMN_1662390 ASPHD1 
ILMN_1752965 GREM1 ILMN_1800412 BMP1 
ILMN_2374683 PTPN13 ILMN_1807177 KIAA1797 
ILMN_1669362 IGFBP6 ILMN_1785380 SLC1A2 
ILMN_1686555 FYN ILMN_3205353 LOC100131294 
ILMN_1784532 COL22A1 ILMN_1682015 GAL 
ILMN_1670490 PDPN ILMN_2150851 SERPINB2 
ILMN_1662795 CA2 ILMN_3211302 LOC646909 
ILMN_1658926 NOTCH3 ILMN_1677814 ABCC3 
ILMN_1685703 ACOX2 ILMN_1682099 TNFAIP8L3 
ILMN_1704376 GLDN ILMN_2406410 RHBDD2 
ILMN_1815057 PDGFRB ILMN_1722981 TLR5 
ILMN_1784948 SPOCD1 ILMN_2188722 GLS 
ILMN_3248591 LTBP2 ILMN_1809437 RHBDD2 
ILMN_2205963 C10orf54 ILMN_1728107 GNG7 
ILMN_1745623 EFCAB4A ILMN_1786326 KCTD15 
ILMN_1728799 FBP1 ILMN_1805930 CSF1 
ILMN_1690170 CRABP2 ILMN_1743275 SH3RF3 
ILMN_1653766 CCL24 ILMN_1718972 MFSD3 
ILMN_1805807 SLC30A3 ILMN_1693552 CD300A 
ILMN_2100437 HBB ILMN_1717262 PROCR 
ILMN_2229261 SIGLEC16 ILMN_1718621 TSPAN32 
ILMN_3245630 ECSCR ILMN_2124221 CLLU1OS 
ILMN_1687857 ST6GALNAC4 ILMN_2086105 SPRY4 
ILMN_1765274 CAPN11 ILMN_3236130 LOC100132547 
ILMN_2340347 PC ILMN_1781791 PRRG1 
ILMN_1779965 AK1 ILMN_1724612 SLC25A35 
ILMN_1715885 PTPN22 ILMN_1751228 C20orf46 
ILMN_2227248 SLAMF9 ILMN_1722738 ROGDI 
ILMN_2068104 TFPI2 ILMN_1716006 C18orf54 
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ILMN_1680110 C10orf116 ILMN_3239500 FAM135B 
ILMN_1731374 CPE ILMN_1678423 SPA17 
ILMN_1914249  ILMN_1784005 LOC644615 
ILMN_2064725 METTL7B ILMN_2131381 PDE3B 
ILMN_1769615 FLRT2 ILMN_2289849 FCGR2A 
ILMN_2101278 RGS18 ILMN_1736127 KIAA0773 
ILMN_1677441 C20orf123 ILMN_3248352 CCDC88C 
ILMN_2374687 PTPN13 ILMN_1785170 ARMCX2 
ILMN_1702501 RPS6KA2 ILMN_1670870 ALCAM 
ILMN_1750181 TESC ILMN_1659888 PPP1R14B 
ILMN_1808226 RGS16 ILMN_1751901 TMEM163 
ILMN_3251672 DSG2 ILMN_3245458 SNORA61 
ILMN_1815690 TIE1 ILMN_1737089 CAPN5 
ILMN_1662619 TFPI ILMN_2077905 PTGFRN 
ILMN_2329927 ABCG1 ILMN_1770338 TM4SF1 
ILMN_2380801 FYN ILMN_1704753 EPAS1 
ILMN_1762899 EGR1 ILMN_3210171 LOC389156 
ILMN_2089329 SPRY2 ILMN_1666902 GPR114 
ILMN_1811736 ENTHD1 ILMN_1665571 LOC644869 
ILMN_1708743 NT5DC2 ILMN_1890614  
ILMN_1698666 CST6 ILMN_2383349 STEAP3 
ILMN_1707124 TFPI ILMN_2119774 CYP2R1 
ILMN_1811470 PLEK2 ILMN_1666932 FCGR2A 
ILMN_2124585 GREM1 ILMN_2148469 RASL11B 
ILMN_1726624 YPEL4 ILMN_1701643 GDPD5 
ILMN_1806434 PAQR5 ILMN_1804568 HOMER1 
ILMN_2289593 FXYD2 ILMN_1709795 RAC2 
ILMN_1747673 RASL10A ILMN_1801043 GSN 
ILMN_2316386 GPBAR1 ILMN_1712352 DOCK3 
ILMN_1711439 EMILIN1 ILMN_1770922 TMEM45A 
ILMN_1675191 GAPT ILMN_1736704 DIXDC1 
ILMN_1781207 FYN ILMN_1752159 AHNAK 
ILMN_2143685 CLDN7 ILMN_3285410 LOC642738 
ILMN_2319000 MATK ILMN_1775257 PROK2 
ILMN_1810996 COL24A1 ILMN_1655614 DSP 
ILMN_1697220 NT5E ILMN_1726306 HMBS 
ILMN_1794782 ABCG1 ILMN_1697115 FLJ12355 
ILMN_1704985 CYP27A1 ILMN_1691736 ST6GALNAC6 
ILMN_1809859 PCGF2 ILMN_2165473 MID1IP1 
ILMN_1659106 PHLDA3 ILMN_1792495 AHNAK 
ILMN_1898723  ILMN_1653026 PLAC8 
ILMN_1724699 ACAD8 ILMN_2357577 PRKAA1 
ILMN_3298511 LOC728537 ILMN_1745130 RBM9 
ILMN_3242271 GAPT ILMN_1758827 RTN4IP1 
ILMN_1783996 DEM1 ILMN_1788180 RAB13 
ILMN_3250257 ACVRL1 ILMN_1717477 PSD3 
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ILMN_1656378 NMT2 ILMN_2359287 ITGA6 
ILMN_2225595 ACAD8 ILMN_2375830 DIXDC1 
ILMN_1666665 COL23A1 ILMN_2364072 CLCNKA 
ILMN_1682781 TEAD2 ILMN_1718128 PABPC3 
ILMN_1680856 MAMLD1 ILMN_1695530 MS4A3 
ILMN_2317923 TMEM132A ILMN_3240524 MFSD6 
ILMN_1885771  ILMN_1680805 IL28RA 
ILMN_1691339 CLEC1A ILMN_1758895 CTSK 
ILMN_1784553 SDC2 ILMN_1751793 PCNXL2 
ILMN_2083469 IRS2 ILMN_2123450 FLJ43093 
ILMN_2200917 SLC4A7 ILMN_1838767  
ILMN_1740875 FPR2 ILMN_2413780 SEZ6L2 
ILMN_2195482 CACNB3 ILMN_1733402 CSF1 
ILMN_1685397 ITGA3 ILMN_2305225 NDRG4 
ILMN_1785405 SLC17A9 ILMN_1773389 PLTP 
ILMN_1699631 GATS ILMN_1723971 SLC29A1 
ILMN_1741014 SLC28A3 ILMN_3236135 FAM86D 
ILMN_2398572 FXYD2 ILMN_1684755 KAZALD1 
ILMN_2261076 NEDD9 ILMN_2364674 TRPT1 
ILMN_3197097 TSTD1 ILMN_1807825 LY86 
ILMN_1701483 SYP ILMN_1754538 C10orf58 
ILMN_2128770 CDR2L ILMN_1724941 CDCP1 
ILMN_1786444 LPL ILMN_1692742 DENND3 
ILMN_2404625 LAT ILMN_1673892 GK5 
ILMN_2201678 FSTL1 ILMN_1770161 BST1 
ILMN_2100287 CCDC147 ILMN_1690099 ITGB1BP1 
ILMN_1765459 S100A13 ILMN_2338963 SLC29A1 
ILMN_2387860 CYP19A1 ILMN_2309180 SMARCD3 
ILMN_1797585 MYO1B ILMN_1813572 IL16 
ILMN_1775486 SSPN ILMN_2398939 MBP 
ILMN_1749792 SORBS1 ILMN_1777342 PREX1 
ILMN_2150856 SERPINB2 ILMN_2117171 LMO4 
ILMN_1685403 MMP7 ILMN_1746819 C5 
ILMN_2405324 IL28RA ILMN_1684210 NPAL3 
ILMN_1808325 TM4SF19 ILMN_1699139 CYP19A1 
ILMN_1730622 EVL ILMN_1710209 MFSD6 
ILMN_1668910 CIDEB ILMN_3235964 HSPA7 
ILMN_3179620 LOC100129673 ILMN_1770641 KLHL3 
ILMN_1781045 FXYD2 ILMN_1793730 TM7SF4 
ILMN_1867119  ILMN_2052335 MYOC 
ILMN_1691539 LAT ILMN_2372915 P2RY2 
ILMN_2192072 MMP7 ILMN_1683755 SOX13 
ILMN_1738147 NES ILMN_1766446 C6orf48 
ILMN_2148913 TMEM45A ILMN_1685009 ITGAM 




Table A3: CD137L-DC DEG which are ≥ 2x fold-change compared to immature 
cDCs 
Probe_ID Gene_Symbol Probe_ID Gene_Symbol 
ILMN_2171384 CXCL5 ILMN_1699139 CYP19A1 
ILMN_1752562 CXCL5 ILMN_1733402 CSF1 
ILMN_1656310 INDO ILMN_1808707 FSCN1 
ILMN_2192072 MMP7 ILMN_1730906 FILIP1L 
ILMN_3239965 IDO1 ILMN_2225595 ACAD8 
ILMN_1780465 CLEC5A ILMN_1699631 GATS 
ILMN_1685403 MMP7 ILMN_2359287 ITGA6 
ILMN_2065773 SCG5 ILMN_1751228 C20orf46 
ILMN_1715131 CCR7 ILMN_1673892 GK5 
ILMN_2124221 CLLU1OS ILMN_1711439 EMILIN1 
ILMN_1802653 EBI3 ILMN_1813338 LAG3 
ILMN_1789502 GPC4 ILMN_1806249 IL1RN 
ILMN_1767113 AOX1 ILMN_1687857 ST6GALNAC4 
ILMN_2317923 TMEM132A ILMN_3205353 LOC100131294 
ILMN_2380163 PTPRF ILMN_2086105 SPRY4 
ILMN_1704376 GLDN ILMN_1682993 NKG7 
ILMN_2098446 PMAIP1 ILMN_1709937 KCNN4 
ILMN_1785380 SLC1A2 ILMN_1814022 NR1H3 
ILMN_2413779 SEZ6L2 ILMN_1675191 GAPT 
ILMN_1740875 FPR2 ILMN_2391150 FILIP1L 
ILMN_2093027 MYO1B ILMN_2150851 SERPINB2 
ILMN_1769926 DBN1 ILMN_3242271 GAPT 
ILMN_2404625 LAT ILMN_1688480 CCND1 
ILMN_1670490 PDPN ILMN_2049766 NFE2L3 
ILMN_2201678 FSTL1 ILMN_1765274 CAPN11 
ILMN_1770338 TM4SF1 ILMN_1807925 GNG2 
ILMN_1769299 MTMR11 ILMN_1793476 PRKCDBP 
ILMN_1681644 BIRC3 ILMN_2395214 FMNL3 
ILMN_1669362 IGFBP6 ILMN_2212909 MELK 
ILMN_1752965 GREM1 ILMN_1805371 HNRPM 
ILMN_1815057 PDGFRB ILMN_1685703 ACOX2 
ILMN_1691539 LAT ILMN_1784005 LOC644615 
ILMN_1811736 ENTHD1 ILMN_1794386 IL2RG 
ILMN_3250257 ACVRL1 ILMN_1867119  
ILMN_2374683 PTPN13 ILMN_1680805 IL28RA 
ILMN_2289593 FXYD2 ILMN_1774806 SLC9A7 
ILMN_1785170 ARMCX2 ILMN_1758827 RTN4IP1 
ILMN_1776181 BIRC3 ILMN_1810267 DNHD1 
ILMN_1699695 TNFRSF21 ILMN_1805930 CSF1 
ILMN_3248591 LTBP2 ILMN_3248352 CCDC88C 
ILMN_3251672 DSG2 ILMN_1707124 TFPI 
ILMN_1775486 SSPN ILMN_1804568 HOMER1 
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ILMN_1698218 TRAF1 ILMN_1662390 ASPHD1 
ILMN_1680110 C10orf116 ILMN_2148913 TMEM45A 
ILMN_2398572 FXYD2 ILMN_2413064 ST6GALNAC4 
ILMN_1762713 C19orf59 ILMN_1726624 YPEL4 
ILMN_2170814 LAMP3 ILMN_1742853 LOC652184 
ILMN_1695290 FERMT2 ILMN_1679979 PLK3 
ILMN_1660806 CSRP2 ILMN_1736127 KIAA0773 
ILMN_1805807 SLC30A3 ILMN_1670302 HK3 
ILMN_1686555 FYN ILMN_1701052 TUBG2 
ILMN_1808226 RGS16 ILMN_1800787 RFTN1 
ILMN_2229261 SIGLEC16 ILMN_1747759 WSB1 
ILMN_2316236 HOPX ILMN_2347592 NMB 
ILMN_1740418 CYP27B1 ILMN_1662619 TFPI 
ILMN_1690170 CRABP2 ILMN_1786444 LPL 
ILMN_2170813 LAMP3 ILMN_1674050 COL8A2 
ILMN_1680856 MAMLD1 ILMN_2375830 DIXDC1 
ILMN_1781867 FOXD4L1 ILMN_1703123 AXUD1 
ILMN_1784948 SPOCD1 ILMN_2102330 COL8A2 
ILMN_2068104 TFPI2 ILMN_1788180 RAB13 
ILMN_1779965 AK1 ILMN_1786326 KCTD15 
ILMN_3245630 ECSCR ILMN_1751793 PCNXL2 
ILMN_2405324 IL28RA ILMN_1732151 COL6A1 
ILMN_1678841 UBD ILMN_1781791 PRRG1 
ILMN_1784532 COL22A1 ILMN_1715068 AQP9 
ILMN_3289508 LOC339192 ILMN_1774874 IL1RN 
ILMN_1735231 ZSWIM4 ILMN_1794803 NDP 
ILMN_1757604 TPM2 ILMN_1898723  
ILMN_2374687 PTPN13 ILMN_1743275 SH3RF3 
ILMN_1731374 CPE ILMN_1669523 FOS 
ILMN_2064725 METTL7B ILMN_2375992 SPINT1 
ILMN_2195482 CACNB3 ILMN_1704656 PPP2R1B 
ILMN_1914249  ILMN_1731783 ATP1A1 
ILMN_1658926 NOTCH3 ILMN_1736704 DIXDC1 
ILMN_1781045 FXYD2 ILMN_1655614 DSP 
ILMN_1717262 PROCR ILMN_2160476 CCL22 
ILMN_1717727 LOC284293 ILMN_2077733 C12orf30 
ILMN_2205963 C10orf54 ILMN_1803988 MCL1 
ILMN_1815690 TIE1 ILMN_2357577 PRKAA1 
ILMN_1707591 TNIP3 ILMN_1796682 PARP3 
ILMN_1656011 RGS1 ILMN_1756992 MUC1 
ILMN_1682099 TNFAIP8L3 ILMN_1783156 LOC650832 
ILMN_1696031 C15orf21 ILMN_1800276 RCN1 
ILMN_1678904 ENO3 ILMN_1693513 LOC644143 
ILMN_3248091 C6orf223 ILMN_1788810 C12orf30 
ILMN_2124585 GREM1 ILMN_2364072 CLCNKA 
ILMN_1748538 ALDH1A2 ILMN_1670638 PITPNC1 
 212 
 
ILMN_2380801 FYN ILMN_1741014 SLC28A3 
ILMN_1780831 SLC6A12 ILMN_1666819 PHLDB1 
ILMN_2261076 NEDD9 ILMN_1703487 LMO4 
ILMN_1773389 PLTP ILMN_2413780 SEZ6L2 
ILMN_2387860 CYP19A1 ILMN_1805916 NIPSNAP1 
ILMN_2329927 ABCG1 ILMN_2397954 PARP3 
ILMN_2227248 SLAMF9 ILMN_1691736 ST6GALNAC6 
ILMN_1682015 GAL ILMN_2316386 GPBAR1 
ILMN_1739001 TACSTD2 ILMN_1717677 ZFHX2 
ILMN_1811470 PLEK2 ILMN_1775566 ATP1A1 
ILMN_1745623 EFCAB4A ILMN_1770911 NRSN2 
ILMN_1697220 NT5E ILMN_1805228 LRG1 
ILMN_1698666 CST6 ILMN_2355168 MGST1 
ILMN_1781207 FYN ILMN_2119774 CYP2R1 
ILMN_1789196 TPM2 ILMN_3302919 MYOF 
ILMN_2100437 HBB ILMN_2148469 RASL11B 
ILMN_3197097 TSTD1 ILMN_1684755 KAZALD1 
ILMN_1704353 IGSF3 ILMN_2092441 LRP12 
ILMN_2143685 CLDN7 ILMN_2305225 NDRG4 
ILMN_1749792 SORBS1 ILMN_1653026 PLAC8 
ILMN_1800412 BMP1 ILMN_1670870 ALCAM 
ILMN_1809859 PCGF2 ILMN_1705297 MYBPH 
ILMN_1689525 PMAIP1 ILMN_1682399 CLOCK 
ILMN_1656904 SLC1A4 ILMN_1728799 FBP1 
ILMN_1806434 PAQR5 ILMN_1678423 SPA17 
ILMN_1769615 FLRT2 ILMN_2123450 FLJ43093 
ILMN_2112256 TNFRSF4 ILMN_1692742 DENND3 
ILMN_2383707 ALDH1A2 ILMN_1810289 FER1L3 
ILMN_1794782 ABCG1 ILMN_1680139 MAFF 
ILMN_1783996 DEM1 ILMN_1797822 SEL1L3 
ILMN_1682781 TEAD2 ILMN_1756572 COQ2 
ILMN_1765459 S100A13 ILMN_1787657 CLDN12 
ILMN_2365383 ENO3 ILMN_3236135 FAM86D 
ILMN_2090802 TMEM79 ILMN_1770641 KLHL3 
ILMN_1666665 COL23A1 ILMN_2117171 LMO4 
ILMN_2100287 CCDC147 ILMN_2364674 TRPT1 
ILMN_1716006 C18orf54 ILMN_1793241 SRD5A1 
ILMN_1666546 DUSP14 ILMN_1672743 ZNF334 
ILMN_1738578 FILIP1L ILMN_1677814 ABCC3 
ILMN_2349393 MDK ILMN_1816342  
ILMN_1797585 MYO1B ILMN_1724612 SLC25A35 
ILMN_3298511 LOC728537 ILMN_2413508 CD97 
ILMN_1724699 ACAD8 ILMN_1747673 RASL10A 
ILMN_1670535 NDRG2 ILMN_1662741 EDG4 
ILMN_1701483 SYP ILMN_1798533 ZNF22 
ILMN_2150856 SERPINB2 ILMN_2370976 FER1L3 
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ILMN_1738147 NES ILMN_1788387 UGCGL2 
ILMN_1744381 SERPINE1 ILMN_1701643 GDPD5 
ILMN_1750181 TESC ILMN_1747395 SLC24A1 
ILMN_1659106 PHLDA3 ILMN_1770922 TMEM45A 
ILMN_2361603 NDRG2 ILMN_1656378 NMT2 
ILMN_1746819 C5 ILMN_2394161 ST8SIA4 
ILMN_1677441 C20orf123 ILMN_1760890 SEPN1 
ILMN_1885771  ILMN_1694400 MSR1 
ILMN_1666902 GPR114   
 
 
Table A4: CD137L-DC DEG which are ≥ 2x fold-change compared to macrophages 
Probe_ID Gene_Symbol Probe_ID Gene_Symbol 
ILMN_2160476 CCL22 ILMN_1797822 SEL1L3 
ILMN_1656310 INDO ILMN_1808325 TM4SF19 
ILMN_2170814 LAMP3 ILMN_1722738 ROGDI 
ILMN_3239965 IDO1 ILMN_1694400 MSR1 
ILMN_1739001 TACSTD2 ILMN_1709937 KCNN4 
ILMN_2192072 MMP7 ILMN_2073604 EBP 
ILMN_1789502 GPC4 ILMN_1724946 SPINT1 
ILMN_1740418 CYP27B1 ILMN_2355168 MGST1 
ILMN_1786444 LPL ILMN_1721623 APOO 
ILMN_1710186 CCL17 ILMN_1700047 ALAS1 
ILMN_1685403 MMP7 ILMN_1810267 DNHD1 
ILMN_1715131 CCR7 ILMN_2261076 NEDD9 
ILMN_1794803 NDP ILMN_1680659 C11orf63 
ILMN_1867119  ILMN_1689842 SC4MOL 
ILMN_2361603 NDRG2 ILMN_1795507 ABCA6 
ILMN_1784948 SPOCD1 ILMN_1800787 RFTN1 
ILMN_1802653 EBI3 ILMN_1677765 LRP8 
ILMN_1688480 CCND1 ILMN_2395214 FMNL3 
ILMN_1911721  ILMN_2413644 TM4SF19 
ILMN_1748538 ALDH1A2 ILMN_1807177 KIAA1797 
ILMN_1785380 SLC1A2 ILMN_1686555 FYN 
ILMN_2124221 CLLU1OS ILMN_1783996 DEM1 
ILMN_1744381 SERPINE1 ILMN_1760890 SEPN1 
ILMN_1752562 CXCL5 ILMN_3181411 ATL1 
ILMN_1659106 PHLDA3 ILMN_2134974 RAB38 
ILMN_1717477 PSD3 ILMN_2399392 SIL1 
ILMN_2319000 MATK ILMN_2399036 SEPN1 
ILMN_2317923 TMEM132A ILMN_2347592 NMB 
ILMN_1733535 ZNF366 ILMN_1813338 LAG3 
ILMN_2227248 SLAMF9 ILMN_1815626 DHCR7 
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ILMN_2201678 FSTL1 ILMN_1680139 MAFF 
ILMN_1769926 DBN1 ILMN_1788387 UGCGL2 
ILMN_2383707 ALDH1A2 ILMN_1704369 LIMA1 
ILMN_2332250 ACOT7 ILMN_3205353 LOC100131294 
ILMN_1776519 RAP1GAP ILMN_1814022 NR1H3 
ILMN_2098446 PMAIP1 ILMN_1784871 FASN 
ILMN_1815190 METTL1 ILMN_1781207 FYN 
ILMN_1698218 TRAF1 ILMN_1663538 CLYBL 
ILMN_1682015 GAL ILMN_1715068 AQP9 
ILMN_1705686 NRGN ILMN_1735231 ZSWIM4 
ILMN_1776181 BIRC3 ILMN_2413508 CD97 
ILMN_1685703 ACOX2 ILMN_1720889 SC4MOL 
ILMN_1678841 UBD ILMN_2090802 TMEM79 
ILMN_1770338 TM4SF1 ILMN_1745623 EFCAB4A 
ILMN_3251672 DSG2 ILMN_1701643 GDPD5 
ILMN_1805930 CSF1 ILMN_1805916 NIPSNAP1 
ILMN_1659352 KCNK13 ILMN_1784005 LOC644615 
ILMN_1747673 RASL10A ILMN_2077733 C12orf30 
ILMN_2405324 IL28RA ILMN_1915188  
ILMN_1712352 DOCK3 ILMN_2413527 VCL 
ILMN_2171384 CXCL5 ILMN_2380801 FYN 
ILMN_1735157 GALNT12 ILMN_1786326 KCTD15 
ILMN_3306997 METTL1 ILMN_1675542 LOC729148 
ILMN_2112256 TNFRSF4 ILMN_1719649 TMEM63A 
ILMN_3289508 LOC339192 ILMN_1772241 SQLE 
ILMN_1666546 DUSP14 ILMN_1690040 TM7SF2 
ILMN_1781867 FOXD4L1 ILMN_1716006 C18orf54 
ILMN_1784553 SDC2 ILMN_1678729 SIL1 
ILMN_1660806 CSRP2 ILMN_1755281 FBXO15 
ILMN_1733402 CSF1 ILMN_1885771  
ILMN_1789196 TPM2 ILMN_2041293 SQLE 
ILMN_2374449 SPP1 ILMN_1767253 RRP12 
ILMN_2289593 FXYD2 ILMN_1756806 MCL1 
ILMN_1780465 CLEC5A ILMN_2165867 DHCR7 
ILMN_3298511 LOC728537 ILMN_1759453 UQCRB 
ILMN_1770641 KLHL3 ILMN_1726624 YPEL4 
ILMN_2370976 FER1L3 ILMN_1786658 BOLA3 
ILMN_2047618 KCNE1 ILMN_1804248 FDPS 
ILMN_1670302 HK3 ILMN_1657395 HMGCR 
ILMN_1704353 IGSF3 ILMN_1712088 CLYBL 
ILMN_3248091 C6orf223 ILMN_2381121 UQCC 
ILMN_1656011 RGS1 ILMN_1684210 NPAL3 
ILMN_1651354 SPP1 ILMN_1667199 SQRDL 
ILMN_1772821 KIAA1671 ILMN_1788180 RAB13 
ILMN_1719627 SLC27A3 ILMN_2224103 PAPSS1 
ILMN_2398572 FXYD2 ILMN_1663751 CYCSL1 
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ILMN_1769299 MTMR11 ILMN_3250257 ACVRL1 
ILMN_1656904 SLC1A4 ILMN_1803988 MCL1 
ILMN_2375992 SPINT1 ILMN_2225595 ACAD8 
ILMN_1763638 BCAR3 ILMN_1758750 EARS2 
ILMN_1696031 C15orf21 ILMN_1693513 LOC644143 
ILMN_3302919 MYOF ILMN_2401927 TTC8 
ILMN_1810289 FER1L3 ILMN_1703228 AGFG2 
ILMN_1717262 PROCR ILMN_1724699 ACAD8 
ILMN_1658926 NOTCH3 ILMN_2373285 MSR1 
ILMN_1725510 DHCR24 ILMN_3234116 LOC730382 
ILMN_1793476 PRKCDBP ILMN_1759023 WFS1 
ILMN_1779965 AK1 ILMN_1703123 AXUD1 
ILMN_1773389 PLTP ILMN_1705849 SPR 
ILMN_1652237 CBR3 ILMN_1768558 LOC727848 
ILMN_1679460 PPFIBP1 ILMN_1781819 PAPSS1 
ILMN_2374865 ATF3 ILMN_1736539 ALDH1L2 
ILMN_1781045 FXYD2 ILMN_1791306 C9orf103 
ILMN_1743199 EGR2 ILMN_1718621 TSPAN32 
ILMN_1655100 LOC644680 ILMN_1657955 FMNL3 
ILMN_1742853 LOC652184 ILMN_3248591 LTBP2 
ILMN_1717727 LOC284293 ILMN_3307791 FAM69A 
ILMN_1670870 ALCAM ILMN_1758281 CALCRL 
ILMN_1678904 ENO3 ILMN_1657550 MVD 
ILMN_1680856 MAMLD1 ILMN_1717677 ZFHX2 
ILMN_1771261 SYNC1 ILMN_2397954 PARP3 
ILMN_2365383 ENO3 ILMN_1770466 ATP5G3 
ILMN_2391150 FILIP1L ILMN_2382648 MID2 
ILMN_1724941 CDCP1 ILMN_1741096 FDFT1 
ILMN_3235176 C2orf89 ILMN_1699737 TRAP1 
ILMN_2229261 SIGLEC16 ILMN_1729167 EFTUD1 
ILMN_1713679 MREG ILMN_1683273 SNAPC5 
ILMN_1704084 CMAH ILMN_2069128 EPB41L2 
ILMN_1775486 SSPN ILMN_1712291 MICALL2 
ILMN_1655796 Mar-03 ILMN_2373763 CASP7 
ILMN_1732151 COL6A1 ILMN_1742547 NRP1 
ILMN_1689525 PMAIP1 ILMN_2049536 TRPV2 
ILMN_2407824 ATP1B1 ILMN_1782635 YARS2 
ILMN_1806249 IL1RN ILMN_1671568 ECHDC2 
ILMN_2188722 GLS ILMN_1782015 FCRLB 
ILMN_2316386 GPBAR1 ILMN_1737580 PPPDE2 
ILMN_1788778 Sep-11 ILMN_1745152 UQCC 
ILMN_1660871 NEK6 ILMN_1724497 ABI2 
ILMN_1688152 IL27RA ILMN_3217276 LOC644517 
ILMN_2340347 PC ILMN_1662741 EDG4 
ILMN_1685397 ITGA3 ILMN_1803945 HCP5 
ILMN_1804568 HOMER1 ILMN_2123450 FLJ43093 
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ILMN_1704656 PPP2R1B ILMN_1770031 ABHD10 
ILMN_2349393 MDK ILMN_3236135 FAM86D 
ILMN_1774806 SLC9A7 ILMN_1793241 SRD5A1 
ILMN_2143685 CLDN7 ILMN_1803392 TAX1BP3 
 
Appendix III: Tissue culture media 
Media Constituent Amount 
RPMI 1640 
(1 L preparation) 
RPMI powder (Sigma-Aldrich) 16.35 g 
200 mM L-glutamine (Gibco, Invitrogen) 10 ml 
Sodium Bicarbonate (Sigma-Aldrich) 2.0 g 
MilliQ water Top to 1L 
R10 PS  
(1 L preparation) 
RPMI 1640 medium 890 ml 
FBS (Biowest) 100 ml 
Penicillin/Streptomycin (Gibco, Invitrogen) 10 ml 
R10 2Ab 
(1 L preparation) 
RPMI 1640 medium 980 ml 
Human Ab serum (Sigma-Aldrich) 20 ml 
R10 PS PM  
(1 L preparation) 
R10 PS media 997 ml 
1M Probenecid solution in NaOH 2 ml 
50 mM -mercaptoethanol stock 1 ml 
AIMV 2Ab 
(1 L preparation) 
AIM V® Medium, containing L-glutamine, 
streptomycin sulphate at 50 µg/ml, and 
gentamicin sulphate at 10 µg/ml (Gibco, 
Invitrogen) 
980 ml 
Human Ab serum (Sigma-Aldrich) 20 ml 
AIMV 2Ab PM 
(1 L preparation) 
AIMV 2Ab medium 997 ml 
1M Probenecid solution in NaOH 2 ml 
50 mM -mercaptoethanol stock 1 ml 
 
The pH of all culture media was adjusted to 7.4 and sterile filtered through a 
0.22 m filter. 
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Appendix IV: Buffers and reagents 
Buffer Constituent Amount 
PBS + 2 mM EDTA 
(1 L preparation) 
10 × PBS (1st Base) 100 ml 
0.5 M EDTA (1st Base) 4 ml 
MilliQ water Top to 1L 
RBC lysis buffer 
(1 L preparation) 
NH4Cl (Sigma-Aldrich) 8.29 g 
NaHCO3 (Sigma-Aldrich) 0.84 g 
0.5 M EDTA (1st Base) 23 l 
MilliQ water Top to 1L 
MACS buffer 
(1 L preparation) 
10 × PBS (1st Base) 100 ml 
0.5 M EDTA (1st Base) 4 ml 
BSA (Biowest) 5 g 
MilliQ water Top to 1L 
Staining buffer 
(1 L preparation) 
FBS 5 ml 
Sodium azide (Sigma-Aldrich) 0.2 g 
10 × PBS (1st Base) 100 ml 
MilliQ water Top to 1L 
Trypsin-EDTA 
(50 ml preparation) 
0.5 % Trypsin-EDTA (Gibco, 
Invitrogen) 5 ml 
10 × PBS (1st Base) 5 ml 
MilliQ water Top to 50 ml 
10 mM EDTA in PBS 
(50 ml preparation) 
0.5 M EDTA (1st Base) 1 ml 
10 × PBS (1st Base) 5 ml 
MilliQ water Top to 50 ml 
 
The pH of all buffers was adjusted to 7.4 and sterile filtered through a 0.22 
m filter (except for staining buffer). 
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International Scientific Publication(s) 
 
1. Harfuddin Z, Kwajah S, Chong Nyi Sim A, MacAry PA, Schwarz H. 
CD137L-stimulated dendritic cells are more potent than conventional 
dendritic cells at eliciting cytotoxic T-cell responses. OncoImmunology 
2013; 2:e26859 
 
2. Tang Q, Jiang D, Harfuddin Z, Cheng CK, Moh MC, Schwarz H. 
Regulation of myelopoiesis by CD137 ligand signalling. (In preparation) 
 
3. Harfuddin Z, Duan K, Poidinger M, Koh LK, Wong SC, Schwarz H. 
Transcriptional regulation in CD137 ligand generated dendritic cells. (In 
preparation) 
 
Selected Local & International Scientific Conference Posters & Oral 
Presentation 
 
1. Harfuddin Z, Kwajah S, Schwarz H. Activation of antigen-specific T 
lymphocytes by CD137 ligand generated dendritic cells. Keystone 
Symposia: Dendritic cells and the Initiation of Adaptive Immunity. Santa 
Fe, New Mexico, USA, February 2011. (Poster Presentation). 
 
2. Harfuddin Z, Kwajah S, Chong Nyi Sim A, MacAry PA, Schwarz H. 
Activation of antigen-specific T lymphocytes by CD137 ligand generated 
dendritic cells. European Macrophage and Dendritic Cell Society. 
Debrecen, Hungary, September 2012. (Poster Presentation). 
 
3. Harfuddin Z, Kwajah S, Chong Nyi Sim A, MacAry PA, Schwarz H. 
Activation of antigen-specific T lymphocytes by CD137 ligand generated 
dendritic cells. Frontiers in Immunology and Inflammation: From 
Molecules to Disease. Tokyo, Japan, February 2013. (Poster Presentation 
and was presented with a travel award). 
 
4. Harfuddin Z, Kwajah S, Chong Nyi Sim A, MacAry PA, Schwarz H. 
Activation of antigen-specific T lymphocytes by CD137 ligand generated 
dendritic cells. 6th International Singapore Symposium of Immunology. 
Singapore, June 2013. (Poster Presentation). 
 
5. Harfuddin Z, Kwajah S, Chong Nyi Sim A, MacAry PA, Schwarz H. CD137 
ligand generated dendritic cells are more potent than classical dendritic 
cells in inducing an antigen-specific T cell response. 15th International 
Congress of Immunology. Milan, Italy, August 2013. (Poster 
Presentation). 
 
6. Harfuddin Z, Duan K, Poidinger M, Koh LK, Wong SC, Schwarz H. 
Transcriptional and functional characterization of dendritic cell 
differentiation induced by CD137 ligand reverse signalling in human 
monocytes. 2nd International Graduate Student Immunology Congress. 
Marseille, France, August 2013. (Selected for Oral Presentation). 
